0001079973-22-000149.txt : 20220214 0001079973-22-000149.hdr.sgml : 20220214 20220214100214 ACCESSION NUMBER: 0001079973-22-000149 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220214 DATE AS OF CHANGE: 20220214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BION ENVIRONMENTAL TECHNOLOGIES INC CENTRAL INDEX KEY: 0000875729 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] IRS NUMBER: 841176672 STATE OF INCORPORATION: CO FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19333 FILM NUMBER: 22626529 BUSINESS ADDRESS: STREET 1: PO BOX 323 CITY: OLD BETHPAGE STATE: NY ZIP: 11804 BUSINESS PHONE: (212) 758-6622 MAIL ADDRESS: STREET 1: PO BOX 323 CITY: OLD BETHPAGE STATE: NY ZIP: 11804 FORMER COMPANY: FORMER CONFORMED NAME: RSTS CORP DATE OF NAME CHANGE: 19930328 10-Q 1 bion_10q-123121.htm FORM 10-Q
0000875729 false 06/30 2022 Q2 0000875729 2021-07-01 2021-12-31 0000875729 2022-02-01 0000875729 2021-12-31 0000875729 2021-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2021-12-31 0000875729 us-gaap:SeriesBPreferredStockMember 2021-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2021-12-31 0000875729 us-gaap:SeriesAPreferredStockMember 2021-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-12-31 0000875729 us-gaap:SeriesCPreferredStockMember 2021-06-30 0000875729 2021-10-01 2021-12-31 0000875729 2020-10-01 2020-12-31 0000875729 2020-07-01 2020-12-31 0000875729 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-06-30 0000875729 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-06-30 0000875729 us-gaap:CommonStockMember 2020-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000875729 bnet:SubscriptionsReceivableMember 2020-06-30 0000875729 us-gaap:RetainedEarningsMember 2020-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2020-06-30 0000875729 2020-06-30 0000875729 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0000875729 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0000875729 us-gaap:CommonStockMember 2021-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000875729 bnet:SubscriptionsReceivableMember 2021-06-30 0000875729 us-gaap:RetainedEarningsMember 2021-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-06-30 0000875729 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-07-01 2020-12-31 0000875729 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-07-01 2020-12-31 0000875729 us-gaap:CommonStockMember 2020-07-01 2020-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-12-31 0000875729 bnet:SubscriptionsReceivableMember 2020-07-01 2020-12-31 0000875729 us-gaap:RetainedEarningsMember 2020-07-01 2020-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-12-31 0000875729 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-07-01 2021-12-31 0000875729 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-07-01 2021-12-31 0000875729 us-gaap:CommonStockMember 2021-07-01 2021-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-12-31 0000875729 bnet:SubscriptionsReceivableMember 2021-07-01 2021-12-31 0000875729 us-gaap:RetainedEarningsMember 2021-07-01 2021-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-12-31 0000875729 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000875729 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000875729 us-gaap:CommonStockMember 2020-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000875729 bnet:SubscriptionsReceivableMember 2020-12-31 0000875729 us-gaap:RetainedEarningsMember 2020-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2020-12-31 0000875729 2020-12-31 0000875729 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000875729 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000875729 us-gaap:CommonStockMember 2021-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000875729 bnet:SubscriptionsReceivableMember 2021-12-31 0000875729 us-gaap:RetainedEarningsMember 2021-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2021-12-31 0000875729 2020-07-01 2021-06-30 0000875729 2019-07-01 2020-06-30 0000875729 2017-07-01 2018-06-30 0000875729 srt:MinimumMember 2021-12-31 0000875729 srt:MaximumMember 2021-12-31 0000875729 bnet:CenterpointMember 2021-12-31 0000875729 us-gaap:WarrantMember 2021-07-01 2021-12-31 0000875729 us-gaap:WarrantMember 2020-07-01 2020-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-12-31 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2021-07-01 2021-12-31 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2020-07-01 2020-12-31 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2021-07-01 2021-12-31 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2020-07-01 2020-12-31 0000875729 bnet:PropertyPlantAndEquipmentOfPA1Member 2021-07-01 2021-12-31 0000875729 srt:ChiefExecutiveOfficerMember 2021-12-31 0000875729 srt:ChiefExecutiveOfficerMember 2020-12-31 0000875729 srt:PresidentMember 2020-12-31 0000875729 bnet:ConsultantsMember 2021-12-31 0000875729 bnet:ConsultantsMember 2020-12-31 0000875729 bnet:FormerEmployeeMember 2021-12-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2021-10-01 2021-12-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2020-10-01 2020-12-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2021-07-01 2021-12-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2020-07-01 2020-12-31 0000875729 bnet:PennvestLoanMember 2021-12-31 0000875729 bnet:YearsOneThroughFiveMember bnet:PennvestLoanMember 2021-07-01 2021-12-31 0000875729 bnet:YearsSixThroughMaturityMember bnet:PennvestLoanMember 2021-07-01 2021-12-31 0000875729 bnet:PennvestLoanMember 2021-10-01 2021-12-31 0000875729 bnet:PennvestLoanMember 2020-10-01 2020-12-31 0000875729 bnet:PennvestLoanMember 2021-07-01 2021-12-31 0000875729 bnet:PennvestLoanMember 2020-07-01 2020-12-31 0000875729 bnet:PA1Member 2014-09-25 0000875729 2021-09-30 0000875729 2021-12-29 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-01-01 0000875729 srt:PresidentMember 2020-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-12-31 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-12-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-12-31 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-12-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-12-31 0000875729 bnet:The2020ConvertibleObligationsMember 2021-07-01 2021-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-10-01 2021-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-10-01 2020-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-07-01 2021-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-07-01 2020-12-31 0000875729 srt:PresidentMember bnet:SecuredPromissoryNoteMember 2021-12-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember 2021-12-31 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember 2021-12-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember 2021-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember 2020-12-31 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember 2020-12-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember 2020-12-31 0000875729 bnet:September2015ConvertibleNotesMember 2021-07-01 2021-12-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2021-10-01 2021-12-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-10-01 2020-12-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2021-07-01 2021-12-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-07-01 2020-12-31 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-02 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-03 0000875729 us-gaap:SeriesBPreferredStockMember 2014-06-25 2014-07-01 0000875729 us-gaap:SeriesBPreferredStockMember 2020-07-01 2021-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2019-07-01 2020-06-30 0000875729 srt:PresidentMember us-gaap:CommonStockMember 2021-07-01 2021-12-31 0000875729 srt:PresidentMember 2021-12-31 0000875729 srt:PresidentMember us-gaap:RestrictedStockMember 2021-12-31 0000875729 srt:PresidentMember 2021-07-01 2021-12-31 0000875729 us-gaap:WarrantMember bnet:TwoConsultantsMember 2021-07-01 2021-12-31 0000875729 us-gaap:WarrantMember 2021-07-01 2021-12-31 0000875729 us-gaap:WarrantMember bnet:TwoConsultantsMember 2021-12-31 0000875729 us-gaap:WarrantMember 2020-07-01 2020-12-31 0000875729 us-gaap:WarrantMember 2021-12-31 0000875729 us-gaap:WarrantMember 2021-10-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2021-12-31 0000875729 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-07-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2021-10-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2020-10-01 2020-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-12-31 0000875729 us-gaap:OptionMember 2021-10-01 2021-12-31 0000875729 us-gaap:OptionMember 2021-07-01 2021-12-31 0000875729 us-gaap:OptionMember 2020-10-01 2020-12-31 0000875729 us-gaap:OptionMember 2020-07-01 2020-12-31 0000875729 2020-08-01 2021-07-31 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-10-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-10-01 2020-12-31 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-12-31 0000875729 us-gaap:GeneralAndAdministrativeExpenseMember 2021-10-01 2021-12-31 0000875729 us-gaap:GeneralAndAdministrativeExpenseMember 2020-10-01 2020-12-31 0000875729 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-12-31 0000875729 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-12-31 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-10-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-10-01 2020-12-31 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-12-31 0000875729 us-gaap:ResearchAndDevelopmentExpenseMember 2021-10-01 2021-12-31 0000875729 us-gaap:ResearchAndDevelopmentExpenseMember 2020-10-01 2020-12-31 0000875729 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-12-31 0000875729 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteMember 2021-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsIssusedSubscriptionReceivableMember 2021-12-31 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2021-12-31 0000875729 bnet:SecuredPromissoryNoteMember bnet:FormerEmployeeMember 2021-12-31 0000875729 bnet:WarrantsIssusedSubscriptionReceivableMember bnet:FormerEmployeeMember 2021-12-31 0000875729 bnet:ConsultantMember 2021-12-31 0000875729 srt:PresidentMember 2016-10-01 2016-10-10 0000875729 srt:PresidentMember bnet:WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember 2021-12-31 0000875729 srt:ChiefExecutiveOfficerMember 2015-02-03 2015-02-10 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2016-10-31 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2017-04-27 0000875729 bnet:BassaniMember 2018-02-28 0000875729 bnet:BassaniMember 2022-12-01 2022-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsExpiringOnDecember312025Member 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2021-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2021-07-01 2021-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2020-07-01 2020-12-31 0000875729 bnet:PennvestMember 2014-09-01 2014-09-25 0000875729 us-gaap:SubsequentEventMember 2022-01-01 2022-01-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure bnet:Decimal

 

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

x   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended December 31, 2021

 

o   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______ to _________

 

Commission File No. 000-19333

 

Bion Environmental Technologies, Inc.

(Name of registrant in its charter)

 

Colorado   84-1176672
(State or other jurisdiction of incorporation or formation)   (I.R.S. employer identification number)

 

9 East Park Court

Old Bethpage, New York 11804

(Address of principal executive offices)

 

516-586-5643

(Registrant’s telephone number, including area code) 

 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Securities Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock BNET OTCQB

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

x Yes o No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). x Yes o No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

    Large accelerated filer  o   Accelerated filer  o  
   

Non-accelerated filer o

 

  Smaller reporting company  x  
    Emerging growth company   o      

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o Yes x No

 

 
 
 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS: Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Not applicable.

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. On February 1, 2022, there were 43,733,820 Common Shares issued and 43,209,511 Common Shares outstanding.

 

 

 

2 
 
 

BION ENVIRONMENTAL TECHNOLOGIES, INC.

 

FORM 10-Q

 

TABLE OF CONTENTS

 

PART I.  FINANCIAL INFORMATION   Page
       
Item 1.

Financial Statements

 

  4
  Consolidated financial statements (unaudited):    
    Balance sheets   4
    Statements of operations   5
    Statement of changes in equity (deficit)   6
    Statements of cash flows   7
    Notes to unaudited consolidated financial statements   8-27
       
Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

  28
       
Item 3. Quantitative and Qualitative Disclosures about Market Risk   46
       
Item 4. Controls and Procedures   46
       
PART II.  OTHER INFORMATION    
       
Item 1. Legal Proceedings   47
       
Item 1A. Risk Factors   48
       
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   48
       
Item 3. Defaults Upon Senior Securities   48
       
Item 4. Mine Safety Disclosures   48
       
Item 5. Other Information   48
       
Item 6. Exhibits   48
       
  Signatures   49

 

 

 

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that involve substantial risks and uncertainties. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expect," "intend," "estimate," "anticipate," "project," "predict," "plan," "believe" or "continue" or the negative thereof or variations thereon or similar terminology. The expectations reflected in forward-looking statements may prove to be incorrect.

 

3 
 
 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

 CONSOLIDATED BALANCE SHEETS

 

           
   December 31,   June 30, 
   2021   2021 
    (unaudited)      
           
ASSETS          
           
Current assets:          
Cash  $4,948,282   $4,216,321 
Prepaid expenses   46,723    124,049 
Deposits   1,000    1,000 
           
Total current assets   4,996,005    4,341,370 
           
Operating lease use- of- asset   171,835       
Property and equipment, net (Note 3)   146,895    541  
           
Total assets  $5,314,735   $4,341,911 
           
LIABILITIES AND EQUITY (DEFICIT)          
           
Current liabilities:          
Accounts payable and accrued expenses  $513,070   $570,050 
Series B Redeemable Convertible Preferred stock, $0.01 par value,50,000 shares authorized; 0 and 200 shares issued and outstanding, liquidation preference of $0 and $40,000, respectively (Note 7)         37,400 
Deferred compensation (Note 4)   477,374    479,208 
Loan payable and accrued interest (Note 5)         9,868,495 
           
Total current liabilities   990,444    10,955,153 
           
Operating lease liability   122,605       
Convertible notes payable - affiliates (Note 6)   5,075,586    4,793,097 
           
Total liabilities   6,188,635    15,748,250 
           
Deficit:          
Bion's stockholders' equity (deficit):          
 Series A Preferred stock, $0.01 par value, 50,000 shares authorized,  no shares issued and outstanding            
Series C Convertible Preferred stock, $0.01 par value, 60,000 shares authorized; no shares issued and outstanding            
Common stock, no par value, 100,000,000 shares authorized, 43,733,820 and 41,315,986 shares issued, respectively; 43,029,511 and 40,611,677 shares outstanding, respectively            
Additional paid-in capital   123,150,676    121,399,067 
Subscription receivable - affiliates (Note 8)   (504,650)   (504,650)
Accumulated deficit   (123,558,048)   (132,339,873)
           
Total Bion's stockholders’ deficit   (912,022)   (11,445,456)
           
Noncontrolling interest   38,122    39,117 
           
Total deficit   (873,900)   (11,406,339)
           
Total liabilities and deficit  $5,314,735   $4,341,911 

 

See notes to consolidated financial statements

 

4 
 
 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

THREE AND SIX MONTHS ENDED DECEMBER 31, 2021 AND 2020
(UNAUDITED)

 

                 
   Three months ended
December 31,
   Six months ended
December 31,
 
   2021   2020   2021   2020 
                 
Revenue  $     $     $     $   
                     
Operating expenses:                    
General and administrative (including stock-based compensation (Note 7))   617,963    291,682    1,109,096    594,559 
Depreciation   332    207    580    414 
Research and development (including stock-based compensation (Note 7))   54,404    155,385    116,213    246,373 
                     
Total operating expenses   672,699    447,274    1,225,889    841,346 
                     
Loss from operations 

 

 

 

(672,699)   (447,274)   (1,225,889)   (841,346)
                     
Other (income) expense:                    
Interest income   (1,269)   (47)   (2,763)   (126)
Interest expense   118,365    303,218    230,545    407,637 
Gain on legal dissolution of subsidiary   (10,234,501)         (10,234,501)      
                     
Total other expense   (10,117,405)   303,171    (10,006,719)   407,511 
                     
Net income (loss)   9,444,706    (750,445)   8,780,830    (1,248,857)
                     
Net loss attributable to the noncontrolling interest   489    524    995    1,039 
                     
Net income (loss) applicable to Bion's common stockholders  $9,445,195   $(749,921)  $8,781,825   $(1,247,818)
                     
Net income (loss) applicable to Bion's common stockholders per basic and diluted common share  $0.23   $(0.02)  $0.21   $(0.04)
                     
Weighted-average number of common shares outstanding:                    
Basic and diluted   41,088,992    31,187,645    40,904,342    30,990,639 

 

 

See notes to consolidated financial statements

 

 

5 
 
 


 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

SIX MONTHS ENDED DECEMBER 31, 2021 AND 2020

(UNAUDITED)

 

Six months ended December 31, 2021

 

                                                        
   Bion's Shareholders'      
   Series A Preferred Stock  Series C Preferred Stock  Common Stock  Additional  Subscription Receivables  Accumulated  Noncontrolling  Total
   Shares  Amount  Shares  Amount  Shares  Amount  paid-in capital  for Shares  deficit  interest  equity/(deficit)
                                  
Balance at July 1, 2020        $           $      31,409,005   $      114,266,683   $(504,650)  $(128,891,893)  $41,902   $(15,087,958)
Sale of units   —            —            720,000          360,000                      360,000 
Commissions on sale of units   —            —            —            (31,000)                     (31,000)
Modification of options   —            —            —            8,775                      8,775 
Modification of warrants   —            —            —            188,890                      188,890 
Issuance of warrants   —            —            —            2,500                      2,500 
Conversion of debt and liabilities   —            —            141,589          70,794                      70,794 
Net loss   —            —            —                        (1,247,818)   (1,039)   (1,248,857)
Balance at December 31, 2020        $           $      32,270,594   $     $114,866,642   $(504,650)  $(130,139,711)  $40,863   $(15,736,856)
                                                        

 

Six months ended December 31, 2021

 

 

   Bion's Shareholders'      
   Series A Preferred Stock  Series C Preferred Stock  Common Stock  Additional paid-in  Subscription Receivables  Accumulated  Noncontrolling  Total
   Shares  Amount  Shares  Amount  Shares  Amount  capital  for Shares  deficit  interest  equity/(deficit)
Balance at July 1, 2021        $           $      41,315,986   $     $121,399,067   $(504,650)  $(132,339,873)  $39,117   $(11,406,339)
Warrants exercised for common shares   —            —            2,315,550          1,736,662                      1,736,662 
Commissions on warrant exercises   —            —            66,860          (18,601)                     (18,601)
Conversion of debt and liabilities   —            —            35,424          17,711                      17,711 
Modification of warrants   —            —            —            8,337                      8,337 
Issuance of warrants   —            —            —            7,500                      7,500 
Net income (loss)   —            —            —                        8,781,825    (995)   8,780,830 
Balance at December 31, 2021        $           $      43,733,820   $     $123,150,676   $(504,650)  $(123,558,048)  $38,122   $(873,900)

 

 

 

See notes to consolidated financial statements

 

6 
 
 

 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

SIX MONTHS ENDED DECEMBER 31, 2021 AND 2020

(UNAUDITED)

 

           
    2021    2020 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net income (loss)  $8,780,830   $(1,248,857)
Adjustments to reconcile net income (loss) to net cash used in operating activities:          
Gain on legal dissolution of subsidiary   (10,234,501)      
Depreciation expense   580    414 
Accrued interest on loans payable, deferred compensation and other   248,409    425,499 
Stock-based compensation   13,125    36,781 
Decrease in prepaid expenses   77,326    3,615 
Decrease in operating lease assets and liabilities   (49,230)      
Increase in accounts payable and accrued expenses   130,628    8,162 
Increase in deferred compensation   179,867    245,742 
           
Net cash used in operating activities   (852,966)   (528,644)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Purchase of property and equipment   (92,134)      
           
Net cash used in investing activities   (92,134)      
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds from exercise of warrants   1,736,662       
Commissions on exercise of warrants   (18,601)      
Redemption of Preferred Series B shares and interest   (41,000)     
Proceeds from sale of units         360,000 
Commissions on sale of units         (31,000)
           
Net cash provided by financing activities   1,677,061    329,000 
           
Net decrease in cash   731,961    (199,644)
           
Cash at beginning of period   4,216,321    560,828 
           
Cash at end of period  $4,948,282   $361,184 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $     $28 
           
Non-cash investing and financing transactions:          
Conversion of debt and liabilities into common units  $17,711   $70,794 
Shares issued for warrant exercise commissions  $50,145   $   
Conversion of deferred compensation to note payable  $190,000      
Purchase of property and equipment for accounts payable  $54,800   $   

 

See notes to consolidated financial statements

 

7 
 
 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

SIX MONTHS ENDED DECEMBER 31, 2021 AND 2020

 

1.       ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:

 

Organization and nature of business:

 

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Our patented and proprietary technology provides comprehensive environmental solutions to one of the greatest water air and water quality problems in the U.S. today: pollution from large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs").  Application of our technology and technology platform can simultaneously remediate environmental problems and improve operational/resource efficiencies by recovering value high-value co-products from the CAFOs’ waste stream that have traditionally been wasted or underutilized, including renewable energy, nutrients (including ammonia nitrogen) and water.

 

From 2016 to 2021 fiscal years, the Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“3G Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of organic ammonium bicarbonate products. The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. An application for our first solid ammonium bicarbonate product – AD Nitrogen – has been filed and is in the review process (which is likely to require an extended period of time and multiple procedural steps due to the novel nature of Bion’s 3G Tech in the context of organic certifications) See “Organic Fertilizer Listing/Certification Process” below.

 

Bion is now focused primarily on: i) development/construction of its initial commercial-scale 3G Tech installation (see below and Note 10, “Subsequent Events”), ii) developing applications and markets for its organic fertilizer products and its sustainable (conventional and organic) animal protein products, and iii) initiation and development of joint ventures (“JVs” as discussed below) (and related projects) based on the augmented capabilities of our 3G Tech, while (iv) continuing to pursue development opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and ongoing R&D activities.

 

The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns ranging including food safety, environmental impacts, and humane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market.

 

The Company believes that its 3G Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a large production/marketing opportunity for Bion. Our 3G Tech will also produce (as co-products) biogas and valuable organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.

 

During late September 2021, Bion entered into a lease for the development site of its initial commercial scale 3G Tech project in September 2021(“Initial Project”), which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project will be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately 300 head of beef cattle. The facility will include Bion’s 3G Tech platform including: i) covered barns (possibly including roof top solar photovoltaic generation), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion 3G Tech facilities capable of treating the waste from approximately 1,500 head). The facility will be large enough to demonstrate engineering capabilities of Bion’s 3G Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly, with operations targeted to commence sometime late in 2022. 3G1 has been moving forward with the development process of the Initial Project. See Note 10 “Subsequent Events” for activities since the start of the 2022 calendar year.

 

 

8 
 
 

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

Specifically, the Initial Project is being developed to provide and/or accomplish the following:

 

  i. Proof of 3G Tech platform scalability

 

  - Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion 3G technology platform.

 

  - Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.

 

  ii. Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.

 

  iii. Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) for commercial testing by potential joint venture partners and/or purchasers and for university growth trials.

 

  iv. Produce sustainable beef products for initial test marketing efforts.

 

Upon achieving optimized and steady-state operations at the Initial Project (and especially of the core modules of our 3G Tech platform), coupled with obtaining organic certifications(s) ( OMRI listing and/or other organic listings/certifications) for its AD Nitrogen product, Bion expects to be ready to move forward with its plans for development of much larger facilities. The Company anticipates that discussions and negotiations regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will commence during the construction of the Initial Project with the goal of establishing JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef during 2023. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its 3G Tech platform.

 

Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘3G Tech Kreider 2 Poultry Project’ below as an example).

 

Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/ dairy/ egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a certain segment of consumers are choosing seemingly sustainable offering, and are also willing to pay a premium for it. Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is 29.5 percent on average.

 

As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s 3G Tech platform, along with its business model, enables the cleanup of the ‘dirtiest’ part of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.

 

Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 retail value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef is 63% more expensive today, while pork and chicken, which are now primarily raised in covered barns, at CAFOs with highly integrated supply chains, are 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.

 

 

9 
 
 

 

Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. Meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, are being heavily promoted by themselves and the media, and have enjoyed steady sales growth. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have recently entered the plant protein space. In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the only ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence). However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy.

 

It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, which represents approximately 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost remains very uncertain at this point.

 

Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium sustainable beef products that satisfy these concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our 3G Tech platform, both sustainable and/or organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, but with the superior taste and texture those consumers have grown to prefer.

 

Sustainable Beef

 

Bion’s goal is to be first to market with meaningfully sustainable, and verified, beef products that can be produced at sufficient scale to service national market demand. The cattle produced at a Bion facility will enjoy a substantially lower carbon footprint, dramatically reduced nutrient impacts to water, and an almost total pathogen kill in the waste stream. A Bion sustainable beef facility will be comprised of covered barns with slotted floors, which allow the waste to pass through and be collected quickly and frequently to reduce ammonia volatilization and loss, as well as odors. Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns represent a very large roof surface area, which will be utilized in appropriate geographical locations for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. Waste treatment and resource recovery will be provided by Bion’s advanced 3G Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.

 

Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small scale livestock producers (largely in the grass fed beef category). The reach and extent of such efforts is limited to date and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ’cow-calf’ segment of the livestock chain) in procurement by major beef processing companies, but a closer look finds that most consist largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.

 

Sustainable Organic Beef

 

Bion believes it has a unique opportunity to produce, at scale, affordable corn-fed organic beef that is certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the 3G Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.

 

10 
 
 

 

Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. Stated directly, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap will put the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.

 

The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.

 

Organic Fertilizer Listing/Certification Process

 

The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“3G Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of organically listed ammonium bicarbonate products. The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020.

 

An application for our first solid ammonium bicarbonate product – AD Nitrogen – was filed during May 2021 and is currently actively proceeding through OMRI’s multi-stage review process ---which process has taken an extended period of time and multiple procedural steps due to the novel nature of Bion’s 3G Tech in the context of organic listings/certifications. OMRI’s Review Panel ‘…. voted to temporarily assign it to “Unresolved” status. This means that OMRI does not currently have the clarity necessary to decide whether the product meets OMRI standards which are based on the USDA National Organic Program regulations (NOP).’ Subsequently the application has gone through ‘Rebuttal’ (OMRI Review Panel) and ‘Appeal’ (Appeals Review Committee) stages which affirmed the “Unresolved” status. The Company has been informed that ‘…the product will remain Unresolved until July 22, 2022 or until resolution is reached by OMRI though consultation with the OMRI Advisory Council.’ The application is now beginning review by OMRI’s Advisory Council. The Company’s product is novel in part due to the fact that OMRI does not have a listing category for a solid form of concentrated and soluble nitrogen fertilizers and there is no clear guidance at present from OMRI internal policy on how to categorize this product and the process that produced it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives are involved in discussions regarding resolution of these matters at all three levels. The Company anticipates positive resolution of this manner well prior to operational dates for the Company’s initial large scale JV 3G projects.

 

 

11 
 
 

 

 3 Tech Kreider 2 Poultry Project

 

Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 3G Tech) for 559,457 nutrient credits under the old EPA’s Chesapeake Bay model. The Company has been in ongoing discussions with the PADEP regarding the appropriate credit calculation methodology for large-scale technology-based nutrient reduction installations such as the KF2 Project utilizing our 3G Tech platform. Based on these discussions and the size of the Kreider 2 Project, we anticipate that if and when designs are finalized, the Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA. Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). A review process to clarify certain issues related to credit calculation and verification commenced during 2014 based on Bion’s 2G Tech but was been placed on hold. The Company anticipates if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our 3G Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s 3G Tech for increased recovery of marketable by-products, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.

 

Note that while Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees related to a ‘sustainable brand’, the Covid-19 pandemic has delayed legislative efforts needed to commence its development. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.

 

Technology Deployment: Bion 3G Tech

 

Widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s 3G Tech has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The 3G Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts (see below and Note 10, “Subsequent Events”). and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion below), and d) payment for verified ecosystem services. The Company’s first patent on its 3G Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s 3G Tech coverage, and the Company has additional applications pending and/or planned.

 

Bion’s business model and technology platform can create the opportunity for JVs (in various contractual forms) between the Company and large livestock/food/fertilizer industry participants, based upon the supplemental cash flow generated by implementation of our 3G Tech business model, which will support the costs of technology implementation (including related debt). We anticipate this will result in long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) may expand to represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

12 
 
 

 

In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits, that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019. However, the Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).

 

The livestock industry and its markets are already changing; with a commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its 3G Tech, during the current 2023 fiscal year. We believe that Bion’s 3G Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.

 

The Livestock Problem

 

The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun - and policies have already begun to change, as well. Bion’s 3G Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21st Century consumer demands for meaningful sustainability.

 

In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.

 

Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.

 

More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition - it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.

 

13 
 
 

 

Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.

 

Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.

 

Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source-- before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture and treat.

 

High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.

 

The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.

 

For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s 3G Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.

 

Going concern and management’s plans:

 

The consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and has incurred net losses (including significant non-cash expenses) of approximately $3,451,000 and $4,553,000 during the years ended June 30, 2021 and 2020, respectively, and a net income of approximately $8,781,000 during the six months ended December 31, 2021. The net income for the six months is due to a one-time, non-cash event of the dissolution of PA-1 and a gain of approximately $10,235,000. There was an operating loss of approximately $1,226,000 for the six months ended December 31, 2021. At December 31, 2021, the Company has working capital and a stockholders’ deficit of approximately $4,006,000 and $912,000, respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.

 

The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.

 

14 
 
 

 

During the years ended June 30, 2021 and 2020, the Company received gross proceeds of approximately $5,209,000 and $1,584,000, respectively, from the sale of its debt and equity securities.

 

During the six months ended December 31, 2021, the Company received total proceeds of approximately $1,737,000 from the sale of its equity securities and paid approximately $18,600 in cash commissions.

 

During fiscal years 2021 and 2020, the Company has faced progressively less difficulty in raising equity funding (but substantial equity dilution has gone along with the larger amounts of equity financing during the periods) than was experienced in the prior 3 years. Note, however, that during the first six months of the current fiscal year, the Company raised equity funds at a rate less than the average rate during fiscal year 2021. The Company anticipates substantial increases in demands for capital and operating expenditures as it moves toward commercial implementation of its 3G Tech and development of JVs and, therefore, is likely to continue to face, significant cash flow management challenges due to limited capital resources and working capital constraints which have only recently begun to be alleviated. To partially mitigate these working capital constraints, the Company’s core senior management and several key employees and consultants have been deferring (and continue to defer) part of their cash compensation and/or are accepting compensation in the form of securities of the Company and/or converting portions of their compensation and deferred compensation to securities of the Company (Notes 5 and 7) and members of the Company’s senior management have made loans to the Company from time to time. During the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to continue its recent success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and curtailment of ongoing activities including research and development activities.

 

The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including the Initial Project, JV Projects, Integrated Projects and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $10,000,000 to $50,000,000 or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us), that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.

 

There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.

 

Covid-19 pandemic related matters:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and are likely to delay and/or increase the cost of construction of the Company’s initial 3G Tech installation if equipment remains difficult to acquire in a timely manner, vi) due to the age and health of our core management team, all of whom are age 70 or older and have had one or more existing health issues, the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

 

15 
 
 

 

2.       SIGNIFICANT ACCOUNTING POLICIES

 

Principles of consolidation:

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc. (“Projects Group”), Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC; and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). The operating loss are included in the consolidation through December 29, 2021.

 

The accompanying consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at December 31, 2021, and the results of operations of the Company for the three and six months ended December 31, 2021 and 2020 and the cash flows of the Company for the six months ended December 31, 2021 and 2020. Operating results for the three and six months ended December 31, 2021 are not necessarily indicative of the results that may be expected for the year ending June 30, 2022.

 

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents.

 

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

 

16 
 
 

 

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

 

17 
 
 

 

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Loss per share:

 

Basic loss per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted loss per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the loss per share or increase the earnings per share. During the three and six months ended December 31, 2021 and 2020, the basic and diluted loss per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

The following table represents the warrants, options and convertible securities excluded from the calculation of basic loss per share:

 

          
   December 31,
2021
   December 31,
2020
 
Warrants   19,726,777    21,270,102 
Options   10,471,600    9,511,600 
Convertible debt   10,673,722    11,215,175 
Convertible preferred stock         19,500 

 

The following is a reconciliation of the denominators of the basic and diluted loss per share computations for the three and six months ended December 31, 2021 and 2020:

 

                    
   Three months
ended
December 31,
2021
   Three months
ended
December 31,
2020
   Six months
ended
December 31,
2021
   Six months
ended
December 31,
2020
 
Shares issued – beginning of period   41,475,573    31,575,656    41,315,986    31,409,005 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)   (704,309)   (704,309)
Shares outstanding – beginning of period   40,771,264    30,871,347    40,611,677    30,704,696 
Weighted average shares issued
    during the period
   317,728    316,298    292,665    285,943 
Diluted weighted average shares –
    end of period
   41,088,992    31,187,645    40,904,342    30,990,639 

 

 

Use of estimates:

 

In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s financial statements properly reflect the change.

 

 

18 
 
 

 

3.  PROPERTY AND EQUIPMENT:

 

Property and equipment consist of the following:

 

          
   December 31,
2021
   June 30,
2021
 
Machinery and equipment  $     $2,222,670 
Buildings and structures         401,470 
Computers and office equipment   11,137    171,485 
3G project construction in process   145,439       
Property and equipment, gross   156,576    2,795,625 
Less accumulated depreciation   (9,681)   (2,795,084)
Property and equipment, net  $146,895   $541 

 

Management has reviewed the remaining property and equipment for impairment as of December 31, 2021 and believes that no impairment exists.

 

Depreciation expense was $332 and $207 for the three months ended December 31, 2021 and 2020, respectively, and $580 and $414 for the six months ended December 31, 2021 and 2020, respectively.

 

On December 29, 2021 Bion PA1 LLC was dissolved which removed all items which were listed under ‘Machinery and equipment’ and Buildings and structures’ plus almost all of the items which were listed under ‘Computers and office equipment’ at June 30, 2021 resulting in the elimination of almost the entire balance of ‘accumulated depreciation’. See Note 5, “LOANS PAYABLE: Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution” below.

4.       DEFERRED COMPENSATION:

The Company owes deferred compensation to various employees, former employees and consultants totaling $477,374 and $998,474 as of December 31, 2021 and 2020, respectively. Included in the deferred compensation balances as of December 31, 2021, are $374,015 and nil owed Dominic Bassani (“Bassani”), the Company’s Chief Executive Officer, and Mark A. Smith (“Smith”), the Company’s President, respectively, pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at 4% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last 10 trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of December 31, 2020 was $307,260 and $71,699, respectively. The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $30,859 and $512,432 as of December 31, 2021 and 2020, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at 3% per annum. The Company also owes a former employee $72,500, which is not convertible and is non-interest bearing.

Bassani and Smith have each been granted the right to convert up to $300,000 of deferred compensation balances at a price of $0.75 per share until December 31, 2022 (to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election.

The Company recorded interest expense of $4,268 ($4,095 with related parties) and $6,693 ($2,950 with related parties) for the three months ended December 31, 2021 and 2020, respectively, and $8,300 ($8,044 with related parties) and $12,476 ($5,159 with related parties) for the six months ended December 31, 2021 and 2020, respectively.

 

19 
 
 

 

5.       LOANS PAYABLE:

 

Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed $10,009,802 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. The terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan is collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $61,722 for both the three months ended December 31, 2021 and 2020, respectively, and $123,444 for both the six months ended December 31, 2021 and 2020, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 has not made any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date.

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment.

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business. PA 1 is prepared to transfer to Pennvest all of PA1’s right, title and interest in its property (by a bill of sale or other acceptable agreement) or alternatively, with Pennvest’s approval and direction, arrange for the sale of its property and deliver all proceeds (net of commissions and customary costs of sale) to Pennvest. PA1 and Pennvest have entered into communication/exchanges to determine how Pennvest would like PA1 to proceed with this process. The Company’s personnel will assist PA1 with this process as needed at no cost to PA1.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA 1 has made no payments to vendors or other creditors in connection with the dissolution. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

20 
 
 

 

Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities will no longer be consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

6.       CONVERTIBLE NOTES PAYABLE - AFFILIATES:

 

2020 Convertible Obligations

 

The 2020 Convertible Obligations, which accrue interest at either 4% per annum or 4% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $0.50 per Unit until July 1, 2024. The warrant contained in the Unit was originally exercisable at $1.00 per unit but was modified to $0.75 during the year ended June 30, 2020 and is exercisable until a date three years after the date of the conversion. During the year ended June 30, 2021, the Company approved the increase of warrants by one-third to be received by the noteholder if a conversion takes place. The original conversion price of $0.50 per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”.

 

As of December 31, 2021, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani (and his donees), Smith and Edward Schafer (“Schafer”), the Company’s Vice Chairman, were $2,550,104, $1,302,049 and $490,197, respectively. As of December 31, 2020, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani, Smith and Schafer were $2,455,656, $1,163,862 and $472,041, respectively.

 

During the six months ended December 31, 2021, Smith elected to add $90,000 of his salary to his 2020 Convertible Obligations.

 

The Company recorded interest expense of $40,864 and $65,468 for the three months ended December 31, 2021 and 2020, respectively. The Company recorded interest expense of $81,424 and $96,428 for the six months ended December 31, 2021 and 2020, respectively.

 

September 2015 Convertible Notes

 

During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani, Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at 4% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.60 per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.

 

The balances of the September 2015 Convertible Notes as of December 31, 2021, including accrued interest owed Bassani, Schafer and Shareholder, are $274,521, $20,517 and $438,198, respectively. The balances of the September 2015 Convertible Notes as of December 31, 2020, including accrued interest, were $168,498, $19,862 and $423,081, respectively.

 

During the six months ended December 31, 2021, Bassani elected to transfer $100,000 from deferred compensation to his 2015 convertible note.

 

The Company recorded interest expense of $5,698 and $5,365 for the three months ended December 31, 2021 and 2020, respectively. The Company recorded interest expense of $11,064 and $10,731 for both the six months ended December 31, 2021 and 2020, respectively.

 

 

21 
 
 

 

7.       STOCKHOLDERS' EQUITY:

 

Series B Preferred stock:

 

Since July 1, 2014, the Company had 200 shares of Series B redeemable convertible Preferred stock outstanding with a par value of $0.01 per share, convertible at the option of the holder at $2.00 per share, with dividends accrued and payable at 2.5% per quarter. The Series B Preferred stock is mandatorily redeemable at $100 per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares have reached their maturity date and the Company approved the redemption of the Series B preferred stock during the quarter ended December 31, 2021. 200 shares of Series B redeemable convertible Preferred stock were redeemed for $41,000, which included the $21,000 in accrued dividend payable.

 

During the years ended June 30, 2021, and 2020, the Company declared dividends of $2,000 and $2,000 respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statement.

 

Common stock:

 

Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.

 

Centerpoint holds 704,309 shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.

 

During the six months ended December 31, 2021, Smith elected to convert accounts payable (based on his unreimbursed expenses) of $17,711 into 35,424 units at $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2024.

During the six months ended December 31, 2021, 2,315,550 warrants were exercised to purchase 2,315,550 shares of the Company’s common stock at $0.75 per share for total proceeds of $1,736,662.

During the six months ended December 31, 2021, the Company issued 66,860 shares of the Company’s common stock to three FINRA brokers as commissions for the warrant exercises. As the issuance was both a reduction and addition to additional paid in capital there was no impact to the financial statements. The Company also paid a FINRA broker $18,601 in commissions for the warrant exercises.

 

 Warrants:

 

As of December 31, 2021, the Company had approximately 19.7 million warrants outstanding, with exercise prices from $0.60 to $1.50 and expiring on various dates through June 30, 2025.

 

The weighted-average exercise price for the outstanding warrants is $0.73, and the weighted-average remaining contractual life as of December 31, 2021 is 2.7 years.

 

During the six months ended December 31, 2021, Smith elected to convert accounts payable of $17,711 into 35,424 units at $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2024.

 

During the six months ended December 31, 2021, the Company approved the issuance of 75,000 warrants for two consultants for consulting services of $7,500. The warrants are exercisable at $1.50 and expire in November 2026.

During the six months ended December 31, 2020, the Company approved the modification of existing warrants held by one former consultants and four investors, which extended certain expiration dates. The modifications resulted in incremental non-cash compensation of $5,625 and interest expenses of $2,712.

During the six months ended December 31, 2021, 2,315,550 warrants were exercised to purchase 2,315,550 shares of the Company’s common stock at $0.75 per share for total proceeds of $1,736,662.

22 
 
 

During the 2021 calendar year, 6,431,538 warrants scheduled to expire on December 31, 2021, in aggregate, were exercised by their holders at an exercise price of $.75 per share of which 2,176,216 warrants were exercised during the quarter ended December 31, 2021. The Company issued, in aggregate, 6,431,538 share of its restricted and legended common stock in connection with these warrant exercises, of which 2,226,216 shares were issued during the quarter ended December 31, 2021. The Company received, in aggregate, $4,823,651 of gross processed from such warrant exercises, of which $1,632,162 was received in the quarter ended December 31, 2021 (these sums do not reflect expenses and commissions related to these warrant exercises). In aggregate, 648,142 warrants expired unexercised on December 31. 2021.

During the six months ended December 31, 2021, the Company issued 66,860 shares of the Company’s common stock to three FINRA brokers as commissions for the warrant exercises. As the issuance was both a reduction and addition to additional paid in capital there was no impact to the financial statements. The Company also paid a FINRA broker $18,601 in commissions for the warrant exercises.

 

Stock options:

 

The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to 36,000,000 shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years.

 

The Company recorded compensation expense related to employee stock options of nil for both the three and six months ended December 31, 2021 and 2020, respectively. The Company granted nil options during both the three and six months ended December 31, 2021 and 2020, respectively.

 

A summary of option activity under the 2006 Plan for the six months ended December 31, 2021 is as follows:

                      
    Options   Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Life
   Aggregate
Intrinsic
Value
 
 Outstanding at July 1, 2021    10,471,600   $0.77    3.7   $6,064,335 
   Granted                       
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at December 31, 2021    10,471,600   $0.77    3.2   $9,624,679 
 Exercisable at December 31, 2021    10,471,600   $0.77    3.2   $9,624,679 

 

The following table presents information relating to nonvested stock options as of December 31, 2021:

 

               
    Options   Weighted Average
Grant-Date Fair
Value
  Nonvested at July 1, 2021          $   
  Granted                
  Vested                
  Nonvested at December 31, 2021          $   

 

 

The total fair value of stock options that vested during both the three and six months ended December 31, 2021 and 2020 was nil. As of December 31, 2021, the Company had no unrecognized compensation cost related to stock options.

 

 

23 
 
 

 

Stock-based employee compensation charges in operating expenses in the Company’s financial statements for the three and six months ended December 31, 2021 and 2020 are as follows:

                    
   Three
months
ended
December 31,
2021
   Three
months
ended
December 31,
2020
   Six months
ended
December 31,
2021
   Six months
ended
December 31,
2020
 
General and administrative:                    
  Change in fair value from modification of
    option terms
  $     $8,775   $     $8,775 
Change in fair value from modification of
    warrant terms
   5,625    25,506    5,625    25,506 
  Fair value of stock options expensed                        
     Total  $5,625   $34,281   $5,625   $34,281 
                     
Research and development:                    
  Fair value of stock options expensed  $     $     $     $   
     Total  $     $     $     $   

 

 

8.       SUBSCRIPTION RECEIVABLE - AFFILIATES:

 

As of December 31, 2021, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $428,250 ($491,975, including interest) from Bassani which were received as consideration for purchases of warrants to purchase 5,565,000 shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $0.75 and have expiry dates ranging from December 31, 2024 to December 31, 2025. The promissory notes bear interest at 4% per annum, and are secured by portions of Bassani’s 2020 Convertible Obligation and Bassani’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.

 

As of December 31, 2021, the Company has an interest bearing, secured promissory note for $30,000 ($34,093 including interest) from Smith as consideration to purchase warrants to purchase 300,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of December 31, 2024. The warrants have a 75% exercise bonus and the promissory note bears interest at 4% per annum, and is secured by $30,000 ($34,093, including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.

As of December 31, 2021, the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $46,400 ($54,088 including interest) from two former employees as consideration to purchase warrants to purchase 928,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.75 and have expiry dates of December 31, 2024. These warrants have a 90% exercise bonus. The promissory notes bear interest at 4% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.

9.       COMMITMENTS AND CONTINGENCIES:

 

Employment and consulting agreements:

 

Smith has held the positions of Director, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month to month contract extension with Smith which includes provisions for i) a monthly salary of $18,000 until the Board of Directors re-instates cash payments to all employees and consultants who are deferring compensation, ii) the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until December 31, 2022), and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis.

 

 

24 
 
 

 

Since March 31, 2005, the Company has had various agreements with Brightcap and/or Bassani, through which the services of Bassani are provided (any reference to Brightcap or Bassani for all purposes are the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017, (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($31,000 per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation. During October 2016 Bassani was granted the right to convert up to $125,000 of his deferred compensation, at his sole election, at $0.75 per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, and subsequently extended until December 31, 2022). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $31,000 per month, which sum would continue to be accrued until the Company there is adequate cash available at which point re-instatement of a least a partial cash payment would be instituted. Additionally, the Company has agreed to pay him $2,000 per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $300,000 from Bassani as consideration to purchase warrants to purchase 3,000,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of December 31, 2021, the principal and accrued interest was $340,093. For the six months ended December 31, 2021 and 2020, Brightcap was paid $120,000 and $55,000, respectively, of cash compensation earned during the period. For the last 2 years, portions of Bassani’s compensation (determined by the Company’s President and the Board of Directors from time to time) has been paid in cash with the balance of his compensation accrued.

 

Execution/exercise bonuses:

 

As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise bonus which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the bonus shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock bonuses, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods have been reduced to $.01 per option or warrant.

 

During the year ended June 30, 2021, the Company added a 75% execution/exercise bonus to the terms of 3,000,000 warrants held by a trust owned by Bassani.

 

As of December 31, 2021, the execution/exercise bonuses ranging from 50-90% were applicable to 10,326,600 of the Company’s outstanding options and 16,778,213 of the Company’s outstanding warrants.

 

Litigation:

 

A: Website

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

 

25 
 
 

 

B: Dissolution of Bion PA1, LLC (“PA1”)

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment.

 

On December 29, 2021, the Company approved and executed a Consent of the Sole Member of Bion PA 1 (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business. PA 1 is prepared to transfer to Pennvest all of PA1’s right, title and interest in its property (by a bill of sale or other acceptable agreement) or alternatively, with Pennvest’s approval and direction, arrange for the sale of its property and deliver all proceeds (net of commissions and customary costs of sale) to Pennvest. PA1 and Pennvest have entered into communication/exchanges to determine how Pennvest would like PA1 to proceed with this process. The Company’s personnel will assist PA1 with this process as needed at no cost to PA1.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA 1 has made no payments to vendors or other creditors in connection with the dissolution. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities will no longer be consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets where nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

 The Company currently is not involved in any other material litigation or similar events.

 

Lease:

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The following table summarized the supplemental cash flow information for the six months ended December 31, 2021:

 

       
    December 31, 2021
Cash paid for noncancelable operating lease included in the operating cash flows   $ 60,000  
Right of use assets obtained in exchange for operating lease liabilities   $ 180,586  

 

 

26 
 
 

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of December 31, 2022:

 

       
From January 2022 to December 2022   $ —    
From January 2023 to December 2023     75,000  
From January 2024 to December 2024     75,000  
Undiscounted cash flow     150,000  
   Less imputed interest     (27,395 )
Total   122,605  

 

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of December 31, 2022 were 3 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

 

10.       SUBSEQUENT EVENTS:

 

The Company has evaluated events that occurred subsequent to December 31, 2021 for recognition and disclosure in the financial statements and notes to the financial statements.

 

On January 26, 2022 OMRI’s Appeals Review Committee affirmed the prior “unresolved’ determination by OMRI’s Review Panel. The OMRI process has now moved to OMRI’s Advisory Council. See Note 1 subsection “Organic Fertilizer Listing/Certification Process” above for related disclosure.

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($665,375)) for the core of the ‘Bion System’ portion (without the crystallization modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete and procurement/fabrication has now been initiated. 3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, etc.) for work related to the Initial Project.

 

The Initial Project is designed to be installed primarily in two targeted primary phases which approach has been adopted to enable more rapid deployment of our 3G technology given pandemic-induced supply chain constraints. The first phase includes procurement and deployment of Bion’s core 3G technology. The modules in this phase include evaporation, distillation, absorption and crystallization modules, along with supporting mechanical/electrical equipment, controls, instrumentation, and facilities, many of which include components with ‘long lead times’ for manufacture and delivery. These items have now been ordered and procurement/manufacturing, as applicable, is underway.  This phase also includes installing a process building to house the system components, full utility installation (electrical, water, internet, natural gas, etc.), tankage to hold process and waste product liquids, facility access, and other items. The second phase, which will require additional permitting, planning and logistics, will consist primarily of design and construction of a 300 head beef cattle feed barn and an anaerobic digester, which items have shorter construction and fabrication/installation lead times than many of the components of the first phase.  The barn will include an innovative slatted floor livestock and an automated manure collection system.  Support structures will include manure collection basins, pumping stations, and automated controls integrated with the 3G system control system. The design and installation for both phases will include adaptive spaces that allow the integration of Initial Project expansions and the refinement of equipment operations that enhance system productivity and reduce energy demand.

 

 

27 
 
 

 

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

 

Statements made in this Form 10-Q that are not historical or current facts, which represent the Company's expectations or beliefs including, but not limited to, statements concerning the Company's operations, performance, financial condition, business strategies, and other information, involve substantial risks and uncertainties. The Company's actual results of operations, most of which are beyond the Company's control, could differ materially. These statements often can be identified by the use of terms such as "may," "will," "expect," "believe," anticipate," "estimate," or "continue" or the negative thereof. We wish to caution readers not to place undue reliance on any such forward looking statements, which speak only as of the date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However, forward looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected.

 

These factors include adverse economic conditions, entry of new and stronger competitors, inadequate capital, unexpected costs, failure (or delay) to gain product certifications and/or regulatory approvals in the United States (or particular states) or foreign countries, loss (permanently or for any extended period of time) of the services of members of the Company’s small core management team (all of whom are age 70 or older) and failure to capitalize upon access to new markets. Additional risks and uncertainties that may affect forward looking statements about Bion's business and prospects include: i) the possibility that markets for nutrient reduction credits (discussed below) and/or other ways to monetize nutrient reductions and other environmental benefits will be slow to develop (or not develop at all), ii) PA1’s dissolution and its effect on how the Company is viewed, (if any), iii) the possibility that competitors will develop more comprehensive and/or less expensive environmental solution, iv) delays in market awareness of Bion and our Systems, v) uncertainties and costs increases related to research and development efforts to update and improve Bion’s technologies and applications thereof, and/or vi) delays and/or costs exceeding expectations relating to Bion's development of the Initial Project, JVs and/or Projects and vii) failure of marketing strategies, each of which could have both immediate and long term material adverse effects by placing us behind our competitors and requiring expenditures of our limited resources.

 

THESE RISKS, UNCERTAINTIES AND FACTORS BEYOND OUR CONTROL ARE MAGNIFIED DURING THE CURRENT UNCERTAIN PERIOD RELATED TO THE COVID-19 PANDEMIC AND THE UNIQUE ECONOMIC, FINANCIAL, GOVERNMENTAL AND HEALTH-RELATED CONDITIONS IN WHICH THE COMPANY, THE ENTIRE COUNTRY AND THE ENTIRE WORLD NOW RESIDE.  TO DATE THE COMPANY HAS EXPERIENCED DIRECT IMPACTS  IN VARIOUS AREAS INCLUDING WITHOUT LIMITATION: I) GOVERNMENT-ORDERED  SHUTDOWNS WHICH HAVE SLOWED THE COMPANY’S RESEARCH AND DEVELOPMENT PROJECTS AND OTHER INITIATIVES, II) SHIFTED FOCUS OF STATE AND FEDERAL GOVERNMENT WHICH IS LIKELY TO NEGATIVELY IMPACT THE COMPANY’S LEGISLATIVE INITIATIVES IN PENNSYLVANIA AND WASHINGTON DC, III) STRAINS AND UNCERTAINTIES IN BOTH THE EQUITY AND DEBT MARKETS HAVE MADE DISCUSSION AND PLANNING OF FUNDING OF THE COMPANY AND ITS INITIATIVES AND PROJECTS WITH INVESTMENT BANKERS, BANKS AND POTENTIAL STRATEGIC PARTNERS MORE TENUOUS, IV) STRAINS AND UNCERTAINTIES IN THE AGRICULTURAL SECTOR AND MARKETS HAVE MADE DISCUSSION AND PLANNING OF FUNDING OF THE COMPANY AND ITS INITIATIVES AND PROJECTS MORE DIFFICULT AS FUTURE INDUSTRY CONDITIONS ARE NOW MORE DIFFICULT TO ASSESS/PREDICT, V) CONSTRAINTS DUE TO PROBLEMS EXPERIENCED IN THE GLOBAL INDUSTRIAL SUPPLY CHAIN WHICH HAVE INCREASED ANTICIPATED PROJECT DEVELOPMENT COSTS, VI) DUE TO THE AGE AND HEALTH OF OUR CORE MANAGEMENT TEAM, ALL OF WHOM ARE AGE 70 OR OLDER AND HAVE HAD ONE OR MORE EXISTING HEALTH ISSUES, THE COVID-19 PANDEMIC PLACES THE COMPANY AT GREATER RISK THAN WAS PREVIOUSLY THE CASE (TO A HIGHER DEGREE THAN WOULD BE THE CASE IF THE COMPANY HAD A LARGER, DEEPER AND/OR YOUNGER CORE MANAGEMENT TEAM), AND VII) THERE ALMOST CERTAINLY WILL BE OTHER UNANTICIPATED CONSEQUENCES FOR THE COMPANY AS A RESULT OF THE CURRENT PANDEMIC EMERGENCY AND ITS AFTERMATH.

 

 

Bion disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

 

The following discussion and analysis should be read in conjunction with the Consolidated Financial Statements and Notes to Consolidated Financial Statements filed with this Report.

 

 

28 
 
 

 

BUSINESS OVERVIEW

 

Our patented and proprietary technology provides economically sustainable comprehensive environmental solutions to one of the greatest water air and water quality problems in the U.S. today: pollution from large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs”).  Application of our technology and technology platform can simultaneously mitigate environmental problems and improve operational/resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream that have traditionally been wasted or underutilized, including renewable energy, nutrients (including ammonia nitrogen and phosphorus) and water.

 

From 2016 to 2021 fiscal years, the Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“3G Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of organic ammonium bicarbonate products. The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. An application for our first solid ammonium bicarbonate product – AD Nitrogen – has been filed and is in the review process (which is likely to require an extended period of time and multiple procedural steps due to the novel nature of Bion’s 3G Tech in the context of organic certifications). See discussion of “Organic Fertilizer Products” below.

 

Bion is now focused primarily on: i) development/construction of its initial commercial-scale 3G Tech installation (see below and Financial Statement Note 10 “Subsequent Events”), ii) developing applications and markets for its organic fertilizer products and its sustainable (conventional and organic) animal protein products, and iii) initiation and development of joint ventures (“JVs”) (and related projects) based on the augmented capabilities of our 3G Tech, while (iv) continuing to pursue development opportunities related to large retrofit projects (such as the Kreider poultry project JV) and ongoing R&D activities. These matters are discussed in more detail in Item 1 of our Form 10-K for the year ended June 30, 2021 and in the Notes to the Financial Statements included herein.

 

The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns ranging including food safety, environmental impacts, and humane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market.

 

The Company believes that its 3G Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a large production/marketing opportunity for Bion. Our 3G Tech will also produce (as co-products) biogas and valuable organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.

 

During the 2021 fiscal year, Bion completed a series of core optimization trials of its 3G Tech platform that were required to move forward with its initial commercial scale 3G Tech project (“Initial Project”). During late September 2021, Bion entered into a lease for the Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana and executed an additional related agreement regarding disposal of certain manure effluent have been agreed upon with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project will be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately 300 head of beef cattle. The facility will include Bion’s 3G Tech platform including: i) covered barns (possibly including solar photovoltaic generation, ii) anaerobic digestion for renewable energy recovery; iii) livestock waste treatment and resource recovery technology; iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion 3G Tech facilities capable of treating the waste from approximately 1,500 head). The facility will be large enough to demonstrate engineering capabilities of Bion’s 3G Tech at commercial scale, but small enough that it can be permitted, constructed and commissioned relatively quickly, with operations targeted to commence sometime during late2022. See Note 10 “Subsequent Events” for activities since the start of the 2022 calendar year.

 

29 
 
 

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners. Specifically, the Initial Project is being developed to provide and/or accomplish the following:

 

  i. Proof of 3G Tech platform scalability

 

  - Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion 3G technology platform.

 

  - Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.

 

  ii. Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.

 

  iii. Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) for commercial testing by potential joint venture partners and/or purchasers and for university growth trials.

 

  iv. Produce sustainable beef products for initial test marketing efforts.

 

Upon achieving optimized and steady-state operations at the Initial Project, coupled with obtaining organic certification(s) (OMRI listing and/or other organic certifications/listings) for its AD Nitrogen product, Bion expects to be ready to move forward with its plans for development of much larger facilities. The Company anticipates that discussions and negotiations regarding potential JVs with strategic partners in the financial and livestock industries to develop large scale projects will commence during the construction of the Initial Project with the goal of establishing JV’s for large scale projects that will produce both sustainable and sustainable-organic corn-fed beef during 2023.

 

Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘3G TECH KREIDER 2 POULTRY PROJECT’ below as an example).

 

We believe that Bion’s 3G Tech platform, coupled with common-sense policy changes to U.S. clean water strategy that are already underway, will combine to provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer.

 

Bion’s business model and technology can open up the opportunity for JVs (in various contractual forms) between the Company and large livestock/food/fertilizer industry participants, based upon the supplemental cash flow generated by implementation our 3G Tech business model (described and discussed below) which will support the costs of technology implementation (including related debt). We anticipate this will result in long term value for Bion. Long term, Bion anticipates that the sustainable branding opportunity may expand to represent the single largest contributor to the economic opportunity provided by Bion.

 

During 2018 the Company had its first patent issued on its 3G Tech and has continued its work to expand its patent coverage for our 3G Tech. During October 2020, the Company the Company’s third 3G patent, which patent significantly expands the breadth and depth of the Company’s 3G Tech coverage. The Company has filed and anticipates filing additional patent applications (and/or continuations of existing patents) related to its technology developments during the next 12 months. The 3G Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas and organic commercial fertilizer products. All processes will be verifiable by third-parties (including regulatory authorities, certifying boards and consumers) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy credits, b) organic certification of the fertilizer coproducts and c) the USDA PVP ‘Environmentally Sustainable’ branding program Bion anticipates moving forward with the development process of its initial large scale commercial installations of its 3G technology during the 2023 calendar year.

 

In parallel, Bion has worked (which work continues) to advance public policy initiatives that will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Competitive procurement of verified credits is now supported by US EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019. However, the Covid-19 pandemic and related financial/budgetary crises have subsequently slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for this and other similar initiatives (see discussion at Item 1 above and below herein).

 

30 
 
 

 

The livestock industry is under tremendous pressure (from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers) to adopt sustainable practices. Environmental cleanup is inevitable - policies are already changing. Bion’s 3G technology was developed for implementation on large scale livestock production facilities, where scale drives lower treatment costs and efficient production of co-products. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the source from which most of the industry’s environmental impacts are initiated. Bion intends to assist the forward-looking segment of the livestock industry in actually bringing animal protein production in line with Twenty-first Century consumer demands for sustainability.

 

Bion’s 3G Tech and technology platform are designed to capture four revenue streams under one umbrella and provide the basis for joint ventures between the Company and larger livestock producers seeking to produce environmental/sustainable product lines. The revenue streams are: a) renewable energy and associated greenhouse gas credits (including US Renewable Fuel Standard (RFS) and/or Low Carbon Fuel Standard (LCFS) credits)(the value and availability of which will vary based on livestock type, geographical locations, and state regulatory programs), b) verified nutrient reductions (primarily nitrogen and phosphorus) that can be used as qualified offsets to the federal Chesapeake Bay mandate and US EPA TMDL (‘total maximum daily limit’) requirements (the value of which will vary based on livestock type, geographical locations, and state regulatory programs), c) co-products consisting of high value fertilizer for use in organic food production for human consumption and/or to grow feed for use by livestock in Projects, and d) an environmentally sustainable USDA certification that will be incorporated into a “brand” that can address the consumer concerns regarding food safety and sustainability (based on incorporation of all of the third party verified data for greenhouse gas reductions, nutrient reductions and fertilizer products into a digital register). The Company believes that the “branding” opportunity will offer large scale livestock producer / processor / distributors of livestock products the opportunity to differentiate and identify their products in the marketplace and, thereby creating the opportunity to achieve “premium pricing” by addressing consumer concerns related to safety and sustainability in a manner similar to the premiums achieved by organic producers.

Operational results from the initial commercial system (Kreider 1 utilizing our 2G Tech) confirmed the ability of Bion’s technologies to meet nutrient reduction goals at commercial scale for an extended period of operation. Bion’s 3G Tech platform (and the new variations under development) center on its patented and proprietary processes that separate and aggregate the various assets in the CAFO waste stream so they become benign, stable and/or transportable. Bion systems can: a) remove up to 95% of the nutrients (primarily nitrogen and phosphorus) in the effluent, b) reduce greenhouse gases by 90% (or more) including elimination of virtually all ammonia emissions, c) while materially reducing pathogens, antibiotics and hormones in the livestock waste stream. Our core technology and its primary CAFO applications were proven in the Kreider 1 commercial operations. It has been accepted by the Environmental Protection Agency (“EPA”) and other regulatory agencies and it is protected by Bion’s portfolio of U.S. and international patents (both issued and applied for).

BION’S 3G TECH PLATFORM PROVIDES THE BASIS FOR A JV BUSINESS MODEL WITH FOUR DISTINCT REVENUE STREAMS: 1) pipeline quality renewable natural gas and related carbon and other environmental credits, 2) premium organic fertilizer products, 3) nutrient credits, and 4) premium pricing from USDA PVP-certified ‘Environmentally Sustainable’ branding at the retail level. Carbon and nutrient credit revenues will be supported by third-party verification of the waste treatment processes that simultaneously capture methane and nutrients, while producing renewable energy and fertilizer products from them with relatively limited incremental cost to Bion. The same verified data will also provide the backbone for the USDA PVP-certified sustainable brand, again with limited incremental cost.

 

1)Renewable energy- and carbon-related credits:

 

Bion’s 3G Tech platform utilizes customized anaerobic digestion (“AD”) to recover biogas (methane) from the waste stream. At sufficient scale, methane produced from AD can be cost-effectively conditioned, compressed and injected into a pipeline. The US Renewable Fuel Standard (“RFS”) program and state programs in California and elsewhere provide ongoing renewable energy credits for the production of biogas and its subsequent use as a renewable transportation fuel. Additional renewable energy-related credit programs are being developed that Bion believes will impact these revenues, including a Carbon Intensity (CI) score that measures the amount of carbon produced per unit of energy produced.

 

2)Organic Fertilizer products:

 

The Company’s initial ammonium bicarbonate liquid product of our 3G Tech completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020 when it was deemed non-synthetic (as discussed below). The 3G Tech platform has been designed to produce multiple fertilizer products, including: i) ammonium bicarbonate liquid, ii) ammonium bicarbonate in solid crystal form – AD Nitrogen – and iii) soil amendment products that will contain the remaining nitrogen, phosphorus and other micronutrients captured from the livestock waste stream. Bion believes each product will qualify for organic certification/listing.

 

 

31 
 
 

 

Bion has developed solid ammonium bicarbonate products containing 14-28 percent nitrogen in a crystalline form that is easily transported, is water soluble and provides a readily available nitrogen source for crops. The products will contain virtually none of the other salt, iron and mineral constituents of the livestock waste stream that often accompany other organic fertilizers. Ammonium bicarbonate (manufactured using chemical processes) has a long history of use as a fertilizer. This product (produced without the use of synthetic processes and/or additives), is being developed to fertilizer industry standards so that it that can be precision-applied to crops using existing equipment. Bion believes that this product will potentially have broad applications in the production of organic grains for livestock feed, row crops, horticulture, greenhouse and hydroponic production, and potentially retail lawn and garden products.

 

An application for our first solid ammonium bicarbonate product – AD Nitrogen – was filed during May 2021 and is currently actively proceeding through OMRI’s multi-stage review process ---which process has taken an extended period of time and multiple procedural steps due to the novel nature of Bion’s 3G Tech in the context of organic listings/certifications. OMRI’s Review Panel ‘…. voted to temporarily assign it to “Unresolved” status. This means that OMRI does not currently have the clarity necessary to decide whether the product meets OMRI standards which are based on the USDA National Organic Program regulations (NOP).’ Subsequently the application has gone through ‘Rebuttal’ (OMRI Review Panel) and ‘Appeal’ (Appeals Review Committee) stages which affirmed the “Unresolved” status. The Company has been informed that ‘…the product will remain Unresolved until July 22, 2022 or until resolution is reached by OMRI though consultation with the OMRI Advisory Council.’ The application is now beginning review by OMRI’s Advisory Council. The Company’s product is novel in part due to the fact that OMRI does not have a listing category for a solid form of concentrated and soluble nitrogen fertilizers and there is no clear guidance at present from OMRI internal policy on how to categorize this product and the process that produced it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives are involved in discussions regarding resolution of these matters at all three levels. The Company anticipates positive resolution of this manner well prior to operational dates for the Company’s initial large scale JV 3G projects.

 

In addition to the OMRI applications discussed above, the Company has engaged in discussions with (and research related to) other state/regional listing/certifying groups and anticipates filing additional applications in subsequent periods with one or more such entities related to its fertilizer products.

 

The AD Nitrogen and other ammonium bicarbonate products produced by Bion’s 3G Tech platform will enjoy a dramatically lower carbon footprint than synthetic fertilizers. The reactive nitrogen captured and upcycled into AD Nitrogen was going to be lost through volatilization and runoff, and that loss would generally need to be offset with a synthetic nitrogen, such as anhydrous ammonia or urea. These synthetic nitrogen products are produced through the Haber-Bosch (and other) synthetic processes, which converts hydrogen and atmospheric nitrogen to ammonia, with methane as the energy source. It is an extremely energy-intensive process with a carbon footprint that, while not yet fully understood, is widely accepted to by very large. While a complete Life Cycle Analysis (LCA) of carbon impacts from synthetic fertilizer production is not available, according to the Institute for Industrial Productivity, its production alone is responsible for approximately 1 percent of total global CO2 emissions. To the extent that Bion can capture and repurpose the nitrogen traditionally lost from livestock waste, that carbon cost will no longer need to be paid

 

To provide a first level degree of clarity regarding organic approvals and the processes/procedures involved, Bion believes that the initial OMRI approval is of importance, because subsequent organic products that are produced by using the very same technology platform (our 3G Tech) can now piggyback on the initial approval to a significant degree. Note that there are different layers to the U.S. organic program (see discussion above) and that fertilizers do not get ‘certified’ as organic, per se. Rather, they are evaluated to determine if they are acceptable for ‘use in organic production’.

 

The National Organic Program (“NOP”) was established by Congress in 2001 under the USDA’s Agricultural Marketing Service. The NOP develops and enforces uniform national standards for organically-produced agricultural end products – meat/dairy/milk, fruits, vegetables – sold in the United States. Operating as a public-private partnership, NOP accredits private companies and helps train their inspectors (USDA-accredited Certifiers) to certify that farms and businesses meet the national organic standards. For example, in a potential Midwest organic beef project (discussed below), each element in the supply chain must provide their certifying agent’s certification that the specific product, such as organic corn, has been produced in accordance with their organic plan. The end product - the beef - would be USDA-certified as organic by an accredited Certifier after a review of ALL the farming practices and inputs (which would include Bion’s ammonium bicarbonate fertilizer).

 

OMRI is a nonprofit organization that provides an independent review of products, such as fertilizers, pest controls, livestock health care products, and numerous other inputs that are intended for use in certified organic production and processing. OMRI reviews these products against the organic standards established by the NOP to determine if they are suitable for use in organic production. Acceptable products are then OMRI Listed®.

 

32 
 
 

 

OMRI enables a national listing through one application in contrast to state/regional programs (including programs based in California, Oregon, Washington, Iowa, Pennsylvania (some of which have agreements with other states in their regions) and others) and the alternative of using certifiers to secure listings in individual states. To those who wish to sell organic fertilizers into national distribution channels, an OMRI listing provides nearly uniform acceptance in the U.S. The OMRI listing Bion received in May was for our initial commercial product, a low-concentration liquid ammonia. It is valid ONLY for that particular product. For future Bion product offerings using the same technology platform, Bion will either need to file for specific state approval, or file with OMRI for a national listing, or a combination of the two. Bion may elect to use an individual state listing initially to be followed by an OMRI application if and when the need for a regional or national listing arises.

The overarching standard of organic production, per NOP guidelines, is that a “product shall have been produced and handled without the use of synthetic chemicals…” That is rule Number One. At NOP, the term "synthetic" means “a substance that is formulated or manufactured by a chemical process or by a process that chemically changes a substance extracted from naturally occurring plant, animal, or mineral sources, except that such term shall not apply to substances created by naturally occurring biological processes.” In evaluating and approving Bion’s liquid ammonia for OMRI listing, Bion’s patented ammonia recovery system was deemed not synthetic. That is an important distinction for future Bion product filings based upon the same patented process.

 

The Company believes that organic approvals for its products will: a) provide access to substantially higher value markets compared to synthetic nitrogen products, and/or b) allow its products to be utilized in growing of organic feed grains to be consumed by livestock raised in JVs which will be sold as organic. Based on preliminary market surveys to date, we believe that existing competing organic fertilizer products in both liquid and granular form are being sold presently at price points significantly greater than Bion’s projected cost and projected pricing. We also believe that livestock products from animals raised with feed grains grown using Bion organic ammonium bicarbonate fertilizer products (and that otherwise qualify) will receive organic approvals. It is anticipated that the Company will continue to seek approvals for such products during the balance of the current fiscal year and will commence initial production and test marketing of such products during the 2023 fiscal year if such approvals have been received.

 

3)Nutrient credits:

 

Bion believes that nutrient reduction (and other similar) credits and/or other methods of monetizing environmental benefits from the capture and re-purposing of the nutrients (largely nitrogen and phosphorus) from the livestock waste stream, will become available in multiple states over the next several years. The passage in the Pennsylvania (“PA”) Senate of key legislation – SB 575 – in June 2019 that would have established a competitively-bid market for nutrient credits in PA, is indicative of the trends. Despite the fact that the bill was not considered in the House, due to the Covid-19 pandemic (a re-introduced bill will have to be considered again in the current and/or future sessions (currently SB 475 and SB 832 have been introduced and are pending), Bion anticipates that after passage of a similar bill in the future, PA will establish a competitively-bid market for nutrient credits within twelve months after legislative passage and being signed into law by the Governor. See below for discussion of the history and status of matters in PA.

 

Note, however, that the current Covid-19 pandemic and resultant social and economic crises and budgetary constraints have delayed policy initiatives related to these matters at both the state and federal levels. As a result, it is not currently possible to reasonably project a timetable for adoption of the policy changes discussed herein.

 

4)Sustainable Branding:

 

Consumers have demonstrated a willingness to pay a premium for their safe and sustainable food choices. Based on Bion’s recognition of the potential opportunities created by such willingness, beginning in 2015, Bion has worked with the USDA’s Process Verified Program (“PVP”) – the gold standard in food verification and branding – to establish a USDA PVP-certified sustainable brand. Bion received conditional approval from the PVP related to its Kreider 1 project (utilizing 2G Tech). It is our intention to submit an application for the 3G Tech platform when the initial 3G Tech Project is operational later this fiscal year and seek an approval for certification based on third-party-verified reductions in nutrient impacts, greenhouse gases and pathogens in the waste stream (and other attributes), based on our 3G Tech. PVP certification incorporated as part of a recognizable brand will provide consumers with products and brands that can be trusted. Bion believes that such a brand and livestock product line will command a pricing premium for Bion’s livestock JVs and their customers.

 

33 
 
 

 

Food safety and sustainability are issues of growing importance in the U.S. and worldwide. Bion’s branding initiative reflects trends already underway in the livestock industry. Driven by growing consumer demand, large food retailers (such as Walmart and Costco) and restaurant chains (including Chipotle and McDonalds) are increasingly demanding greater responsibility and improved sustainability in food production practices from their suppliers. The Global Roundtable for Sustainable Beef (“Roundtable”) was created to advance a sustainable global beef value chain that is “environmentally sound, socially responsible and economically viable”. The Roundtable represents members from across the supply chain, including U.S., Canadian and Australian cattlemen’s associations, Cargill, JBS, Elanco, McDonalds and A&W.

 

Large institutional investors have begun to pressure the livestock industry. Ceres and several other large activist institutional investors have already expressed concerns about carbon footprint, water quality, antibiotic usage and animal welfare in letters to management of their investment holdings in the food production industry. The Collier Farm Animal Investment Risk & Return (“FAIRR”) Initiative was recently launched to highlight the environmental, social, and governance (“ESG”) risks associated with large-scale livestock production.

 

In past years, the UN FAO has issued several highly critical reports of the livestock industry, more recently focused on its impacts on climate change. While some of their early reports were based on incomplete data and faulty methodologies and have since been somewhat quietly ‘retracted’, a wide array of activist groups, including climate, animal rights, and anti-factory farming advocates, have seized on them to create a global “anti-meat” messaging campaign. Their messaging is predicated on the (incorrect) notion that agriculture, and the livestock sector specifically, is the largest contributor to climate change, greater than the energy and transportation sectors. While this fact has been publicly ‘debunked’, the anti-meat campaign has been joined and amplified by various other stakeholders, governments, and more recently, competitors in the alternative protein space, such as plant-based and cellular meats.

 

Over the last few years, most large meat and dairy product retailers have announced ‘sustainability’ initiatives, although the definition of sustainability is often unclear. Based on recent statements from the industry regarding sustainability policy, many that identify goals that are 10 to 30 years in the future, Bion believes that sustainability on the production side will look a lot like what the Company’s 3G Tech platform can provide today. The 3G Tech platform can deliver verifiable metrics that demonstrate meaningful improvements in sustainability for livestock production that are unmatched in the industry today, including a dramatically reduced carbon and nutrient footprint; lower negative impacts to water, soil and air; increased pathogen destruction; and other environmental and public health impacts. The Covid-19 pandemic has further heightened consumer awareness and concerns related to a) environmental sustainability, b) food safety, c) sourcing and traceability and d) humane treatment of both animals and workers.

 

Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass fed beef category) The extent and reach of such efforts is limited to date and it is difficult to determine its effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ’cow-calf’ segment of the livestock chain) by major beef processing companies, but a closer look finds that most consist largely of ‘green washing’ public proclamations in the wake of environmental and social criticism and re-packaging of prior initiatives lacking any new substance.

 

The more the livestock industry’s supply chain practices become transparent and known by consumers, the more consumers are seeking alternatives. Bion’s ‘Sustainable’ branding program is designed to address a wide array of consumer concerns ranging from: a) ‘where does your food come from?’ (animal heritage information); b) environmental impacts; c) antibiotic use/ standards; d) animal welfare/ humane treatment; e) laborer welfare/ working conditions. These issues can be addressed with the consumer through general advertising and/or at the point of sale with a QR code on the packaging that links back to product-specific data. The verification processes that will be employed by Bion’s 3G Tech platform support block chain traceability, providing accountability throughout that part of the supply chain addressed by Bion’s platform and enabling any quality issues to be quickly identified by lot and location, minimizing risk to its consumers. In essence, Bion’s comprehensive technology platform will enable its livestock JVs and other adopters to be not only the provider of the product the consumer wants, but also the businesses that shares their consumers’ values.

 

34 
 
 

 

KREIDER 1 (HISTORY AND STATUS)/DISSOLUTION OF BION PA 1 LLC (‘PA1”)

During 2008 the Company commenced actively pursuing the opportunity presented by environmental retrofit and remediation of the waste streams of existing CAFOs which effort has met with very limited success to date. The first commercial activity in this area is represented by our agreement with Kreider Farms (“KF”), pursuant to which the Kreider 1 system to treat KF's dairy waste streams to reduce nutrient releases to the environment while generating marketable nutrient credits and renewable energy was designed, constructed and entered full-scale operation during 2011. On January 26, 2009 the Board of the Pennsylvania Infrastructure Investment Authority (“Pennvest”) approved a $7.75 million loan to Bion PA 1, LLC (“PA1”), a wholly-owned subsidiary of the Company, for the initial Kreider Farms project (“Kreider 1 System”). The terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan is collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined.

After substantial unanticipated delays, on August 12, 2010 PA1 received a permit for construction of the Kreider 1 System based our 2G Tech (which the Company is no longer implementing). Construction activities commenced during November 2010. The closing/settlement of the Pennvest Loan took place on November 3, 2010. PA1 finished the construction of the Kreider 1 System and entered a period of system ‘operational shakedown’ during May 2011. The Kreider 1 System reached full, stabilized operation by the end of the 2012 fiscal year. During 2011 the PADEP re-certified the nutrient credits for this project. The PADEP issued final permits for the Kreider 1 System (including the credit verification plan) on August 1, 2012 on which date the Company deemed that the Kreider 1 System was ‘placed in service’. As a result, PA1 commenced generating nutrient reduction credits for potential sale while continuing to utilize the Kreider 1 System to test improvements and add-ons. However, liquidity in the Pennsylvania nutrient credit market failed to develop significant breadth and depth, which limited liquidity/depth has negatively impacted Bion’s business plans and has resulted in insurmountable challenges to monetizing the nutrient reductions created by PA1’s existing Kreider 1 project (and Bion’s other proposed projects in the state). These difficulties prevented PA1 from generating any material revenues from the Kreider 1 project. PA1 had sporadic discussions/negotiations with Pennvest related to forbearance and/or re-structuring its obligations pursuant to the Pennvest Loan for more than 7 years. In the context of such discussions/negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the Company has not made any principal payments, which were to begin in fiscal 2013, and, therefore, the Company has classified the Pennvest Loan as a current liability as of December 31, 2021. Due to the failure of the Pennsylvania nutrient reduction credit market to develop, the Company determined that the carrying amount of the property and equipment related to the Kreider 1 project exceeded its estimated future undiscounted cash flows based on certain assumptions regarding timing, level and probability of revenues from sales of nutrient reduction credits and, therefore, PA1 and the Company recorded impairments related to the value of the Kreider 1 assets of $1,750,000 and $2,000,000 at June 30, 2015 and June 30, 2014, respectively. During the 2016 fiscal year, PA1 and the Company recorded an impairment of $1,684,562 to the value of the Kreider 1 assets which reduced the value on the Company’s books to zero. This impairment reflects management’s judgment that the salvage value of the Kreider 1 assets roughly equaled PA1’s contractual obligations related to the Kreider 1 System, including expenses related to decommissioning of the Kreider 1 System.

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 System met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents.

The economics (potential revenues, profitability and continued operation) of the Kreider 1 System were based almost entirely on the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. See below for further discussion.

On September 25, 2014, Pennvest exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment.

 

35 
 
 

 

On December 29, 2021, the Company approved and executed a Consent of the Sole Member of Bion PA 1 (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business. PA 1 is prepared to transfer to Pennvest all of PA1’s right, title and interest in its property (by a bill of sale or other acceptable agreement) or alternatively, with Pennvest’s approval and direction, arrange for the sale of its property and deliver all proceeds (net of commissions and customary costs of sale) to Pennvest. PA1 and Pennvest have entered into communication/exchanges to determine how Pennvest would like PA1 to proceed with this process. The Company’s personnel will assist PA1 with this process as needed at no cost to PA1.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA 1 has made no payments to vendors or other creditors in connection with the dissolution. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities will no longer be consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,502 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

The Company has incurred interest expense related to the Pennvest Loan of $61,722 for both the three months ended December 31, 2021 and 2020, respectively, and $123,444 for both the six months ended December 31, 2021 and 2020, respectively.

 

SUSTAINABLE/ORGANIC GRAIN-FINISHED BEEF JV OPPORTUNITY

 

The Company believes that its 3G Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of: i) verifiably sustainable-branded livestock products and ii) verifiably sustainable organic-branded livestock products that will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a large production/marketing opportunity for Bion. Our 3G Tech platform will also produce revenues from co-products: i) pipeline quality biogas (and related environmental credits) and ii) valuable organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market. These matters are discussed in more detail in Item 1 of our Form 10-K for the year ended June 30, 2021 and in the Notes to the Financial Statements included herein.

 

36 
 
 

 

3G TECH KREIDER 2 POULTRY PROJECT

 

Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 3G Tech) for 559,457 nutrient credits under the old EPA’s Chesapeake Bay model. The Company has been in ongoing discussions with the PADEP regarding the appropriate credit calculation methodology for large-scale technology-based nutrient reduction installations such as the KF2 Project utilizing our 3G Tech platform. Based on these discussions and the size of the Kreider 2 Project, we anticipate that when designs are finalized, the Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the Company’s subsequent amended application during the current fiscal year pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA. Note that this Project may be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). A review process to clarify certain issues related to credit calculation and verification commenced during 2014 based on Bion’s 2G Tech but was been placed on hold. The Company anticipates if and when PA2 re-commences work on the Kreider 2 Project, it will submit an amended or new application based on our 3G Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during then following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s 3G Tech for increased recovery of marketable by-products, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.

 

Note that while Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees related to a ‘sustainable brand’ the Covid-19 pandemic has delayed legislative efforts needed to commence its development. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.

 

PUBLIC POLICY INITIATIVES

 

A substantial portion of our activities involve public policy initiatives (by the Company and other stakeholders) to encourage the establishment of appropriate public policies and regulations (at federal, regional, state and local levels) to facilitate cost effective environmental clean-up and, thereby, support our business activities. Bion has been joined by National Milk Producers Federation, Land O’Lakes, JBS and other national livestock interests to support changes to our nation’s clean water strategy that will allow states to acquire low-cost nutrient reductions through a competitive procurement process, in a similar manner to how government entities now acquire many other goods and services on behalf of the taxpayer. As developing markets for nutrient reductions become fully-established, Bion anticipates a robust business opportunity to retrofit existing CAFOs and develop Projects, based primarily on the sale of nutrient credits that provide cost-effective alternatives to today’s high-cost and failing clean water strategy.

 

37 
 
 

 

To date the market for long-term nutrient reduction credits in Pennsylvania (‘PA’) has been very slow to develop and the Company’s activities have been negatively affected by such lack of development. However, Bion is confident that once these markets are established, the credits it produces will be competitive in the credit trading markets, based on its cost to remove nitrogen from the livestock waste stream, compared to the cost to remove nitrogen through various other treatment activities.

 

Several independent studies have calculated the average cost to remove nitrogen through various sector practices. Reports prepared for the PA Senate (2008), Chesapeake Bay Commission (2012) and PA legislature (2013; described below), as well as the Maryland Chesapeake Bay Financing Strategy Report (2015), demonstrate that the cost to remove nitrogen (per pound on average) from agriculture is $44 to $54, municipal wastewater: $28 to $43, and storm water: $386 to $633. Pursuant to the PA legislative Report, by replacing sector allocation (for all sectors) with competitive bidding, up to 80 percent savings could be achieved in PA’s Chesapeake Bay compliance costs ($1.5 billion annually) by 2025. If the legislative study had focused on the cost differentials of competitive bidding compared only with storm water, the relative savings would be substantially greater.

 

Since these studies were completed, most of the larger (Tier 1) municipal wastewater treatment plants in PA have been upgraded, at a cost of approximately $2.5 billion (vs initial 2004 PA DEP cost estimates of $376 million). US EPA is now focused on PA’s storm water allocation (3.5 million pounds (per last published data)) and has this sector on ‘backstop level actions’, the highest level of EPA-oversight and the final step before sanctions. In the same 2004 PA DEP cost estimate that led to the more than a $2 billion underestimate/miscalculation in municipal wastewater plant upgrade costs, the estimate for storm water cost was $5.6 billion. In April 2017, US EPA sent a Letter of Expectation to PA DEP, expressing the agency’s support for the use of nutrient credit trading and competitive bidding to engage the private-sector to lower costs. The letter specifically encouraged the use of credit trading to offset the state’s looming storm water obligations.

 

The Company believes that: i) the April 2015 release of a report from the Pennsylvania Auditor General titled “Special Report on the Importance of Meeting Pennsylvania’s Chesapeake Bay Nutrient Reduction Targets” which highlighted the economic consequences of EPA-imposed sanctions if the state fails to meet the 2017 TMDL targets, as well as the need to support using low-cost solutions and technologies as alternatives to higher-cost public infrastructure projects, where possible, and ii) Senate Bill 575 (introduced in April 2019 as successor to prior SB 799 (which was passed by PA Senate during January 2018 but was not voted on in the House)) which, if adopted, will establish a program that will allow the Pennsylvania’s tax- and rate-payers to meet significant portions of their EPA-mandated Chesapeake Bay pollution reductions at significantly lower cost by purchasing verified reductions (by competitive bidding) from all sources, including those that Bion can produce through livestock waste treatment, represent visible evidence of progress being made on these matters in Pennsylvania. SB 575 was passed by the PA Senate in 2019 and introduced in the PA House which is scheduled to be taken up the bill during its current session which is now underway. Such legislation (which has bi-partisan support), if passed and signed into law (of which there is no assurance), will potentially enable Bion (and others) to compete for public funding on an equal basis with subsidized agricultural ‘best management practices’ and public works and storm water authorities. Note, however, that there is opposition to currently filed SB 475 and SB832 (as was the case for SB 575 and its predecessors) from threatened stakeholders committed to the existing status quo approaches--- a significant portion of which was focused on attacking (in often inaccurate and/or vilifying ways) Bion in/through social media and internet articles, blogs, press releases, twitter posts and re-tweets, rather than engaging the substantive issues. Further note that the current COVID-19 crisis has shifted government, legislative and budget focuses in PA in manners which may delay our efforts. If SB 475 and/or SB832 (or similar legislation) is passed (on a stand-alone basis or as part of a larger piece of legislation) and implemented (in a form which maintains its core provisions), Bion expects that the policies and strategies being developed in PA will not only benefit the Company’s existing and proposed PA projects, but will also subsequently provide the basis for a larger Chesapeake Bay watershed strategy and, thereafter, a national clean water strategy.

 

THE COVID-19 PANDEMIC HAS FURTHER INCREASED UNCERTAINTIES RE SB 575 AND ALL POLICY INITIATIVES. SEE FURTHER DISCUSSION HEREIN.

 

The Company believes that Pennsylvania may be ‘ground zero’ in the long-standing clean water battle between agriculture and the further regulation of agriculture relative to nutrient impacts. The ability of Bion and other technology providers to achieve verified reductions from agricultural non-point sources can resolve the current stalemate and enable implementation of constructive solutions that benefit all stakeholders, providing a mechanism that ensures that taxpayer funds will be used to achieve the most beneficial result at the lowest cost, regardless of source. All sources, point and non-point, rural and urban, will be able to compete for tax payer-funded nitrogen reductions in a fair and transparent process; and since payment from the tax and rate payers would now be performance-based, these providers will be held financially accountable.

 

38 
 
 

 

We believe that the overwhelming environmental, economic, quality of life and public health benefits to all stakeholders in the watershed, both within and outside of Pennsylvania, make the case for adoption of the strategies outlined in the Report less an issue of ‘if’, but of ‘when and how’. The adoption of a competitive procurement program will have significant positive impact on technology providers that can deliver verified nitrogen reductions such as Bion, by allocating existing tax- and rate-payer clean water funding to low-cost solutions based upon a voluntary and transparent procurement process. The Company believes that implementation of a competitively-bid nutrient reduction program to achieve the goals for the Chesapeake Bay watershed can also provide a working policy model and platform for other states to adopt that will enhance their efforts to comply with both current and future requirements for local and federal estuarine watersheds, including the Mississippi River/Gulf of Mexico, the Great Lakes Basin and other nutrient-impaired watersheds. (Note, however, that current COVID-19 crisis has shifted government, legislative and budget focuses in manners which may delay the fruition of our efforts.)

 

The Company currently anticipates that a Sustainable/Sustainable Organic Grain-Fed Beef JV is likely to be its initial full-scale 3G Project (but the Kreider 2 poultry JV in PA remains a possibility). Now that Bion has commenced development of its initial project 3G Tech by leasing land, beginning the site-specific design and permitting processes and commenced procurement of project modules, we believe it will be possible to commence development of a full-scale 3G Project during the 2023 calendar year, but further delays are possible. It is not possible at this time to firmly predict where the initial JVs and Project will be developed or the order in which Projects will be developed. All potential Projects are in very early discussion and pre-development stages and may never progress to actual development or may be developed after other Projects not yet under active consideration.

 

Bion also hopes to be able to move forward on multiple JVs/Projects through 2023-2027 to create a pipeline of Projects. Management has a 5-year development target (through calendar year 2027) of approximately commencing 3-8 or more JVs/Projects pursuant to joint ventures (or similar agreements). Management hopes to have identified and begun development work related to 3 (or more) JV Projects over the next 3 years. At the end of the 5-year period, Bion projects that 3-5 or more of these JVs/Projects will be in commercial operation in 3 or more states, and the balance would be in various stages ranging from partial operation to early development stage. It is possible that one or more Projects will be developed in joint ventures specifically targeted to meet the growing animal protein demand outside of the United States (including without limitation Asia, Europe and/or the Middle East). No such large scale JVs/Projects (including Integrated Projects) have been developed to date.

The Company’s audited financial statements for the years ended June 30, 2021 and 2020 were prepared assuming the Company will continue as a going concern. The Company has incurred net losses of approximately $3,451,000 and $4,553,000 during the years ended June 30, 2021 and 2020, respectively. The Report of the Independent Registered Public Accounting Firm on the Company’s consolidated financial statements as of and for the year ended June 30, 2021 includes a “going concern” explanatory paragraph which means that there are factors that raise substantial doubt about the Company’s ability to continue as a going concern. The Company has incurred net losses from operations of approximately $673,000 and $447,000 for the three months ended December 31, 2021 and 2020, respectively. At December 31, 2021, the Company has working capital and a stockholders’ deficit of approximately $4,006,000 and $912,000, respectively. Management’s plans with respect to these matters are described in this section and in our consolidated financial statements (and notes thereto), and this material does not include any adjustments that might result from the outcome of this uncertainty. However, there is no guarantee that we will be able to raise sufficient funds or further capital for the operations planned in the near future.

COVID-19 PANDEMIC RELATED MATTERS:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and are likely to delay and/or increase the cost of construction of the initial 3G Tech installation as equipment remains difficult to acquire/fabricate in a timely manner and labor shortages slow the production processes, vi) due to the age and health of our core management team, all of whom are age 70 or older and have had one or more existing health issues, the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

 

39 
 
 

 

CRITICAL ACCOUNTING POLICIES

 

Revenue Recognition

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of Accounting Standards Codification (“ASC”) 606 “Revenue from Contracts with Customers”.

Stock-based compensation

 

The Company follows the provisions of ASC 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of income based upon their grant date fair values.

 

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

THREE MONTHS ENDED DECEMBER 31, 2021 COMPARED TO THE THREE MONTHS ENDED DECEMBER 31, 2020

Revenue

Total revenues were nil for both the three months ended December 31, 2021 and 2020, respectively.

General and Administrative

Total general and administrative expenses were $618,000 and $292,000 for the three months ended December 31, 2021 and 2020, respectively.

40 
 
 

 

General and administrative expenses, excluding stock-based compensation charges of $13,000 and $34,000, were $605,000 and $258,000 for the three months ended December 31, 2021 and 2020, respectively, representing a $347,000 increase. Salaries and related payroll tax expenses were $110,000 and $75,000 for the three months ended December 31, 2021 and 2020, respectively, representing a $35,000 increase due to a consultant being partially paid as an employee and a pay increase for employees during the three months ended December 31, 2021. Consulting costs were $188,000 and $95,000 for the three months ended December 31, 2021 and 2020, respectively. The $93,000 increase in consulting costs is the result of hiring a branding and marketing consultant for the Company. Investor relations expenses were $89,000 and $9,000 for the three months ended December 31, 2021 and 2020, respectively, and the increase is due to a new contract with an investor relations firm and increased activity during the three months ended December 31, 2021 due to the resumption of investor conferences. Legal costs were $121,000 and nil for the three months ended September 30, 2021 and 2020, respectively, due to the hiring of a law firm to represent the Company in a lawsuit for the hack and attempt to steal the Company’s domain, engaging a law firm on the dissolution of PA-1, legal work in relation to corporate structure matters and preparation for the 2022 shareholder meeting and other matters.

General and administrative stock-based employee compensation for the three months ended December 31, 2021 and 2020 consists of the following:

   Three months
ended
December 31,
2021
   Three months
ended
December 31,
2020
 
General and administrative:          
  Change in fair value from modification of option terms  $—     $9,000 
  Change in fair value from modification of warrant terms   6,000    25,000 
  Fair value of stock options expensed under ASC 718   —      —   
      Total  $6,000   $34,000 

 

Stock-based compensation charges were $13,000 and $34,000 for the three months ended December 31, 2021 and 2020, respectively. The fair value of stock options expensed for the three months ended December 31, 2021 and 2020 was nil for both periods, respectively. The Company granted no options during the three months ended December 31, 2021 and 2020. Compensation expense relating to the change in fair value from the modification of option terms was nil and $9,000 the three months ended December 31, 2021 and 2020, respectively, as the Company granted an extension of certain option expiration dates for two consultants during the three months ended December 31, 2020. During the three months ended December 31, 2021 and 2020, respectively, the Company extended expiration dates of warrants for certain consultants and issued additional warrants to certain consultants which resulted in the recognition of $13,000 and $25,000 in non-cash compensation.

Depreciation

Total depreciation expense was $332 and $207 for the three months ended December 31, 2021 and 2020, respectively.

Research and Development

Total research and development expenses were $54,000 and $155,000 for the three months ended December 31, 2021 and 2020, respectively.

Salaries and related payroll tax expenses were nil and $22,000 for the three months ended December 31, 2021 and 2020, respectively as more salary expense was allocated to administrative expense for the three months ended December 31, 2021. Consulting costs were $35,000 and $54,000 for the three months ended December 31, 2021 and 2020, respectively.  The Company also incurred $19,000 and nil for the three months ended December 31, 2021 and 2020, respectively in legal costs related to patent applications and renewals. The Company incurred nil and $67,000 for the three months ended December 31, 2021 and 2020, respectively in the development of new technologies for its anaerobic digestate process.

 Loss from Operations

As a result of the factors described above, the loss from operations was $673,000 and $447,000 for the three months ended December 31, 2021 and 2020, respectively.

Other (Income) Expense

Other (income) expense was $(10,117,000) and $303,000 for the three months ended December 31, 2021 and 2020, respectively. The Company recognized a gain on the legal dissolution of PA-1 of $10,235,000. Interest expense of $3,000 and $163,000 was recorded during the three months ended December 31, 2021 and 2020, respectively, for the modification of warrant expiry dates for 108,500 and 3,244,110 warrants held by investors. Interest expense related to deferred compensation and convertible notes was $51,000 and $78,000 for the three months ended December 31, 2021 and 2020.

Net Loss Attributable to the Noncontrolling Interest

The net loss attributable to the noncontrolling interest was $489 and $524 for the three months ended December 31, 2021 and 2020, respectively.

41 
 
 

Net Loss Attributable to Bion’s Common Stockholders

As a result of the factors described above, the net (income) loss attributable to Bion’s stockholders was $(9,444,000) and $750,000 for the three months ended December 31, 2021 and 2020, respectively, and the net (income) loss per basic common share was $(.23) and $0.02 for the three months ended December 31, 2021 and 2020, respectively.

SIX MONTHS ENDED DECEMBER 31, 2021 COMPARED TO THE SIX MONTHS ENDED DECEMBER 31, 2020

Revenue

Total revenues were nil for both the six months ended December 31, 2021 and 2020, respectively.

General and Administrative

Total general and administrative expenses were $1,109,000 and $595,000 for the six months ended December 31, 2021 and 2020, respectively.

General and administrative expenses, excluding stock-based compensation charges of $13,000 and $34,000, were $1,042,000 and $561,000 for the six months ended December 31, 2021 and 2020, respectively, representing a $481,000 increase. Salaries and related payroll tax expenses were $207,000 and $144,000 for the six months ended December 31, 2021 and 2020, respectively, representing a $63,000 increase due to a consultant being partially paid as an employee during the six months ended December 31, 2020. Consulting costs were $340,000 and $191,000 for the six months ended December 31, 2021 and 2020, respectively. The increase in consulting costs is partially due to work related to preparation for and development of our initial 3G Tech project. Investor relations expenses were $175,000 and $35,000 for the six months ended December 31, 2021 and 2020, respectively, and the increase is due to a new contract with an investor relations firm and increased activity during the three months ended December 31, 2021 due to the resumption of investor conferences. Legal costs were $146,000 and $1,000 for the six months ended December 31, 2021 and 2020, respectively, with increase due to the hiring of a law firm to represent the Company in a lawsuit for the hack and attempt to steal the Company’s domain, engaging a law firm on the dissolution of PA-1, legal work in relation to corporate structure matters and preparation for the 2022 shareholder meeting and other matters.

General and administrative stock-based employee compensation for the six months ended December 31, 2021 and 2020 consists of the following:

 

   Six months
ended
December 31,
2021
   Six months
ended
December 31,
2020
 
General and administrative:          
  Change in fair value from modification of option terms  $—     $9,000 
  Change in fair value from modification of warrant terms   6,000    25,000 
  Fair value of stock options expensed under ASC 718   —      —   
      Total  $6,000   $34,000 

 

Stock-based compensation charges were $13,000 and $34,000 for the six months ended December 31, 2021 and 2020, respectively. The fair value of stock options expensed for the six months ended December 31, 2021 and 2020 was nil for both periods. No options were granted during the six months ended December 31, 2021 and 2020. Compensation expense relating to the change in fair value from the modification of option terms was nil and $9,000 for the six months ended December 31, 2021 and 2020, respectively, as the Company granted an extension of certain option expiration dates for two consultants during the six months ended December 31, 2020. During the six months ended December 31, 2021 and 2020, respectively, the Company extended expiration dates of warrants for certain consultants and issued additional warrants to certain consultants which resulted in the recognition of $13,000 and $25,000 in non-cash compensation.

Depreciation

Total depreciation expense was $580 and $414 for the six months ended December 31, 2021 and 2020, respectively.

42 
 
 

Research and Development

Total research and development expenses were $116,000 and $246,000 for the six months ended December 31, 2021 and 2020, respectively.

Research and development expenses, excluding stock-based compensation expenses of nil and nil were $116,000 and $246,000 for the six months ended December 31, 2021 and 2020, respectively. Salaries and related payroll tax expenses were $7,000 and $44,000 for the six months ended December 31, 2021 and 2020, respectively. Consulting costs were $66,000 and $104,000 for the six months ended December 31, 2021 and 2020, respectively.  The Company also incurred nil and $73,000 for the six months ended December 31, 2021 and 2020, respectively in the development of new components of the pilot program for its anaerobic digestate process.

 

Research and development stock-based employee compensation for the six months ended December 31, 2021 and 2020 consists of the following:

 

    

Six Months ended

December 31, 2021

    

Six Months ended

December 31, 2020

 
Research and development:          
  Fair value of stock options expensed under ASC 718  $—     $—   
      Total  $—     $—   

 

Stock-based compensation expenses were nil for both the six months ended December 31, 2021 and 2020, respectively. The Company expensed nil and nil for the fair value of stock options that vested during the six months ended December 31, 2021 and 2020.

Loss from Operations

As a result of the factors described above, the loss from operations was $1,226,000 and $841,000 for the six months ended December 31, 2021 and 2020, respectively.

Other Expense

Other (income) expense was $(10,007,000) and $408,000 for the six months ended December 31, 2021 and 2020, respectively. The Company recognized a gain on the legal dissolution of PA-1 of $10,235,000. Interest expense of $3,000 and $163,000 was recorded during the six months ended December 31, 2021 and 2020, respectively, due to the modification of warrant expiry dates for warrants held by investors. Interest expense related to convertible notes was $92,000 and $107,000 for the six months ended December 31, 2021 and 2020.

Net Loss Attributable to the Noncontrolling Interest

The net loss attributable to the noncontrolling interest was $1,000 for both the six months ended December 31, 2021 and 2020, respectively.

Net Loss Attributable to Bion’s Common Stockholders

As a result of the factors described above, the net (income) loss attributable to Bion’s stockholders was ($8,782,000) and $1,248,000 for the six months ended December 31, 2021 and 2020, respectively, and the net (income) loss per basic common share was $(.21) and 0.04 for both the six months ended December 31, 2021 and 2020, respectively.

 

LIQUIDITY AND CAPITAL RESOURCES

 

The Company's consolidated financial statements for the six months ended December 31, 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Report of our Independent Registered Public Accounting Firm on the Company's consolidated financial statements as of and for the year ended June 30, 2021 includes a "going concern" explanatory paragraph which means that the auditors stated that conditions exist that raise substantial doubt about the Company's ability to continue as a going concern.

 

43 
 
 

 

Operating Activities

 

As of December 31, 2021, the Company had cash of approximately $4,948,000. During the six months ended December 31, 2021, net cash used in operating activities was $853,000, primarily consisting of cash operating expenses related to salaries and benefits, and other general and administrative costs such as insurance, legal, accounting, consulting and investor relations expenses. As previously noted, the Company is currently not generating significant revenue and accordingly has not generated cash flows from operations. The Company does not anticipate generating sufficient revenues to offset operating and capital costs for a minimum of two to five years. While there are no assurances that the Company will be successful in its efforts to develop and construct its Projects and market its Systems, it is certain that the Company will require substantial funding from external sources. Given the unsettled state of the current credit and capital markets for companies such as Bion, there is no assurance the Company will be able to raise the funds it needs on reasonable terms.

 

Investing Activities

 

During the six months ended December 31, 2021, the Company invested $92,000 in the purchase of property and equipment, primarily related to project construction in process.

 

Financing Activities

During the six months ended December 31, 2021, the Company received gross cash proceeds of $1,737,000 from the exercise of 2,315,550 warrants into shares of the Company’s common stock and paid approximately $19,000 in cash commissions related to the exercise of warrants.

As of December 31, 2021, the Company has debt obligations consisting of: a) deferred compensation of $477,000 and b) convertible notes payable – affiliates of $5,076,000.

 

Plan of Operations and Outlook

 

As of December 31, 2021, the Company had cash of approximately $4,948,000.

 

The Company continues to explore sources of additional financing to satisfy its current operating requirements as it is not currently generating any significant revenues. During fiscal years 2021 and 2020, the Company has faced progressively less difficulty in raising equity funding (but substantial equity dilution has resulted from the larger amounts of equity financing during the periods). However, the Company anticipates substantial increases in demands for capital and operating expenditures as it moves toward commercial implementation of its 3G Tech and development of JVs and, therefore, is likely to continue to face, significant cash flow management challenges due to limited capital resources and working capital constraints which have only recently begun to be alleviated. As a result, the Company has faced, and continues to face, significant cash flow management challenges due to material working capital constraints. To partially mitigate these working capital constraints, the Company's core senior management and some key employees and consultants have been deferring all or part of their cash compensation and/or are accepting compensation in the form of securities of the Company (Notes 5 and 7 to Financial Statements) and members of the Company's senior management have from time to time made loans to the Company. During the year ended June 30, 2018 senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. As of December 31, 2021, such deferrals/loans totaled approximately $5,076,000 (including accrued interest and deferred compensation converted into convertible obligations and convertible promissory notes but excluding conversions of deferred compensation into the Company's common stock by officers, employees and consultants that have already been completed). The extended constraints on available resources have had, and continue to have, negative effects on the pace and scope of the Company's effort to develop its business. The Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again in 2018. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to continue its recent increased success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and curtailment of ongoing activities including research and development activities.

 

The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop the Initial Project, JVs, Projects (including Integrated Projects) and CAFO Retrofit waste remediation systems (including the Kreider 2 facility) and to continue to maintain equipment at the Kreider 1 facility (subject to agreements being reached with Pennvest as discussed above). The Company anticipates that it will seek to raise from $10,000,000 to $50,000,000 or more (debt and equity) during the next twelve months. However, as discussed above, there is no guarantee that we will be able to raise sufficient funds or further capital for the operations planned in the near future.

 

 

44 
 
 

 

The Company is not currently generating any significant revenues. Further, the Company’s anticipated revenues, if any, from existing projects, JVs and proposed projects will not be sufficient to meet the Company’s anticipated operational and capital expenditure needs for many years. During the year ended June 30, 2021 the Company raised gross proceeds of approximately $5,209,000 through the sale of its securities and paid commissions of approximately $165,000, and anticipates raising additional funds from such sales and transactions. During the six month ended December 31, 2021, the Company raised gross proceeds for approximately $1,737,000 and paid cash commissions of approximately $18,600. However, there is no guarantee that we will be able to raise sufficient funds or further capital for the operations planned in the near future.

 

Because the Company is not currently generating significant revenues, the Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop the Initial Project and subsequent Projects.

 

As indicated above, the Company anticipates that it will seek to raise from $10,000,000 to $50,000,000 or more (from debt, equity, joint venture, strategic partnering, etc.) during the next twelve months, some of which may be in the context of joint ventures for the development of one or more large scale projects. We reiterate that there is no assurance, especially in the extremely unsettled capital markets that presently exist for companies such as Bion, that the Company will be able to obtain the funds that it needs to stay in business, finance its Projects and other activities, continue its technology development and/or to successfully develop its business.

 

For more details regarding the Company’s first commercial activity in the Retrofit segment which was represented by our agreement with Kreider Farms ("KF"), pursuant to which the Kreider 1 system to treat KF's dairy waste streams to reduce nutrient releases to the environment while generating marketable nutrient credits and renewable energy was designed, constructed and entered full-scale operation during 2011, see “KREIDER 1 (HISTORY AND STATUS)/DISSOLUTION OF BION PA 1 LLC (‘PA1”)” above and the Company’s Form 10-K for the year ended June 30, 2021.

See KREIDER 1 (HISTORY AND STATUS)/DISSOLUTION OF BION PA 1 LLC (‘PA1”) above for discussion of the dissolution of PA1, the Pennvest Loan and the Kreider 1 project.

 

As indicated above, the Company anticipates that it will seek to raise from $10,000,000 to $50,000,000 or more (from debt, equity, joint venture, strategic partnering, etc.) during the next twelve months, some of which may be in the context of joint ventures for the development of one or more large scale projects. We reiterate that there is no assurance, especially in the extremely unsettled capital markets that presently exist for companies such as Bion, that the Company will be able to obtain the funds that it needs to stay in business, finance its Projects, JVs and other activities, continue its technology development and/or to successfully develop its business.

 

There is extremely limited likelihood that funds required during the next twelve months or in the periods immediately thereafter will be generated from operations and there is no assurance that those funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company's existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for companies such as Bion.

Covid-19 pandemic related matters:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain, vi) due to the age and health of our core management team, all of whom are age 70 or older and have had one or more existing health issues, the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

45 
 
 

 

CONTRACTUAL OBLIGATIONS

 

We have the following material contractual obligations (in addition to employment and consulting agreements with management and employees):

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The following table summarized the supplemental cash flow information for the six months ended December 31, 2021:

 

   December 31, 2021
Cash paid for noncancelable operating lease included in the operating cash flows  $60,000 
Right of use assets obtained in exchange for operating lease liabilities  $180,586 

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of December 31, 2022:

 

From January 2022 to December 2022    —    
From January 2023 to December 2023   75,000 
From January 2024 to December 2024   75,000 
Undiscounted cash flow   150,000 
   Less imputed interest   (27,395)
Total  $122,605 

 

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of December 31, 2022 were 3 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

 

Through 3G1 the Company is in the process of developing the Initial Project. See discussion above and in the Notes to our Financial Statements. 

 

OFF-BALANCE SHEET ARRANGEMENTS

 

We do not have any off-balance sheet arrangements (as that term is defined in Item 303 of Regulation S-K) that are reasonably likely to have a current or future material effect on our financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4.  Controls and Procedures.

(a) Evaluation of Disclosure Controls and Procedures.

The term "disclosure controls and procedures" is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This term refers to the controls and procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is recorded, processed, summarized, and reported within the required time periods. Our Chief Executive Officer and Principal Financial Officer has evaluated the effectiveness of the design and operations of our disclosure controls and procedures as of the end of the period covered by this quarterly report, and has concluded that, as of that date, our disclosure controls and procedures were not effective at ensuring that required information will be disclosed on a timely basis in our reports filed under the Exchange Act, as a result of the material weakness in internal control over financial reporting discussed in Item 9(A) of our Form 10-K for the year ended June 30, 2021.

(b) Changes in Internal Control over Financial Reporting.

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

46 
 
 

PART II – OTHER INFORMATION

Item 1.  Legal Proceedings.

The Company is currently involved in no litigation matters except:

 

 

A: Website

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

B: Dissolution of Bion PA1, LLC (“PA1”)

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment.

 

On December 29, 2021, the Company approved and executed a Consent of the Sole Member of Bion PA 1 (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business. PA 1 is prepared to transfer to Pennvest all of PA1’s right, title and interest in its property (by a bill of sale or other acceptable agreement) or alternatively, with Pennvest’s approval and direction, arrange for the sale of its property and deliver all proceeds (net of commissions and customary costs of sale) to Pennvest. PA1 and Pennvest have entered into communication/exchanges to determine how Pennvest would like PA1 to proceed with this process. The Company’s personnel will assist PA1 with this process as needed at no cost to PA1.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA 1 has made no payments to vendors or other creditors in connection with the dissolution. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

47 
 
 

 

Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are not and will no longer be consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets where nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense. See Item 1, “Financial Statements” above.

Item 1A.  Risk Factors.

Not applicable.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds.

During the quarter ended December 31, 2021, the Company sold the following restricted securities: a) 25,171 shares of common stock issued pursuant to our 2006 Consolidated Incentive Plan (“Plan”) upon the conversion of debt and b) 2,176,216 shares of common stock issued pursuant to exercise of 2,176,216 @ $0.75/warrant and the Company received gross proceeds of $1,632,162. All of these transactions the Company relied on the exemptions in Section 4(2) of the Securities Act of 1933, as amended, and/or under Rule 506 of Regulation D under the Securities Act of 1933, as amended. See Notes to Financial Statements (included herein) for additional details.

The proceeds were utilized for general corporate purposes.

Item 3.  Defaults Upon Senior Securities.

Not applicable.

Item 4.  Mine Safety Disclosures.

Not applicable.

Item 5.  Other Information.

Not applicable.

Item 6.  Exhibits.

(a)Exhibits required by Item 601 of Regulation S-K.

Exhibit  

Description

 

     
31.1   Certification of CEO pursuant to Rule 13a-14(a) or Rule 15d-14(a) - Filed herewith electronically
     
31.2   Certification of Executive Chairman, President and CFO pursuant to Rule 13a-14(a) or Rule 15d-14(a) - Filed herewith electronically
     
32.1   Certification of CEO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 - Filed herewith electronically
     
32.2   Certification of Executive Chairman, President and CFO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 - Filed herewith electronically
     
101   Inline interactive data files pursuant to Rule 405 of Regulation S-T: (i) the Unaudited Balance Sheets, (ii) the Unaudited Statements of Operations, (iii) the Unaudited Consolidated Statements of Changes in Stockholder’s Equity (Deficit), (iv) Unaudited of Cash Flows and (v) the Notes to Financial Statements. 

 

48 
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    BION ENVIRONMENTAL TECHNOLOGIES, INC.
     
     
Date: February 14, 2022 By: /s/ Mark A. Smith
    Mark A. Smith, President and Chief Financial Officer (Principal Financial and Accounting Officer)
     
     
     
Date:  February 14, 2022 By: /s/ Dominic Bassani
    Dominic Bassani, Chief Executive Officer
     
     

 

 

49 
 
 

 

 

 

 

 

 

 

 

 

 

 

 

 

EX-31.1 2 ex31x1.htm EXHIBIT 31.1

Exhibit 31.1

SECTION 302 CERTIFICATION

I, Dominic Bassani, certify that:

1.   I have reviewed this quarterly report on Form 10-Q of Bion Environmental Technologies, Inc.;

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.   Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;

4.   The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)  Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.   The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 

February 14, 2022
/s/ Dominic Bassani
 
 
Dominic Bassani
Chief Executive Officer
 

 
EX-31.2 3 ex31x2.htm EXHIBIT 312

Exhibit 31.2

SECTION 302 CERTIFICATION

I, Mark A. Smith, certify that:

1.   I have reviewed this quarterly report on Form 10-Q of Bion Environmental Technologies, Inc.;

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.   Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;

4.   The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)  Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.   The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
       
Date:  February 14, 2022
 
/s/ Mark A. Smith  
   
Mark A. Smith
Executive Chairman, President and
Interim Chief Financial Officer
 
     
       


EX-32.1 4 ex32x1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION OF CEO PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Form 10-Q of Bion Environmental Technologies, Inc., a company duly formed under the laws of Colorado (the "Company"), for the period ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Dominic Bassani, Chief Executive Officer of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

February 14, 2022
/s/ Dominic Bassani
 
 
Dominic Bassani
Chief Executive Officer
 

 
This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to Bion Environmental Technologies, Inc. and will be retained by Bion Environmental Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
 
 
EX-32.2 5 ex32x2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION OF CFO PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Form 10-Q of Bion Environmental Technologies, Inc., a company duly formed under the laws of Colorado (the "Company"), for the period ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Mark A. Smith, President (Executive Chairman) and Interim Chief Financial Officer (Principal Financial and  Accounting Officer) of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
       
Date:  February 14, 2022
 
/s/ Mark A. Smith  
   
Mark A. Smith
Executive Chairman, President and
Interim Chief Financial Officer
 
       

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to Bion Environmental Technologies, Inc. and will be retained by Bion Environmental Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
 
 
 
 
 
EX-101.SCH 6 bnet-20211231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - DEFERRED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - LOANS PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - DEFERRED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - LOANS PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - STOCKHOLDERS' EQUITY - Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - STOCKHOLDERS' EQUITY - Nonvested Share Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - STOCKHOLDERS' EQUITY - Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details1) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 bnet-20211231_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 bnet-20211231_def.xml XBRL DEFINITION FILE EX-101.LAB 9 bnet-20211231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series B Preferred Stock [Member] Series A Preferred Stock [Member] Series C Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Subscriptions Receivable [Member] Retained Earnings [Member] Noncontrolling Interest [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Ownership [Axis] Centerpoint [Member] Antidilutive Securities [Axis] Warrant [Member] Share-based Payment Arrangement, Option [Member] Convertible Debt Securities [Member] Convertible Preferred Stock Antidilutive Securities [Member] Long-Lived Tangible Asset [Axis] Property, Plant and Equipment of PA1 [Member] Title of Individual [Axis] Chief Executive Officer [Member] President [Member] Consultants [Member] Former Employee [Member] Nature of Expense [Axis] Interest Expense on Deferred Compensation Obligation [Member] Debt Instrument [Axis] Pennvest Loan [Member] Scenario [Axis] Years One Through Five [Member] Years Six Through Maturity [Member] Legal Entity [Axis] PA-1 [Member] The 2020 Convertible Obligations [Member] Long-term Debt, Type [Axis] Convertible Debt [Member] Executive Vice Chairman [Member] Receivable Type [Axis] Secured Promissory Note [Member] September 2015 Convertible Notes [Member] Award Type [Axis] Restricted Stock [Member] Two Consultants [Member] Financial Instrument [Axis] Options Held [Member] Income Statement Location [Axis] General and Administrative Expense [Member] Research and Development Expense [Member] Class of Warrant or Right [Axis] Warrants Issused, Subscription Receivable [Member] Consultant [Member] Warrants Issued in Connection with Sale of Units in Exchange for Salary [Member] Extension Bonus [Member] Plan Name [Axis] FY2016 Extension Agreement [Member] Bassani [Member] Warrants Expiring on December 31, 2025 [Member] Secured Promissory Note, Consideration for Warrants Expiring on December 31, 2025 [Member] Investment Type [Axis] Pennvest [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS Current assets: Cash Prepaid expenses Deposits Total current assets Operating lease use- of- asset Property and equipment, net (Note 3) Total assets LIABILITIES AND EQUITY (DEFICIT) Current liabilities: Accounts payable and accrued expenses Preferred stock Deferred compensation (Note 4) Loan payable and accrued interest (Note 5) Total current liabilities Operating lease liability Convertible notes payable - affiliates (Note 6) Total liabilities Deficit: Bion's stockholders' equity (deficit): Common stock, no par value, 100,000,000 shares authorized, 43,733,820 and 41,315,986 shares issued, respectively; 43,029,511 and 40,611,677 shares outstanding, respectively Additional paid-in capital Subscription receivable - affiliates (Note 8) Accumulated deficit Total Bion's stockholders’ deficit Noncontrolling interest Total deficit Total liabilities and deficit Preferred stock, par value (in dollars per share) Preferred stock, authorized (in shares) Preferred stock, issued (in shares) Preferred stock, outstanding (in shares) Preferred stock, liquidation Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Value, Outstanding Income Statement [Abstract] Revenue Operating expenses: General and administrative (including stock-based compensation (Note 7)) Depreciation Research and development (including stock-based compensation (Note 7)) Total operating expenses Loss from operations Other (income) expense: Interest income Interest expense Gain on legal dissolution of subsidiary Total other expense Net income (loss) Net loss attributable to the noncontrolling interest Net income (loss) applicable to Bion's common stockholders Net income (loss) applicable to Bion's common stockholders per basic and diluted common share Weighted-average number of common shares outstanding: Basic and diluted Beginning balance, value Beginning balance, shares Sale of units Sale of units (in shares) Warrants exercised for common shares Commissions on sale of units Modification of options Modification of warrants Issuance of warrants Conversion of debt and liabilities Conversion of debt and liabilities (in shares) Net income (loss) Warrants exercised for common shares, shares Commissions on warrant exercises Commissions on warrant exercises, shares Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net income (loss) Adjustments to reconcile net income (loss) to net cash used in operating activities: Gain on legal dissolution of subsidiary Depreciation expense Accrued interest on loans payable, deferred compensation and other Stock-based compensation Decrease in prepaid expenses Decrease in operating lease assets and liabilities Increase in accounts payable and accrued expenses Increase in deferred compensation Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from exercise of warrants Commissions on exercise of warrants Redemption of Preferred Series B shares and interest Proceeds from sale of units Commissions on sale of units Net cash provided by financing activities Net decrease in cash Cash at beginning of period Cash at end of period Supplemental disclosure of cash flow information: Cash paid for interest Non-cash investing and financing transactions: Conversion of debt and liabilities into common units Shares issued for warrant exercise commissions Conversion of deferred compensation to note payable Purchase of property and equipment for accounts payable Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS Accounting Policies [Abstract] SIGNIFICANT ACCOUNTING POLICIES Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Share-based Payment Arrangement [Abstract] DEFERRED COMPENSATION Debt Disclosure [Abstract] LOANS PAYABLE Convertible Notes Payable - Affiliates CONVERTIBLE NOTES PAYABLE - AFFILIATES Equity [Abstract] STOCKHOLDERS' EQUITY Subscription Receivable - Affiliates SUBSCRIPTION RECEIVABLE - AFFILIATES Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Principles of consolidation Cash and cash equivalents Property and equipment Patents Stock-based compensation Derivative Financial Instruments Warrants Concentrations of credit risk Noncontrolling interests Fair value measurements Lease Accounting Revenue Recognition Loss per share Use of estimates Recent Accounting Pronouncements Schedule of anti dilutive securities Schedule of earnings per share, basic and diluted Schedule of property and equipment Schedule of option activity Schedule of non vested stock options Condensed Financial Statement Schedule Of Cash Flow Supplemental Disclosure Schedule Of Future Minimum Lease Payment Cattle per head Tech wastage Percentage of sustainable Description of kreider 2 poultry project Net Income (loss) Net income Operating loss Working Capital Stockholders' Equity Attributable to Parent Proceeds from Issuance or Sale of Equity Commissions paid Deferred Compensation Liability, Amount Cancelled Capital Required for Capital Adequacy Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities Shares issued – beginning of period Shares held by subsidiaries (Note 7) Shares outstanding – beginning of period Weighted average shares issued     during the period Diluted weighted average shares –     end of period Noncontrolling interest, ownership percentage by parent Machinery and equipment Buildings and structures Computers and office equipment 3G project construction in process Property and equipment, gross Less accumulated depreciation Property and equipment, net Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Impairment of Long-Lived Assets Held-for-use Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] Deferred compensation liability Interest Rate on Deferred Compensation Deferred Compensation Consecutive Trading Days (Day) Deferred Compensation, Convertible to Common Stock Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share) Interest Expense Interest Expense, Related Party Schedule of Short-term Debt [Table] Short-term Debt [Line Items] Construction Loan Accrued Interest and Late Charges Payable Line of Credit Facility, Maximum Borrowing Capacity Debt Instrument, Interest Rate During Period Debt Instrument, Annual Principal Payment Long-Term Debt, Maturity, Year Two Long-Term Debt, Maturity, Year Three Long-Term Debt, Maturity, Year Four Interest Expense, Debt Debt Instrument, Debt Default, Amount Total assets Total liabilities Accounts payable and accrued liabilities Accounts payable Accrued Liabilities, Current Gain on legal dissolution of subsidiary Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage, Quarterly Conversion Price Per Unit (in dollars per share) Number of Warrants Per Unit (in shares) Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Convertible Notes Payable, Noncurrent Salary paid Financing Receivable, Interest Rate, Stated Percentage Convertible Notes Payable Deferred compensation Options outstanding, beginning (in shares) Options outstanding, beginning weighted-average exercise price Outstanding, weighted-average remaining contractual life (Year) Outstanding, aggregate intrinsic value beginning Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted, weighted-average exercise price Exercised, options (in shares) Exercised, weighted-average exercise price Forfeited, options (in shares) Forfeited, weighted-average exercise price Expired, options (in shares) Expired, weighted-average exercise price Options outstanding, ending (in shares) Options outstanding, beginning weighted-average exercise price Outstanding, aggregate intrinsic value ending Exercisable, options (in shares) Options outstanding, beginning weighted-average exercise price Exercisable, weighted-average remaining contractual life (Year) Exercisable, aggregate intrinsic value Nonvested options, beginning (in shares) Nonvested, weighted-average grant-date fair value beginning Granted, options (in shares) Granted, weighted-average grant-date fair value Vested (in shares) Vested, weighted-average grant-date fair value Nonvested options, ending (in shares) Nonvested, weighted-average grant-date fair value, ending Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Change in fair value from modification of option terms Change in fair value from modification of warrant terms Allocated Share-based Compensation Expense Schedule of Stock by Class [Table] Class of Stock [Line Items] Preferred Stock, Shares Outstanding, Ending Balance (in shares) Preferred Stock, Par or Stated Value Per Share (in dollars per share) Preferred Stock, Convertible Option Per Share (in dollars per share) Preferred Stock, Dividend Rate, Percentage Preferred Stock, Redemption Price Per Share (in dollars per share) Redemption of convertible Preferred stock Dividends Payable Dividends, Preferred Stock Shares Held by Subsidiaries (in shares) Converted to Units, Amount Accounts Payable Converted to Units, Shares Accounts Payable Converted to Units, Price Per Unit Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right, Exercised During Period (in shares) Common Stock Shares Issued upon Exercise of Warrants (in shares) Warrant Exercised for Common Stock Stock Issued During Period, Shares, Commission on Sale of Units and Warrant Exercises (in shares) Payments of Commissions on Exercise of Warrants Class of Warrant or Right, Outstanding (in shares) Weighted Average Exercise Price for Outstanding Warrants (in dollars per share) Weighted Average Remaining Contractual Life for Outstanding Warrants (Year) Share-based Payment Arrangement, Plan Modification, Incremental Cost Interest expenses Warrants issued Warrant exercised Common stock share restricted Proceeds from warrant Warrant unexercised Commissions on warrant exercises Stock options, authorized (in shares) Options expiration period (Year) Share-based Payment Arrangement, Expense Share-based Compensation, Granted Financing Receivable, after Allowance for Credit Loss, Total Notes receivable interest Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Financing Receivable, Principal Amount Cash paid for noncancelable operating lease included in the operating cash flows Right of use assets obtained in exchange for operating lease liabilities From January 2022 to December 2022 From January 2023 to December 2023 From January 2024 to December 2024 Undiscounted cash flow    Less imputed interest Total Loss Contingencies [Table] Loss Contingencies [Line Items] Monthly Officers' Cash Compensation Deferred Compensation, Maximum Convertible Amount Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share) Salaries and wages Additional paid amount Interest bearing secured promissory note Expiration date Repayments of Long-term Debt, Total Exercise bonus Warrants held by trust owned Warrants and Rights Outstanding Principal, interest Assets Accounts Payable And Accrued Liabilities Accrued liabilities Gains Losses On Extinguishment Of Debt Weighted average remaining lease term Subsequent Event [Table] Subsequent Event [Line Items] Debt instrument paid amount Debt instrument rate Debt instrument principal payment Represents the equity impact of units issued during the period. Represents the value of stock issued during the period for commissions on sale of units. Represents the equity impact of the warrants exercised for common stock. This item represents the capital available for operations for the Company. The amount of deferred compensation liability cancelled during the period. This item represents the convertible preferred stock securities that have been excluded from the computation of earnings per share. Number of shares held by subsidiaries. Represents the weighted average number of additional shares issued during period. This item represents the separate legal entity of Centerpoint. This item represents the gross amount computers and office equipment held by the Company. Represents the Property, Plant and Equipment of PA1. This item represents the interest rate that is accrued on deferred compensation. Consultants of the Company. Represents former employee. Represents the amount of deferred compensation liability convertible to shares of the entity's common stock as of the balance sheet date. Represents the price per share at which the deferred compensation liability is convertible to shares of the entity's common stock as of the balance sheet date. This item represents the obligation accrued for interest expense of deferred compensation. Number of specified trading days during the end of a month for which the share price of common stock during that period will be applied to deferred compensation if converted. This item represents the Pennvest Loan. The carrying amount of accrued interest and late charges payable to lender. This item represents events that will occur during years one through five. This item represents events that occur during years six through loan maturity. Depicts the subsidiary PA-1. Represents 2020 Convertible Obligations (formerly January 2015 Convertible Notes) and 2019 Convertible Note. Represents quarterly stated percentage of debt instrument. Represents the conversion price on a per Unit basis of convertible debt instruments. The number of warrants per unit. Represents the Executive Vice Chairman. Contractual interest rate for financing receivable, under the agreement. Related to a secured promissory note. Represents information about the September 2015 convertible notes. The amount of change in fair value of share-based payment awards due to modifications in warrants terms. The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is convertible to an option. The number of warrants or rights exercised during period. Represents warrants exercised for common stock shares. The number of shares issued during the period for commissions on sale of units and warrant exercises. The amount of cash outflow of commissions on exercise of warrants. Represents weighted average remaining contractual life for outstanding warrants. The warrants issued in exchange for promissory notes. The principal amount of financing receivable. Represents information pertaining to a consultant. Represents information about monthly officers' cash compensation. Represents information about warrants issued in connection with sale of units in exchange for salary. The maximum amount of deferred compensation that is deemed to be convertible. The price per share in which an individual can convert their deferred compensation. Information concerning the secured promissory note that was received as consideration toward the Bassani Warrants that expire on December 31, 2025. Represents information concerning warrants that expire on December 31, 2025. This item represents the adjustment To additional paid in capital as a result of modification of options. This item represents the adjustment to additional paid in capital as a result of modification of warrants. The value of stock issued during the period for commissions on sale of units and warrant exercises. Number of units issued pursuant to a subscription agreement. Assets, Current Liabilities, Current Common Stock, Share Subscribed but Unissued, Subscriptions Receivable Stockholders' Equity Attributable to Parent Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Income, Operating GainOnLegalDissolutionOfSubsidiary Nonoperating Income (Expense) Net Income (Loss) Available to Common Stockholders, Basic Net Income (Loss) Attributable to Noncontrolling Interest NetIncomeLossApplicableToBionsCommonStockholders Shares, Outstanding Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities CommissionsOnExerciseOfWarrants CommissionsOnSaleOfUnits Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Share-based Payment Arrangement [Policy Text Block] Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, Plant and Equipment, Other, Net Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price Commissions on warrant exercises [Default Label] EX-101.PRE 10 bnet-20211231_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover - shares
6 Months Ended
Dec. 31, 2021
Feb. 01, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Dec. 31, 2021  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --06-30  
Entity File Number 000-19333  
Entity Registrant Name Bion Environmental Technologies, Inc.  
Entity Central Index Key 0000875729  
Entity Tax Identification Number 84-1176672  
Entity Incorporation, State or Country Code CO  
Entity Address, Address Line One 9 East Park Court  
Entity Address, City or Town Old Bethpage  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 11804  
City Area Code 516  
Local Phone Number 586-5643  
Title of 12(b) Security Common Stock  
Trading Symbol BNET  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   43,209,511
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
Dec. 31, 2021
Jun. 30, 2021
Current assets:    
Cash $ 4,948,282 $ 4,216,321
Prepaid expenses 46,723 124,049
Deposits 1,000 1,000
Total current assets 4,996,005 4,341,370
Operating lease use- of- asset 171,835
Property and equipment, net (Note 3) 146,895 541
Total assets 5,314,735 4,341,911
Current liabilities:    
Accounts payable and accrued expenses 513,070 570,050
Deferred compensation (Note 4) 477,374 479,208
Loan payable and accrued interest (Note 5) 9,868,495
Total current liabilities 990,444 10,955,153
Operating lease liability 122,605
Convertible notes payable - affiliates (Note 6) 5,075,586 4,793,097
Total liabilities 6,188,635 15,748,250
Bion's stockholders' equity (deficit):    
Common stock, no par value, 100,000,000 shares authorized, 43,733,820 and 41,315,986 shares issued, respectively; 43,029,511 and 40,611,677 shares outstanding, respectively
Additional paid-in capital 123,150,676 121,399,067
Subscription receivable - affiliates (Note 8) (504,650) (504,650)
Accumulated deficit (123,558,048) (132,339,873)
Total Bion's stockholders’ deficit (912,022) (11,445,456)
Noncontrolling interest 38,122 39,117
Total deficit (873,900) (11,406,339)
Total liabilities and deficit 5,314,735 4,341,911
Series B Preferred Stock [Member]    
Current liabilities:    
Preferred stock 37,400
Series A Preferred Stock [Member]    
Current liabilities:    
Preferred stock
Series C Preferred Stock [Member]    
Current liabilities:    
Preferred stock
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)
Dec. 31, 2021
Jun. 30, 2021
Common Stock, Par or Stated Value Per Share $ 0 $ 0
Common Stock, Shares Authorized 100,000,000 100,000,000
Common Stock, Shares, Issued 43,733,820 41,315,986
Common Stock, Value, Outstanding $ 43,029,511 $ 40,611,677
Series B Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 50,000 50,000
Preferred stock, issued (in shares) 0 200
Preferred stock, outstanding (in shares) 0 200
Preferred stock, liquidation $ 0 $ 40,000
Series A Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 50,000 50,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Series C Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 60,000 60,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]        
Revenue
Operating expenses:        
General and administrative (including stock-based compensation (Note 7)) 617,963 291,682 1,109,096 594,559
Depreciation 332 207 580 414
Research and development (including stock-based compensation (Note 7)) 54,404 155,385 116,213 246,373
Total operating expenses 672,699 447,274 1,225,889 841,346
Loss from operations (672,699) (447,274) (1,225,889) (841,346)
Other (income) expense:        
Interest income (1,269) (47) (2,763) (126)
Interest expense 118,365 303,218 230,545 407,637
Gain on legal dissolution of subsidiary (10,234,501) (10,234,501)
Total other expense (10,117,405) 303,171 (10,006,719) 407,511
Net income (loss) 9,444,706 (750,445) 8,780,830 (1,248,857)
Net loss attributable to the noncontrolling interest 489 524 995 1,039
Net income (loss) applicable to Bion's common stockholders $ 9,445,195 $ (749,921) $ 8,781,825 $ (1,247,818)
Net income (loss) applicable to Bion's common stockholders per basic and diluted common share $ 0.23 $ (0.02) $ 0.21 $ (0.04)
Weighted-average number of common shares outstanding:        
Basic and diluted 41,088,992 31,187,645 40,904,342 30,990,639
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) - USD ($)
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series C Preferred Stock [Member]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Subscriptions Receivable [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Jun. 30, 2020 $ 114,266,683 $ (504,650) $ (128,891,893) $ 41,902 $ (15,087,958)
Beginning balance, shares at Jun. 30, 2020 31,409,005          
Sale of units 360,000 360,000
Sale of units (in shares)     720,000          
Commissions on sale of units (31,000) (31,000)
Modification of options 8,775 8,775
Modification of warrants 188,890 188,890
Issuance of warrants 2,500 2,500
Conversion of debt and liabilities 70,794 70,794
Conversion of debt and liabilities (in shares)     141,589          
Net income (loss) (1,247,818) (1,039) (1,248,857)
Ending balance, value at Dec. 31, 2020 114,866,642 (504,650) (130,139,711) 40,863 (15,736,856)
Ending balance, shares at Dec. 31, 2020 32,270,594          
Beginning balance, value at Jun. 30, 2021 121,399,067 (504,650) (132,339,873) 39,117 (11,406,339)
Beginning balance, shares at Jun. 30, 2021 41,315,986          
Warrants exercised for common shares 1,736,662 1,736,662
Modification of warrants 8,337 8,337
Issuance of warrants 7,500 7,500
Conversion of debt and liabilities 17,711 17,711
Conversion of debt and liabilities (in shares)     35,424          
Net income (loss) 8,781,825 (995) 8,780,830
Warrants exercised for common shares, shares     2,315,550          
Commissions on warrant exercises (18,601) (18,601)
Commissions on warrant exercises, shares     66,860          
Ending balance, value at Dec. 31, 2021 $ 123,150,676 $ (504,650) $ (123,558,048) $ 38,122 $ (873,900)
Ending balance, shares at Dec. 31, 2021 43,733,820          
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
6 Months Ended
Dec. 31, 2021
Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES    
Net income (loss) $ 8,780,830 $ (1,248,857)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Gain on legal dissolution of subsidiary (10,234,501)
Depreciation expense 580 414
Accrued interest on loans payable, deferred compensation and other 248,409 425,499
Stock-based compensation 13,125 36,781
Decrease in prepaid expenses 77,326 3,615
Decrease in operating lease assets and liabilities (49,230)
Increase in accounts payable and accrued expenses 130,628 8,162
Increase in deferred compensation 179,867 245,742
Net cash used in operating activities (852,966) (528,644)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of property and equipment (92,134)
Net cash used in investing activities (92,134)
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from exercise of warrants 1,736,662
Commissions on exercise of warrants (18,601)
Redemption of Preferred Series B shares and interest (41,000)  
Proceeds from sale of units 360,000
Commissions on sale of units (31,000)
Net cash provided by financing activities 1,677,061 329,000
Net decrease in cash 731,961 (199,644)
Cash at beginning of period 4,216,321 560,828
Cash at end of period 4,948,282 361,184
Supplemental disclosure of cash flow information:    
Cash paid for interest 28
Non-cash investing and financing transactions:    
Conversion of debt and liabilities into common units 17,711 70,794
Shares issued for warrant exercise commissions 50,145
Conversion of deferred compensation to note payable 190,000
Purchase of property and equipment for accounts payable $ 54,800
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS
6 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS

1.       ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:

 

Organization and nature of business:

 

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Our patented and proprietary technology provides comprehensive environmental solutions to one of the greatest water air and water quality problems in the U.S. today: pollution from large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs").  Application of our technology and technology platform can simultaneously remediate environmental problems and improve operational/resource efficiencies by recovering value high-value co-products from the CAFOs’ waste stream that have traditionally been wasted or underutilized, including renewable energy, nutrients (including ammonia nitrogen) and water.

 

From 2016 to 2021 fiscal years, the Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“3G Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of organic ammonium bicarbonate products. The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. An application for our first solid ammonium bicarbonate product – AD Nitrogen – has been filed and is in the review process (which is likely to require an extended period of time and multiple procedural steps due to the novel nature of Bion’s 3G Tech in the context of organic certifications) See “Organic Fertilizer Listing/Certification Process” below.

 

Bion is now focused primarily on: i) development/construction of its initial commercial-scale 3G Tech installation (see below and Note 10, “Subsequent Events”), ii) developing applications and markets for its organic fertilizer products and its sustainable (conventional and organic) animal protein products, and iii) initiation and development of joint ventures (“JVs” as discussed below) (and related projects) based on the augmented capabilities of our 3G Tech, while (iv) continuing to pursue development opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and ongoing R&D activities.

 

The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns ranging including food safety, environmental impacts, and humane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market.

 

The Company believes that its 3G Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a large production/marketing opportunity for Bion. Our 3G Tech will also produce (as co-products) biogas and valuable organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.

 

During late September 2021, Bion entered into a lease for the development site of its initial commercial scale 3G Tech project in September 2021(“Initial Project”), which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project will be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately 300 head of beef cattle. The facility will include Bion’s 3G Tech platform including: i) covered barns (possibly including roof top solar photovoltaic generation), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion 3G Tech facilities capable of treating the waste from approximately 1,500 head). The facility will be large enough to demonstrate engineering capabilities of Bion’s 3G Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly, with operations targeted to commence sometime late in 2022. 3G1 has been moving forward with the development process of the Initial Project. See Note 10 “Subsequent Events” for activities since the start of the 2022 calendar year.

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

Specifically, the Initial Project is being developed to provide and/or accomplish the following:

 

  i. Proof of 3G Tech platform scalability

 

  - Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion 3G technology platform.

 

  - Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.

 

  ii. Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.

 

  iii. Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) for commercial testing by potential joint venture partners and/or purchasers and for university growth trials.

 

  iv. Produce sustainable beef products for initial test marketing efforts.

 

Upon achieving optimized and steady-state operations at the Initial Project (and especially of the core modules of our 3G Tech platform), coupled with obtaining organic certifications(s) ( OMRI listing and/or other organic listings/certifications) for its AD Nitrogen product, Bion expects to be ready to move forward with its plans for development of much larger facilities. The Company anticipates that discussions and negotiations regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will commence during the construction of the Initial Project with the goal of establishing JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef during 2023. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its 3G Tech platform.

 

Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘3G Tech Kreider 2 Poultry Project’ below as an example).

 

Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/ dairy/ egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a certain segment of consumers are choosing seemingly sustainable offering, and are also willing to pay a premium for it. Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is 29.5 percent on average.

 

As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s 3G Tech platform, along with its business model, enables the cleanup of the ‘dirtiest’ part of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.

 

Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 retail value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef is 63% more expensive today, while pork and chicken, which are now primarily raised in covered barns, at CAFOs with highly integrated supply chains, are 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.

 

Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. Meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, are being heavily promoted by themselves and the media, and have enjoyed steady sales growth. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have recently entered the plant protein space. In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the only ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence). However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy.

 

It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, which represents approximately 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost remains very uncertain at this point.

 

Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium sustainable beef products that satisfy these concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our 3G Tech platform, both sustainable and/or organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, but with the superior taste and texture those consumers have grown to prefer.

 

Sustainable Beef

 

Bion’s goal is to be first to market with meaningfully sustainable, and verified, beef products that can be produced at sufficient scale to service national market demand. The cattle produced at a Bion facility will enjoy a substantially lower carbon footprint, dramatically reduced nutrient impacts to water, and an almost total pathogen kill in the waste stream. A Bion sustainable beef facility will be comprised of covered barns with slotted floors, which allow the waste to pass through and be collected quickly and frequently to reduce ammonia volatilization and loss, as well as odors. Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns represent a very large roof surface area, which will be utilized in appropriate geographical locations for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. Waste treatment and resource recovery will be provided by Bion’s advanced 3G Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.

 

Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small scale livestock producers (largely in the grass fed beef category). The reach and extent of such efforts is limited to date and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ’cow-calf’ segment of the livestock chain) in procurement by major beef processing companies, but a closer look finds that most consist largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.

 

Sustainable Organic Beef

 

Bion believes it has a unique opportunity to produce, at scale, affordable corn-fed organic beef that is certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the 3G Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.

 

Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. Stated directly, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap will put the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.

 

The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.

 

Organic Fertilizer Listing/Certification Process

 

The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“3G Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of organically listed ammonium bicarbonate products. The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020.

 

An application for our first solid ammonium bicarbonate product – AD Nitrogen – was filed during May 2021 and is currently actively proceeding through OMRI’s multi-stage review process ---which process has taken an extended period of time and multiple procedural steps due to the novel nature of Bion’s 3G Tech in the context of organic listings/certifications. OMRI’s Review Panel ‘…. voted to temporarily assign it to “Unresolved” status. This means that OMRI does not currently have the clarity necessary to decide whether the product meets OMRI standards which are based on the USDA National Organic Program regulations (NOP).’ Subsequently the application has gone through ‘Rebuttal’ (OMRI Review Panel) and ‘Appeal’ (Appeals Review Committee) stages which affirmed the “Unresolved” status. The Company has been informed that ‘…the product will remain Unresolved until July 22, 2022 or until resolution is reached by OMRI though consultation with the OMRI Advisory Council.’ The application is now beginning review by OMRI’s Advisory Council. The Company’s product is novel in part due to the fact that OMRI does not have a listing category for a solid form of concentrated and soluble nitrogen fertilizers and there is no clear guidance at present from OMRI internal policy on how to categorize this product and the process that produced it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives are involved in discussions regarding resolution of these matters at all three levels. The Company anticipates positive resolution of this manner well prior to operational dates for the Company’s initial large scale JV 3G projects.

 

 3 Tech Kreider 2 Poultry Project

 

Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 3G Tech) for 559,457 nutrient credits under the old EPA’s Chesapeake Bay model. The Company has been in ongoing discussions with the PADEP regarding the appropriate credit calculation methodology for large-scale technology-based nutrient reduction installations such as the KF2 Project utilizing our 3G Tech platform. Based on these discussions and the size of the Kreider 2 Project, we anticipate that if and when designs are finalized, the Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA. Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). A review process to clarify certain issues related to credit calculation and verification commenced during 2014 based on Bion’s 2G Tech but was been placed on hold. The Company anticipates if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our 3G Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s 3G Tech for increased recovery of marketable by-products, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.

 

Note that while Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees related to a ‘sustainable brand’, the Covid-19 pandemic has delayed legislative efforts needed to commence its development. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.

 

Technology Deployment: Bion 3G Tech

 

Widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s 3G Tech has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The 3G Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts (see below and Note 10, “Subsequent Events”). and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion below), and d) payment for verified ecosystem services. The Company’s first patent on its 3G Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s 3G Tech coverage, and the Company has additional applications pending and/or planned.

 

Bion’s business model and technology platform can create the opportunity for JVs (in various contractual forms) between the Company and large livestock/food/fertilizer industry participants, based upon the supplemental cash flow generated by implementation of our 3G Tech business model, which will support the costs of technology implementation (including related debt). We anticipate this will result in long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) may expand to represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits, that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019. However, the Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).

 

The livestock industry and its markets are already changing; with a commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its 3G Tech, during the current 2023 fiscal year. We believe that Bion’s 3G Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.

 

The Livestock Problem

 

The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun - and policies have already begun to change, as well. Bion’s 3G Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21st Century consumer demands for meaningful sustainability.

 

In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.

 

Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.

 

More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition - it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.

 

Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.

 

Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.

 

Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source-- before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture and treat.

 

High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.

 

The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.

 

For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s 3G Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.

 

Going concern and management’s plans:

 

The consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and has incurred net losses (including significant non-cash expenses) of approximately $3,451,000 and $4,553,000 during the years ended June 30, 2021 and 2020, respectively, and a net income of approximately $8,781,000 during the six months ended December 31, 2021. The net income for the six months is due to a one-time, non-cash event of the dissolution of PA-1 and a gain of approximately $10,235,000. There was an operating loss of approximately $1,226,000 for the six months ended December 31, 2021. At December 31, 2021, the Company has working capital and a stockholders’ deficit of approximately $4,006,000 and $912,000, respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.

 

The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.

 

During the years ended June 30, 2021 and 2020, the Company received gross proceeds of approximately $5,209,000 and $1,584,000, respectively, from the sale of its debt and equity securities.

 

During the six months ended December 31, 2021, the Company received total proceeds of approximately $1,737,000 from the sale of its equity securities and paid approximately $18,600 in cash commissions.

 

During fiscal years 2021 and 2020, the Company has faced progressively less difficulty in raising equity funding (but substantial equity dilution has gone along with the larger amounts of equity financing during the periods) than was experienced in the prior 3 years. Note, however, that during the first six months of the current fiscal year, the Company raised equity funds at a rate less than the average rate during fiscal year 2021. The Company anticipates substantial increases in demands for capital and operating expenditures as it moves toward commercial implementation of its 3G Tech and development of JVs and, therefore, is likely to continue to face, significant cash flow management challenges due to limited capital resources and working capital constraints which have only recently begun to be alleviated. To partially mitigate these working capital constraints, the Company’s core senior management and several key employees and consultants have been deferring (and continue to defer) part of their cash compensation and/or are accepting compensation in the form of securities of the Company and/or converting portions of their compensation and deferred compensation to securities of the Company (Notes 5 and 7) and members of the Company’s senior management have made loans to the Company from time to time. During the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to continue its recent success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and curtailment of ongoing activities including research and development activities.

 

The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including the Initial Project, JV Projects, Integrated Projects and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $10,000,000 to $50,000,000 or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us), that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.

 

There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.

 

Covid-19 pandemic related matters:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and are likely to delay and/or increase the cost of construction of the Company’s initial 3G Tech installation if equipment remains difficult to acquire in a timely manner, vi) due to the age and health of our core management team, all of whom are age 70 or older and have had one or more existing health issues, the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES

2.       SIGNIFICANT ACCOUNTING POLICIES

 

Principles of consolidation:

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc. (“Projects Group”), Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC; and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). The operating loss are included in the consolidation through December 29, 2021.

 

The accompanying consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at December 31, 2021, and the results of operations of the Company for the three and six months ended December 31, 2021 and 2020 and the cash flows of the Company for the six months ended December 31, 2021 and 2020. Operating results for the three and six months ended December 31, 2021 are not necessarily indicative of the results that may be expected for the year ending June 30, 2022.

 

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents.

 

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Loss per share:

 

Basic loss per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted loss per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the loss per share or increase the earnings per share. During the three and six months ended December 31, 2021 and 2020, the basic and diluted loss per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

The following table represents the warrants, options and convertible securities excluded from the calculation of basic loss per share:

 

          
   December 31,
2021
   December 31,
2020
 
Warrants   19,726,777    21,270,102 
Options   10,471,600    9,511,600 
Convertible debt   10,673,722    11,215,175 
Convertible preferred stock         19,500 

 

The following is a reconciliation of the denominators of the basic and diluted loss per share computations for the three and six months ended December 31, 2021 and 2020:

 

                    
   Three months
ended
December 31,
2021
   Three months
ended
December 31,
2020
   Six months
ended
December 31,
2021
   Six months
ended
December 31,
2020
 
Shares issued – beginning of period   41,475,573    31,575,656    41,315,986    31,409,005 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)   (704,309)   (704,309)
Shares outstanding – beginning of period   40,771,264    30,871,347    40,611,677    30,704,696 
Weighted average shares issued
    during the period
   317,728    316,298    292,665    285,943 
Diluted weighted average shares –
    end of period
   41,088,992    31,187,645    40,904,342    30,990,639 

 

 

Use of estimates:

 

In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s financial statements properly reflect the change.

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
PROPERTY AND EQUIPMENT
6 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

3.  PROPERTY AND EQUIPMENT:

 

Property and equipment consist of the following:

 

          
   December 31,
2021
   June 30,
2021
 
Machinery and equipment  $     $2,222,670 
Buildings and structures         401,470 
Computers and office equipment   11,137    171,485 
3G project construction in process   145,439       
Property and equipment, gross   156,576    2,795,625 
Less accumulated depreciation   (9,681)   (2,795,084)
Property and equipment, net  $146,895   $541 

 

Management has reviewed the remaining property and equipment for impairment as of December 31, 2021 and believes that no impairment exists.

 

Depreciation expense was $332 and $207 for the three months ended December 31, 2021 and 2020, respectively, and $580 and $414 for the six months ended December 31, 2021 and 2020, respectively.

 

On December 29, 2021 Bion PA1 LLC was dissolved which removed all items which were listed under ‘Machinery and equipment’ and Buildings and structures’ plus almost all of the items which were listed under ‘Computers and office equipment’ at June 30, 2021 resulting in the elimination of almost the entire balance of ‘accumulated depreciation’. See Note 5, “LOANS PAYABLE: Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution” below.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
DEFERRED COMPENSATION
6 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
DEFERRED COMPENSATION

4.       DEFERRED COMPENSATION:

The Company owes deferred compensation to various employees, former employees and consultants totaling $477,374 and $998,474 as of December 31, 2021 and 2020, respectively. Included in the deferred compensation balances as of December 31, 2021, are $374,015 and nil owed Dominic Bassani (“Bassani”), the Company’s Chief Executive Officer, and Mark A. Smith (“Smith”), the Company’s President, respectively, pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at 4% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last 10 trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of December 31, 2020 was $307,260 and $71,699, respectively. The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $30,859 and $512,432 as of December 31, 2021 and 2020, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at 3% per annum. The Company also owes a former employee $72,500, which is not convertible and is non-interest bearing.

Bassani and Smith have each been granted the right to convert up to $300,000 of deferred compensation balances at a price of $0.75 per share until December 31, 2022 (to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election.

The Company recorded interest expense of $4,268 ($4,095 with related parties) and $6,693 ($2,950 with related parties) for the three months ended December 31, 2021 and 2020, respectively, and $8,300 ($8,044 with related parties) and $12,476 ($5,159 with related parties) for the six months ended December 31, 2021 and 2020, respectively.

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
LOANS PAYABLE
6 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
LOANS PAYABLE

5.       LOANS PAYABLE:

 

Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed $10,009,802 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. The terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan is collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $61,722 for both the three months ended December 31, 2021 and 2020, respectively, and $123,444 for both the six months ended December 31, 2021 and 2020, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 has not made any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date.

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment.

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business. PA 1 is prepared to transfer to Pennvest all of PA1’s right, title and interest in its property (by a bill of sale or other acceptable agreement) or alternatively, with Pennvest’s approval and direction, arrange for the sale of its property and deliver all proceeds (net of commissions and customary costs of sale) to Pennvest. PA1 and Pennvest have entered into communication/exchanges to determine how Pennvest would like PA1 to proceed with this process. The Company’s personnel will assist PA1 with this process as needed at no cost to PA1.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA 1 has made no payments to vendors or other creditors in connection with the dissolution. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities will no longer be consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONVERTIBLE NOTES PAYABLE - AFFILIATES
6 Months Ended
Dec. 31, 2021
Convertible Notes Payable - Affiliates  
CONVERTIBLE NOTES PAYABLE - AFFILIATES

6.       CONVERTIBLE NOTES PAYABLE - AFFILIATES:

 

2020 Convertible Obligations

 

The 2020 Convertible Obligations, which accrue interest at either 4% per annum or 4% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $0.50 per Unit until July 1, 2024. The warrant contained in the Unit was originally exercisable at $1.00 per unit but was modified to $0.75 during the year ended June 30, 2020 and is exercisable until a date three years after the date of the conversion. During the year ended June 30, 2021, the Company approved the increase of warrants by one-third to be received by the noteholder if a conversion takes place. The original conversion price of $0.50 per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”.

 

As of December 31, 2021, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani (and his donees), Smith and Edward Schafer (“Schafer”), the Company’s Vice Chairman, were $2,550,104, $1,302,049 and $490,197, respectively. As of December 31, 2020, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani, Smith and Schafer were $2,455,656, $1,163,862 and $472,041, respectively.

 

During the six months ended December 31, 2021, Smith elected to add $90,000 of his salary to his 2020 Convertible Obligations.

 

The Company recorded interest expense of $40,864 and $65,468 for the three months ended December 31, 2021 and 2020, respectively. The Company recorded interest expense of $81,424 and $96,428 for the six months ended December 31, 2021 and 2020, respectively.

 

September 2015 Convertible Notes

 

During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani, Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at 4% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.60 per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.

 

The balances of the September 2015 Convertible Notes as of December 31, 2021, including accrued interest owed Bassani, Schafer and Shareholder, are $274,521, $20,517 and $438,198, respectively. The balances of the September 2015 Convertible Notes as of December 31, 2020, including accrued interest, were $168,498, $19,862 and $423,081, respectively.

 

During the six months ended December 31, 2021, Bassani elected to transfer $100,000 from deferred compensation to his 2015 convertible note.

 

The Company recorded interest expense of $5,698 and $5,365 for the three months ended December 31, 2021 and 2020, respectively. The Company recorded interest expense of $11,064 and $10,731 for both the six months ended December 31, 2021 and 2020, respectively.

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS' EQUITY
6 Months Ended
Dec. 31, 2021
Equity [Abstract]  
STOCKHOLDERS' EQUITY

7.       STOCKHOLDERS' EQUITY:

 

Series B Preferred stock:

 

Since July 1, 2014, the Company had 200 shares of Series B redeemable convertible Preferred stock outstanding with a par value of $0.01 per share, convertible at the option of the holder at $2.00 per share, with dividends accrued and payable at 2.5% per quarter. The Series B Preferred stock is mandatorily redeemable at $100 per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares have reached their maturity date and the Company approved the redemption of the Series B preferred stock during the quarter ended December 31, 2021. 200 shares of Series B redeemable convertible Preferred stock were redeemed for $41,000, which included the $21,000 in accrued dividend payable.

 

During the years ended June 30, 2021, and 2020, the Company declared dividends of $2,000 and $2,000 respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statement.

 

Common stock:

 

Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.

 

Centerpoint holds 704,309 shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.

 

During the six months ended December 31, 2021, Smith elected to convert accounts payable (based on his unreimbursed expenses) of $17,711 into 35,424 units at $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2024.

During the six months ended December 31, 2021, 2,315,550 warrants were exercised to purchase 2,315,550 shares of the Company’s common stock at $0.75 per share for total proceeds of $1,736,662.

During the six months ended December 31, 2021, the Company issued 66,860 shares of the Company’s common stock to three FINRA brokers as commissions for the warrant exercises. As the issuance was both a reduction and addition to additional paid in capital there was no impact to the financial statements. The Company also paid a FINRA broker $18,601 in commissions for the warrant exercises.

 

 Warrants:

 

As of December 31, 2021, the Company had approximately 19.7 million warrants outstanding, with exercise prices from $0.60 to $1.50 and expiring on various dates through June 30, 2025.

 

The weighted-average exercise price for the outstanding warrants is $0.73, and the weighted-average remaining contractual life as of December 31, 2021 is 2.7 years.

 

During the six months ended December 31, 2021, Smith elected to convert accounts payable of $17,711 into 35,424 units at $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2024.

 

During the six months ended December 31, 2021, the Company approved the issuance of 75,000 warrants for two consultants for consulting services of $7,500. The warrants are exercisable at $1.50 and expire in November 2026.

During the six months ended December 31, 2020, the Company approved the modification of existing warrants held by one former consultants and four investors, which extended certain expiration dates. The modifications resulted in incremental non-cash compensation of $5,625 and interest expenses of $2,712.

During the six months ended December 31, 2021, 2,315,550 warrants were exercised to purchase 2,315,550 shares of the Company’s common stock at $0.75 per share for total proceeds of $1,736,662.

During the 2021 calendar year, 6,431,538 warrants scheduled to expire on December 31, 2021, in aggregate, were exercised by their holders at an exercise price of $.75 per share of which 2,176,216 warrants were exercised during the quarter ended December 31, 2021. The Company issued, in aggregate, 6,431,538 share of its restricted and legended common stock in connection with these warrant exercises, of which 2,226,216 shares were issued during the quarter ended December 31, 2021. The Company received, in aggregate, $4,823,651 of gross processed from such warrant exercises, of which $1,632,162 was received in the quarter ended December 31, 2021 (these sums do not reflect expenses and commissions related to these warrant exercises). In aggregate, 648,142 warrants expired unexercised on December 31. 2021.

During the six months ended December 31, 2021, the Company issued 66,860 shares of the Company’s common stock to three FINRA brokers as commissions for the warrant exercises. As the issuance was both a reduction and addition to additional paid in capital there was no impact to the financial statements. The Company also paid a FINRA broker $18,601 in commissions for the warrant exercises.

 

Stock options:

 

The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to 36,000,000 shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years.

 

The Company recorded compensation expense related to employee stock options of nil for both the three and six months ended December 31, 2021 and 2020, respectively. The Company granted nil options during both the three and six months ended December 31, 2021 and 2020, respectively.

 

A summary of option activity under the 2006 Plan for the six months ended December 31, 2021 is as follows:

                      
    Options   Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Life
   Aggregate
Intrinsic
Value
 
 Outstanding at July 1, 2021    10,471,600   $0.77    3.7   $6,064,335 
   Granted                       
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at December 31, 2021    10,471,600   $0.77    3.2   $9,624,679 
 Exercisable at December 31, 2021    10,471,600   $0.77    3.2   $9,624,679 

 

The following table presents information relating to nonvested stock options as of December 31, 2021:

 

               
    Options   Weighted Average
Grant-Date Fair
Value
  Nonvested at July 1, 2021          $   
  Granted                
  Vested                
  Nonvested at December 31, 2021          $   

 

 

The total fair value of stock options that vested during both the three and six months ended December 31, 2021 and 2020 was nil. As of December 31, 2021, the Company had no unrecognized compensation cost related to stock options.

 

Stock-based employee compensation charges in operating expenses in the Company’s financial statements for the three and six months ended December 31, 2021 and 2020 are as follows:

                    
   Three
months
ended
December 31,
2021
   Three
months
ended
December 31,
2020
   Six months
ended
December 31,
2021
   Six months
ended
December 31,
2020
 
General and administrative:                    
  Change in fair value from modification of
    option terms
  $     $8,775   $     $8,775 
Change in fair value from modification of
    warrant terms
   5,625    25,506    5,625    25,506 
  Fair value of stock options expensed                        
     Total  $5,625   $34,281   $5,625   $34,281 
                     
Research and development:                    
  Fair value of stock options expensed  $     $     $     $   
     Total  $     $     $     $   

 

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUBSCRIPTION RECEIVABLE - AFFILIATES
6 Months Ended
Dec. 31, 2021
Subscription Receivable - Affiliates  
SUBSCRIPTION RECEIVABLE - AFFILIATES

8.       SUBSCRIPTION RECEIVABLE - AFFILIATES:

 

As of December 31, 2021, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $428,250 ($491,975, including interest) from Bassani which were received as consideration for purchases of warrants to purchase 5,565,000 shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $0.75 and have expiry dates ranging from December 31, 2024 to December 31, 2025. The promissory notes bear interest at 4% per annum, and are secured by portions of Bassani’s 2020 Convertible Obligation and Bassani’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.

 

As of December 31, 2021, the Company has an interest bearing, secured promissory note for $30,000 ($34,093 including interest) from Smith as consideration to purchase warrants to purchase 300,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of December 31, 2024. The warrants have a 75% exercise bonus and the promissory note bears interest at 4% per annum, and is secured by $30,000 ($34,093, including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.

As of December 31, 2021, the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $46,400 ($54,088 including interest) from two former employees as consideration to purchase warrants to purchase 928,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.75 and have expiry dates of December 31, 2024. These warrants have a 90% exercise bonus. The promissory notes bear interest at 4% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
COMMITMENTS AND CONTINGENCIES
6 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

9.       COMMITMENTS AND CONTINGENCIES:

 

Employment and consulting agreements:

 

Smith has held the positions of Director, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month to month contract extension with Smith which includes provisions for i) a monthly salary of $18,000 until the Board of Directors re-instates cash payments to all employees and consultants who are deferring compensation, ii) the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until December 31, 2022), and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis.

 

Since March 31, 2005, the Company has had various agreements with Brightcap and/or Bassani, through which the services of Bassani are provided (any reference to Brightcap or Bassani for all purposes are the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017, (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($31,000 per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation. During October 2016 Bassani was granted the right to convert up to $125,000 of his deferred compensation, at his sole election, at $0.75 per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, and subsequently extended until December 31, 2022). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $31,000 per month, which sum would continue to be accrued until the Company there is adequate cash available at which point re-instatement of a least a partial cash payment would be instituted. Additionally, the Company has agreed to pay him $2,000 per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $300,000 from Bassani as consideration to purchase warrants to purchase 3,000,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of December 31, 2021, the principal and accrued interest was $340,093. For the six months ended December 31, 2021 and 2020, Brightcap was paid $120,000 and $55,000, respectively, of cash compensation earned during the period. For the last 2 years, portions of Bassani’s compensation (determined by the Company’s President and the Board of Directors from time to time) has been paid in cash with the balance of his compensation accrued.

 

Execution/exercise bonuses:

 

As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise bonus which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the bonus shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock bonuses, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods have been reduced to $.01 per option or warrant.

 

During the year ended June 30, 2021, the Company added a 75% execution/exercise bonus to the terms of 3,000,000 warrants held by a trust owned by Bassani.

 

As of December 31, 2021, the execution/exercise bonuses ranging from 50-90% were applicable to 10,326,600 of the Company’s outstanding options and 16,778,213 of the Company’s outstanding warrants.

 

Litigation:

 

A: Website

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

B: Dissolution of Bion PA1, LLC (“PA1”)

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment.

 

On December 29, 2021, the Company approved and executed a Consent of the Sole Member of Bion PA 1 (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business. PA 1 is prepared to transfer to Pennvest all of PA1’s right, title and interest in its property (by a bill of sale or other acceptable agreement) or alternatively, with Pennvest’s approval and direction, arrange for the sale of its property and deliver all proceeds (net of commissions and customary costs of sale) to Pennvest. PA1 and Pennvest have entered into communication/exchanges to determine how Pennvest would like PA1 to proceed with this process. The Company’s personnel will assist PA1 with this process as needed at no cost to PA1.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA 1 has made no payments to vendors or other creditors in connection with the dissolution. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities will no longer be consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets where nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

 The Company currently is not involved in any other material litigation or similar events.

 

Lease:

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The following table summarized the supplemental cash flow information for the six months ended December 31, 2021:

 

       
    December 31, 2021
Cash paid for noncancelable operating lease included in the operating cash flows   $ 60,000  
Right of use assets obtained in exchange for operating lease liabilities   $ 180,586  

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of December 31, 2022:

 

       
From January 2022 to December 2022   $ —    
From January 2023 to December 2023     75,000  
From January 2024 to December 2024     75,000  
Undiscounted cash flow     150,000  
   Less imputed interest     (27,395 )
Total   122,605  

 

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of December 31, 2022 were 3 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUBSEQUENT EVENTS
6 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

10.       SUBSEQUENT EVENTS:

 

The Company has evaluated events that occurred subsequent to December 31, 2021 for recognition and disclosure in the financial statements and notes to the financial statements.

 

On January 26, 2022 OMRI’s Appeals Review Committee affirmed the prior “unresolved’ determination by OMRI’s Review Panel. The OMRI process has now moved to OMRI’s Advisory Council. See Note 1 subsection “Organic Fertilizer Listing/Certification Process” above for related disclosure.

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($665,375)) for the core of the ‘Bion System’ portion (without the crystallization modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete and procurement/fabrication has now been initiated. 3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, etc.) for work related to the Initial Project.

 

The Initial Project is designed to be installed primarily in two targeted primary phases which approach has been adopted to enable more rapid deployment of our 3G technology given pandemic-induced supply chain constraints. The first phase includes procurement and deployment of Bion’s core 3G technology. The modules in this phase include evaporation, distillation, absorption and crystallization modules, along with supporting mechanical/electrical equipment, controls, instrumentation, and facilities, many of which include components with ‘long lead times’ for manufacture and delivery. These items have now been ordered and procurement/manufacturing, as applicable, is underway.  This phase also includes installing a process building to house the system components, full utility installation (electrical, water, internet, natural gas, etc.), tankage to hold process and waste product liquids, facility access, and other items. The second phase, which will require additional permitting, planning and logistics, will consist primarily of design and construction of a 300 head beef cattle feed barn and an anaerobic digester, which items have shorter construction and fabrication/installation lead times than many of the components of the first phase.  The barn will include an innovative slatted floor livestock and an automated manure collection system.  Support structures will include manure collection basins, pumping stations, and automated controls integrated with the 3G system control system. The design and installation for both phases will include adaptive spaces that allow the integration of Initial Project expansions and the refinement of equipment operations that enhance system productivity and reduce energy demand.

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Principles of consolidation

Principles of consolidation:

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc. (“Projects Group”), Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC; and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). The operating loss are included in the consolidation through December 29, 2021.

 

The accompanying consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at December 31, 2021, and the results of operations of the Company for the three and six months ended December 31, 2021 and 2020 and the cash flows of the Company for the six months ended December 31, 2021 and 2020. Operating results for the three and six months ended December 31, 2021 are not necessarily indicative of the results that may be expected for the year ending June 30, 2022.

 

Cash and cash equivalents

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents.

 

Property and equipment

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

Stock-based compensation

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

Derivative Financial Instruments

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

 

Warrants

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Concentrations of credit risk

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

Revenue Recognition

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Loss per share

Loss per share:

 

Basic loss per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted loss per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the loss per share or increase the earnings per share. During the three and six months ended December 31, 2021 and 2020, the basic and diluted loss per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

The following table represents the warrants, options and convertible securities excluded from the calculation of basic loss per share:

 

          
   December 31,
2021
   December 31,
2020
 
Warrants   19,726,777    21,270,102 
Options   10,471,600    9,511,600 
Convertible debt   10,673,722    11,215,175 
Convertible preferred stock         19,500 

 

The following is a reconciliation of the denominators of the basic and diluted loss per share computations for the three and six months ended December 31, 2021 and 2020:

 

                    
   Three months
ended
December 31,
2021
   Three months
ended
December 31,
2020
   Six months
ended
December 31,
2021
   Six months
ended
December 31,
2020
 
Shares issued – beginning of period   41,475,573    31,575,656    41,315,986    31,409,005 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)   (704,309)   (704,309)
Shares outstanding – beginning of period   40,771,264    30,871,347    40,611,677    30,704,696 
Weighted average shares issued
    during the period
   317,728    316,298    292,665    285,943 
Diluted weighted average shares –
    end of period
   41,088,992    31,187,645    40,904,342    30,990,639 

 

 

Use of estimates

Use of estimates:

 

In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s financial statements properly reflect the change.

 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Schedule of anti dilutive securities
          
   December 31,
2021
   December 31,
2020
 
Warrants   19,726,777    21,270,102 
Options   10,471,600    9,511,600 
Convertible debt   10,673,722    11,215,175 
Convertible preferred stock         19,500 
Schedule of earnings per share, basic and diluted
                    
   Three months
ended
December 31,
2021
   Three months
ended
December 31,
2020
   Six months
ended
December 31,
2021
   Six months
ended
December 31,
2020
 
Shares issued – beginning of period   41,475,573    31,575,656    41,315,986    31,409,005 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)   (704,309)   (704,309)
Shares outstanding – beginning of period   40,771,264    30,871,347    40,611,677    30,704,696 
Weighted average shares issued
    during the period
   317,728    316,298    292,665    285,943 
Diluted weighted average shares –
    end of period
   41,088,992    31,187,645    40,904,342    30,990,639 

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
PROPERTY AND EQUIPMENT (Tables)
6 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment
          
   December 31,
2021
   June 30,
2021
 
Machinery and equipment  $     $2,222,670 
Buildings and structures         401,470 
Computers and office equipment   11,137    171,485 
3G project construction in process   145,439       
Property and equipment, gross   156,576    2,795,625 
Less accumulated depreciation   (9,681)   (2,795,084)
Property and equipment, net  $146,895   $541 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS' EQUITY (Tables)
6 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Schedule of option activity
                      
    Options   Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Life
   Aggregate
Intrinsic
Value
 
 Outstanding at July 1, 2021    10,471,600   $0.77    3.7   $6,064,335 
   Granted                       
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at December 31, 2021    10,471,600   $0.77    3.2   $9,624,679 
 Exercisable at December 31, 2021    10,471,600   $0.77    3.2   $9,624,679 
Schedule of non vested stock options
               
    Options   Weighted Average
Grant-Date Fair
Value
  Nonvested at July 1, 2021          $   
  Granted                
  Vested                
  Nonvested at December 31, 2021          $   
Condensed Financial Statement
                    
   Three
months
ended
December 31,
2021
   Three
months
ended
December 31,
2020
   Six months
ended
December 31,
2021
   Six months
ended
December 31,
2020
 
General and administrative:                    
  Change in fair value from modification of
    option terms
  $     $8,775   $     $8,775 
Change in fair value from modification of
    warrant terms
   5,625    25,506    5,625    25,506 
  Fair value of stock options expensed                        
     Total  $5,625   $34,281   $5,625   $34,281 
                     
Research and development:                    
  Fair value of stock options expensed  $     $     $     $   
     Total  $     $     $     $   
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
COMMITMENTS AND CONTINGENCIES (Tables)
6 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Schedule Of Cash Flow Supplemental Disclosure
       
    December 31, 2021
Cash paid for noncancelable operating lease included in the operating cash flows   $ 60,000  
Right of use assets obtained in exchange for operating lease liabilities   $ 180,586  
Schedule Of Future Minimum Lease Payment
       
From January 2022 to December 2022   $ —    
From January 2023 to December 2023     75,000  
From January 2024 to December 2024     75,000  
Undiscounted cash flow     150,000  
   Less imputed interest     (27,395 )
Total   122,605  
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative)
6 Months Ended 12 Months Ended
Dec. 31, 2021
USD ($)
Decimal
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2018
USD ($)
Cattle per head | Decimal 300      
Tech wastage | Decimal 1,500      
Percentage of sustainable 29.50%      
Description of kreider 2 poultry project Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 3G Tech) for 559,457 nutrient credits under the old EPA’s Chesapeake Bay model. The Company has been in ongoing discussions with the PADEP regarding the appropriate credit calculation methodology for large-scale technology-based nutrient reduction installations such as the KF2 Project utilizing our 3G Tech platform. Based on these discussions and the size of the Kreider 2 Project, we anticipate that if and when designs are finalized, the Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA      
Net Income (loss) $ 8,781,000 $ 3,451,000 $ 4,553,000  
Net income 10,235,000      
Operating loss 1,226,000      
Working Capital 4,006,000      
Stockholders' Equity Attributable to Parent 912,022 11,445,456    
Proceeds from Issuance or Sale of Equity 1,737,000 $ 5,209,000 $ 1,584,000  
Commissions paid 18,600      
Deferred Compensation Liability, Amount Cancelled       $ 2,404,000
Minimum [Member]        
Capital Required for Capital Adequacy 10,000,000      
Maximum [Member]        
Capital Required for Capital Adequacy $ 50,000,000      
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) - shares
6 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 19,726,777 21,270,102
Share-based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 10,471,600 9,511,600
Convertible Debt Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 10,673,722 11,215,175
Convertible Preferred Stock Antidilutive Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 19,500
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) - shares
3 Months Ended 6 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Accounting Policies [Abstract]        
Shares issued – beginning of period 41,475,573 31,575,656 41,315,986 31,409,005
Shares held by subsidiaries (Note 7) (704,309) (704,309) (704,309) (704,309)
Shares outstanding – beginning of period 40,771,264 30,871,347 40,611,677 30,704,696
Weighted average shares issued     during the period 317,728 316,298 292,665 285,943
Diluted weighted average shares –     end of period 41,088,992 31,187,645 40,904,342 30,990,639
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
Dec. 31, 2021
Centerpoint [Member]  
Noncontrolling interest, ownership percentage by parent 58.90%
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
PROPERTY AND EQUIPMENT - Property and Equipment (Details) - USD ($)
Dec. 31, 2021
Jun. 30, 2021
Property, Plant and Equipment [Abstract]    
Machinery and equipment $ 2,222,670
Buildings and structures 401,470
Computers and office equipment 11,137 171,485
3G project construction in process 145,439
Property and equipment, gross 156,576 2,795,625
Less accumulated depreciation (9,681) (2,795,084)
Property and equipment, net $ 146,895 $ 541
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]        
Depreciation expense $ 332 $ 207 $ 580 $ 414
Property, Plant and Equipment of PA1 [Member]        
Property, Plant and Equipment [Line Items]        
Impairment of Long-Lived Assets Held-for-use     $ 0  
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
DEFERRED COMPENSATION (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Jun. 30, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]          
Deferred compensation liability $ 477,374 $ 998,474 $ 477,374 $ 998,474 $ 479,208
Interest Rate on Deferred Compensation   4.00%   4.00%  
Deferred Compensation Consecutive Trading Days (Day)     10 days    
Interest Expense 118,365 $ 303,218 $ 230,545 $ 407,637  
Interest Expense on Deferred Compensation Obligation [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]          
Interest Expense 4,268 6,693 8,300 12,476  
Interest Expense, Related Party 4,095 2,950 8,044 5,159  
Chief Executive Officer [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]          
Deferred compensation liability 374,015 307,260 374,015 307,260  
Deferred Compensation, Convertible to Common Stock $ 300,000   $ 300,000    
Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share) $ 0.75   $ 0.75    
President [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]          
Deferred compensation liability   71,699   71,699  
Consultants [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]          
Deferred compensation liability $ 30,859 $ 512,432 $ 30,859 $ 512,432  
Interest Rate on Deferred Compensation 3.00%   3.00%    
Former Employee [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]          
Deferred compensation liability $ 72,500   $ 72,500    
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
LOANS PAYABLE (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 29, 2021
Sep. 30, 2021
Jun. 30, 2021
Sep. 25, 2014
Short-term Debt [Line Items]                
Total assets $ 5,314,735   $ 5,314,735     $ 297 $ 4,341,911  
Total liabilities 6,188,635   6,188,635   $ 10,234,501 10,154,334 15,748,250  
Accounts payable and accrued liabilities 513,070   513,070   10,009,802 9,939,148 $ 570,050  
Accounts payable         212,263 214,235    
Accrued Liabilities, Current         $ 12,436 $ 950    
Gain on legal dissolution of subsidiary     10,234,501        
PA-1 [Member]                
Short-term Debt [Line Items]                
Debt Instrument, Debt Default, Amount               $ 8,137,117
Pennvest Loan [Member]                
Short-term Debt [Line Items]                
Construction Loan 10,009,802   10,009,802          
Accrued Interest and Late Charges Payable 2,255,802   2,255,802          
Line of Credit Facility, Maximum Borrowing Capacity 7,754,000   7,754,000          
Debt Instrument, Annual Principal Payment 5,886,000   5,886,000          
Long-Term Debt, Maturity, Year Two 846,000   846,000          
Long-Term Debt, Maturity, Year Three 873,000   873,000          
Long-Term Debt, Maturity, Year Four 149,000   149,000          
Interest Expense, Debt $ 61,722 $ 61,722 $ 123,444 $ 123,444        
Pennvest Loan [Member] | Years One Through Five [Member]                
Short-term Debt [Line Items]                
Debt Instrument, Interest Rate During Period     2.547%          
Pennvest Loan [Member] | Years Six Through Maturity [Member]                
Short-term Debt [Line Items]                
Debt Instrument, Interest Rate During Period     3.184%          
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Jan. 01, 2020
Short-term Debt [Line Items]              
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.75   $ 0.75        
Convertible Notes Payable, Noncurrent $ 5,075,586   $ 5,075,586   $ 4,793,097    
Interest Expense $ 118,365 $ 303,218 $ 230,545 $ 407,637      
President [Member]              
Short-term Debt [Line Items]              
Number of Warrants Per Unit (in shares)           1.00  
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.75   $ 0.75        
President [Member] | Secured Promissory Note [Member]              
Short-term Debt [Line Items]              
Financing Receivable, Interest Rate, Stated Percentage 4.00%   4.00%        
The 2020 Convertible Obligations [Member]              
Short-term Debt [Line Items]              
Salary paid     $ 90,000        
The 2020 Convertible Obligations [Member] | Convertible Debt [Member]              
Short-term Debt [Line Items]              
Debt Instrument, Interest Rate, Stated Percentage             4.00%
Debt Instrument, Interest Rate, Stated Percentage, Quarterly             4.00%
Conversion Price Per Unit (in dollars per share)             $ 0.50
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)           $ 0.75  
Interest Expense $ 40,864 65,468 81,424 96,428      
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | President [Member]              
Short-term Debt [Line Items]              
Convertible Notes Payable, Noncurrent 1,302,049 1,163,862 1,302,049 1,163,862      
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | Chief Executive Officer [Member]              
Short-term Debt [Line Items]              
Convertible Notes Payable, Noncurrent 2,550,104 2,455,656 2,550,104 2,455,656      
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | Executive Vice Chairman [Member]              
Short-term Debt [Line Items]              
Convertible Notes Payable, Noncurrent 490,197 472,041 490,197 472,041      
September 2015 Convertible Notes [Member]              
Short-term Debt [Line Items]              
Deferred compensation     100,000        
September 2015 Convertible Notes [Member] | Chief Executive Officer [Member]              
Short-term Debt [Line Items]              
Convertible Notes Payable 274,521 168,498 274,521 168,498      
September 2015 Convertible Notes [Member] | Executive Vice Chairman [Member]              
Short-term Debt [Line Items]              
Convertible Notes Payable 438,198 423,081 438,198 423,081      
September 2015 Convertible Notes [Member] | Consultants [Member]              
Short-term Debt [Line Items]              
Convertible Notes Payable 20,517 $ 19,862 20,517 $ 19,862      
September 2015 Convertible Notes [Member] | Convertible Debt [Member]              
Short-term Debt [Line Items]              
Conversion Price Per Unit (in dollars per share)   $ 0.60   $ 0.60      
Interest Expense $ 5,698 $ 5,365 $ 11,064 $ 10,731      
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS' EQUITY - Stock Options Activity (Details)
6 Months Ended 12 Months Ended
Dec. 31, 2021
USD ($)
$ / shares
shares
Jul. 31, 2021
Equity [Abstract]    
Options outstanding, beginning (in shares) | shares 10,471,600  
Options outstanding, beginning weighted-average exercise price | $ / shares $ 0.77  
Outstanding, weighted-average remaining contractual life (Year) 3 years 2 months 12 days 3 years 8 months 12 days
Outstanding, aggregate intrinsic value beginning | $ $ 6,064,335  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares  
Granted, weighted-average exercise price | $ / shares  
Exercised, options (in shares) | shares  
Exercised, weighted-average exercise price | $ / shares  
Forfeited, options (in shares) | shares  
Forfeited, weighted-average exercise price | $ / shares  
Expired, options (in shares) | shares  
Expired, weighted-average exercise price | $ / shares  
Options outstanding, ending (in shares) | shares 10,471,600  
Options outstanding, beginning weighted-average exercise price | $ / shares $ 0.77  
Outstanding, aggregate intrinsic value ending | $ $ 9,624,679  
Exercisable, options (in shares) | shares 10,471,600  
Options outstanding, beginning weighted-average exercise price | $ / shares $ 0.77  
Exercisable, weighted-average remaining contractual life (Year) 3 years 2 months 12 days  
Exercisable, aggregate intrinsic value | $ $ 9,624,679  
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS' EQUITY - Nonvested Share Activity (Details)
6 Months Ended
Dec. 31, 2021
$ / shares
shares
Equity [Abstract]  
Nonvested options, beginning (in shares) | shares
Nonvested, weighted-average grant-date fair value beginning | $ / shares
Granted, options (in shares) | shares
Granted, weighted-average grant-date fair value | $ / shares
Vested (in shares) | shares
Vested, weighted-average grant-date fair value | $ / shares
Nonvested options, ending (in shares) | shares
Nonvested, weighted-average grant-date fair value, ending | $ / shares
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS' EQUITY - Financial Statements (Details) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
General and Administrative Expense [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Change in fair value from modification of warrant terms $ 5,625 $ 25,506 $ 5,625 $ 25,506
Allocated Share-based Compensation Expense 5,625 34,281 5,625 34,281
Research and Development Expense [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Allocated Share-based Compensation Expense
Share-based Payment Arrangement, Option [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Allocated Share-based Compensation Expense 0 0 0 0
Share-based Payment Arrangement, Option [Member] | General and Administrative Expense [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Change in fair value from modification of option terms 8,775 8,775
Allocated Share-based Compensation Expense
Share-based Payment Arrangement, Option [Member] | Research and Development Expense [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Allocated Share-based Compensation Expense
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jul. 01, 2014
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Jul. 03, 2014
Jul. 02, 2014
Class of Stock [Line Items]                  
Redemption of convertible Preferred stock       $ 41,000          
Shares Held by Subsidiaries (in shares)   704,309 704,309 704,309 704,309        
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 0.75   $ 0.75          
Class of Warrant or Right, Exercised During Period (in shares)       2,315,550          
Common Stock Shares Issued upon Exercise of Warrants (in shares)       2,315,550          
Warrant Exercised for Common Stock       $ 1,736,662          
Stock Issued During Period, Shares, Commission on Sale of Units and Warrant Exercises (in shares)       66,860          
Payments of Commissions on Exercise of Warrants       $ 18,601          
Class of Warrant or Right, Outstanding (in shares)   19,700,000   19,700,000          
Weighted Average Exercise Price for Outstanding Warrants (in dollars per share)       $ 0.73          
Weighted Average Remaining Contractual Life for Outstanding Warrants (Year)       2 years 8 months 12 days          
Issuance of warrants       $ 7,500 $ 2,500        
Interest expenses   $ 118,365 $ 303,218 $ 230,545 407,637        
Warrant exercised                
Proceeds from warrant       $ 1,736,662        
Share-based Compensation, Granted                
Options Held [Member]                  
Class of Stock [Line Items]                  
Share-based Compensation, Granted   0 0 0 0        
Minimum [Member]                  
Class of Stock [Line Items]                  
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 0.60   $ 0.60          
Maximum [Member]                  
Class of Stock [Line Items]                  
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 1.50   $ 1.50          
Share-based Payment Arrangement, Option [Member]                  
Class of Stock [Line Items]                  
Stock options, authorized (in shares)   36,000,000   36,000,000          
Share-based Payment Arrangement, Expense   $ 0 $ 0 $ 0 $ 0        
Share-based Payment Arrangement, Option [Member] | Maximum [Member]                  
Class of Stock [Line Items]                  
Options expiration period (Year)       10 years          
Common Stock [Member]                  
Class of Stock [Line Items]                  
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 0.75   $ 0.75          
Issuance of warrants              
Commissions on warrant exercises, shares       66,860          
Warrant [Member]                  
Class of Stock [Line Items]                  
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 0.75   $ 0.75          
Class of Warrant or Right, Exercised During Period (in shares)       2,315,550          
Common Stock Shares Issued upon Exercise of Warrants (in shares)       2,315,550          
Warrant Exercised for Common Stock       $ 1,736,662          
Issuance of warrants       $ 7,500          
Share-based Payment Arrangement, Plan Modification, Incremental Cost         5,625        
Interest expenses         2,712        
Warrants issued   2,226,216   6,431,538          
Warrant exercised       2,176,216          
Common stock share restricted       6,431,538          
Proceeds from warrant   $ 1,632,162   $ 4,823,651          
Warrant unexercised       648,142          
Additional Paid-in Capital [Member]                  
Class of Stock [Line Items]                  
Issuance of warrants       $ 7,500 $ 2,500        
Commissions on warrant exercises       18,601          
President [Member]                  
Class of Stock [Line Items]                  
Converted to Units, Amount       $ 17,711          
Accounts Payable Converted to Units, Shares       35,424          
Accounts Payable Converted to Units, Price Per Unit   $ 0.50   $ 0.50          
Class of Warrant or Right, Exercise Price of Warrants or Rights   0.75   0.75          
President [Member] | Restricted Stock [Member]                  
Class of Stock [Line Items]                  
Class of Warrant or Right, Exercise Price of Warrants or Rights   0.75   $ 0.75          
President [Member] | Common Stock [Member]                  
Class of Stock [Line Items]                  
Converted to Units, Amount       $ 17,711          
Accounts Payable Converted to Units, Shares       35,424          
Two Consultants [Member] | Warrant [Member]                  
Class of Stock [Line Items]                  
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 1.50   $ 1.50          
Class of Warrant or Right, Exercised During Period (in shares)       75,000          
Series B Preferred Stock [Member]                  
Class of Stock [Line Items]                  
Preferred Stock, Shares Outstanding, Ending Balance (in shares)   0   0   200     200
Preferred Stock, Par or Stated Value Per Share (in dollars per share)   $ 0.01   $ 0.01   $ 0.01     $ 0.01
Preferred Stock, Convertible Option Per Share (in dollars per share)               $ 2.00  
Preferred Stock, Dividend Rate, Percentage 2.50%                
Preferred Stock, Redemption Price Per Share (in dollars per share)                 $ 100
Dividends Payable   $ 21,000   $ 21,000          
Dividends, Preferred Stock           $ 2,000 $ 2,000    
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative)
Dec. 31, 2021
USD ($)
$ / shares
shares
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]  
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares $ 0.75
Chief Executive Officer [Member] | Warrants Issused, Subscription Receivable [Member]  
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares 5,565,000
Chief Executive Officer [Member] | Secured Promissory Note [Member]  
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]  
Financing Receivable, after Allowance for Credit Loss, Total $ 428,250
Notes receivable interest $ 491,975
President [Member]  
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]  
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares $ 0.75
President [Member] | Warrants Issused, Subscription Receivable [Member]  
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares 300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares $ 0.60
President [Member] | Secured Promissory Note [Member]  
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]  
Financing Receivable, after Allowance for Credit Loss, Total $ 34,093
Financing Receivable, Principal Amount $ 30,000
Financing Receivable, Interest Rate, Stated Percentage 4.00%
Former Employee [Member] | Warrants Issused, Subscription Receivable [Member]  
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares 928,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares $ 0.75
Former Employee [Member] | Secured Promissory Note [Member]  
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]  
Financing Receivable, after Allowance for Credit Loss, Total $ 5,408,800
Financing Receivable, Principal Amount $ 4,640,000
Financing Receivable, Interest Rate, Stated Percentage 4.00%
Consultant [Member]  
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]  
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares $ 0.90
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
COMMITMENTS AND CONTINGENCIES (Details)
Dec. 31, 2021
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Cash paid for noncancelable operating lease included in the operating cash flows $ 60,000
Right of use assets obtained in exchange for operating lease liabilities $ 180,586
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended 12 Months Ended
Oct. 10, 2016
Feb. 10, 2015
Dec. 31, 2022
Sep. 25, 2014
Dec. 31, 2021
Dec. 31, 2020
Jun. 30, 2021
Dec. 29, 2021
Sep. 30, 2021
Aug. 01, 2018
Feb. 28, 2018
Apr. 27, 2017
Oct. 31, 2016
Loss Contingencies [Line Items]                          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)         $ 0.75                
Expiration date         Jun. 30, 2025                
Exercise bonus             75.00%            
Warrants held by trust owned             $ 3,000,000            
Warrants and Rights Outstanding         $ 16,778,213                
Assets         5,314,735   4,341,911   $ 297        
Total liabilities         6,188,635   15,748,250 $ 10,234,501 10,154,334        
Accounts Payable And Accrued Liabilities         513,070   $ 570,050 10,009,802 9,939,148        
Accounts payable               212,263 214,235        
Accrued liabilities               $ 12,436 $ 950        
Gains Losses On Extinguishment Of Debt         $ 10,234,501              
Weighted average remaining lease term         The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of December 31, 2022 were 3 years and 10%, respectively                
Pennvest [Member]                          
Loss Contingencies [Line Items]                          
Principal, interest       $ 8,137,117                  
Minimum [Member]                          
Loss Contingencies [Line Items]                          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)         $ 0.60                
Exercise bonus         50.00%                
Maximum [Member]                          
Loss Contingencies [Line Items]                          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)         $ 1.50                
Exercise bonus         90.00%                
President [Member]                          
Loss Contingencies [Line Items]                          
Monthly Officers' Cash Compensation $ 18,000                        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)         $ 0.75                
President [Member] | Extension Bonus [Member] | FY2016 Extension Agreement [Member]                          
Loss Contingencies [Line Items]                          
Deferred Compensation, Maximum Convertible Amount                       $ 300,000 $ 125,000
Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)                       $ 0.75 $ 0.75
President [Member] | Warrants Issused, Subscription Receivable [Member]                          
Loss Contingencies [Line Items]                          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)         300,000                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)         $ 0.60                
President [Member] | Warrants Issued in Connection with Sale of Units in Exchange for Salary [Member]                          
Loss Contingencies [Line Items]                          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)         $ 0.75                
Chief Executive Officer [Member]                          
Loss Contingencies [Line Items]                          
Monthly Officers' Cash Compensation   $ 31,000                      
Chief Executive Officer [Member] | Secured Promissory Note, Consideration for Warrants Expiring on December 31, 2025 [Member]                          
Loss Contingencies [Line Items]                          
Financing Receivable, after Allowance for Credit Loss, Total         $ 340,093                
Repayments of Long-term Debt, Total         $ 120,000 $ 55,000              
Chief Executive Officer [Member] | Warrants Issused, Subscription Receivable [Member]                          
Loss Contingencies [Line Items]                          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)         5,565,000                
Chief Executive Officer [Member] | Warrants Expiring on December 31, 2025 [Member]                          
Loss Contingencies [Line Items]                          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                   3,000,000      
Bassani [Member]                          
Loss Contingencies [Line Items]                          
Salaries and wages                     $ 31,000    
Additional paid amount                     $ 2,000    
Interest bearing secured promissory note     $ 300,000                    
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member]
1 Months Ended
Jan. 28, 2022
USD ($)
Subsequent Event [Line Items]  
Debt instrument paid amount $ 2,665,500
Debt instrument rate 25.00%
Debt instrument principal payment $ 665,375
XML 49 bion_10q-123121_htm.xml IDEA: XBRL DOCUMENT 0000875729 2021-07-01 2021-12-31 0000875729 2022-02-01 0000875729 2021-12-31 0000875729 2021-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2021-12-31 0000875729 us-gaap:SeriesBPreferredStockMember 2021-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2021-12-31 0000875729 us-gaap:SeriesAPreferredStockMember 2021-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-12-31 0000875729 us-gaap:SeriesCPreferredStockMember 2021-06-30 0000875729 2021-10-01 2021-12-31 0000875729 2020-10-01 2020-12-31 0000875729 2020-07-01 2020-12-31 0000875729 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-06-30 0000875729 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-06-30 0000875729 us-gaap:CommonStockMember 2020-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000875729 bnet:SubscriptionsReceivableMember 2020-06-30 0000875729 us-gaap:RetainedEarningsMember 2020-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2020-06-30 0000875729 2020-06-30 0000875729 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0000875729 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0000875729 us-gaap:CommonStockMember 2021-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000875729 bnet:SubscriptionsReceivableMember 2021-06-30 0000875729 us-gaap:RetainedEarningsMember 2021-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-06-30 0000875729 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-07-01 2020-12-31 0000875729 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-07-01 2020-12-31 0000875729 us-gaap:CommonStockMember 2020-07-01 2020-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-12-31 0000875729 bnet:SubscriptionsReceivableMember 2020-07-01 2020-12-31 0000875729 us-gaap:RetainedEarningsMember 2020-07-01 2020-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-12-31 0000875729 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-07-01 2021-12-31 0000875729 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-07-01 2021-12-31 0000875729 us-gaap:CommonStockMember 2021-07-01 2021-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-12-31 0000875729 bnet:SubscriptionsReceivableMember 2021-07-01 2021-12-31 0000875729 us-gaap:RetainedEarningsMember 2021-07-01 2021-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-12-31 0000875729 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000875729 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000875729 us-gaap:CommonStockMember 2020-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000875729 bnet:SubscriptionsReceivableMember 2020-12-31 0000875729 us-gaap:RetainedEarningsMember 2020-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2020-12-31 0000875729 2020-12-31 0000875729 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000875729 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000875729 us-gaap:CommonStockMember 2021-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000875729 bnet:SubscriptionsReceivableMember 2021-12-31 0000875729 us-gaap:RetainedEarningsMember 2021-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2021-12-31 0000875729 2020-07-01 2021-06-30 0000875729 2019-07-01 2020-06-30 0000875729 2017-07-01 2018-06-30 0000875729 srt:MinimumMember 2021-12-31 0000875729 srt:MaximumMember 2021-12-31 0000875729 bnet:CenterpointMember 2021-12-31 0000875729 us-gaap:WarrantMember 2021-07-01 2021-12-31 0000875729 us-gaap:WarrantMember 2020-07-01 2020-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-12-31 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2021-07-01 2021-12-31 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2020-07-01 2020-12-31 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2021-07-01 2021-12-31 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2020-07-01 2020-12-31 0000875729 bnet:PropertyPlantAndEquipmentOfPA1Member 2021-07-01 2021-12-31 0000875729 srt:ChiefExecutiveOfficerMember 2021-12-31 0000875729 srt:ChiefExecutiveOfficerMember 2020-12-31 0000875729 srt:PresidentMember 2020-12-31 0000875729 bnet:ConsultantsMember 2021-12-31 0000875729 bnet:ConsultantsMember 2020-12-31 0000875729 bnet:FormerEmployeeMember 2021-12-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2021-10-01 2021-12-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2020-10-01 2020-12-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2021-07-01 2021-12-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2020-07-01 2020-12-31 0000875729 bnet:PennvestLoanMember 2021-12-31 0000875729 bnet:YearsOneThroughFiveMember bnet:PennvestLoanMember 2021-07-01 2021-12-31 0000875729 bnet:YearsSixThroughMaturityMember bnet:PennvestLoanMember 2021-07-01 2021-12-31 0000875729 bnet:PennvestLoanMember 2021-10-01 2021-12-31 0000875729 bnet:PennvestLoanMember 2020-10-01 2020-12-31 0000875729 bnet:PennvestLoanMember 2021-07-01 2021-12-31 0000875729 bnet:PennvestLoanMember 2020-07-01 2020-12-31 0000875729 bnet:PA1Member 2014-09-25 0000875729 2021-09-30 0000875729 2021-12-29 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-01-01 0000875729 srt:PresidentMember 2020-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-12-31 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-12-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-12-31 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-12-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-12-31 0000875729 bnet:The2020ConvertibleObligationsMember 2021-07-01 2021-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-10-01 2021-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-10-01 2020-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-07-01 2021-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-07-01 2020-12-31 0000875729 srt:PresidentMember bnet:SecuredPromissoryNoteMember 2021-12-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember 2021-12-31 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember 2021-12-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember 2021-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember 2020-12-31 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember 2020-12-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember 2020-12-31 0000875729 bnet:September2015ConvertibleNotesMember 2021-07-01 2021-12-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2021-10-01 2021-12-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-10-01 2020-12-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2021-07-01 2021-12-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-07-01 2020-12-31 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-02 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-03 0000875729 us-gaap:SeriesBPreferredStockMember 2014-06-25 2014-07-01 0000875729 us-gaap:SeriesBPreferredStockMember 2020-07-01 2021-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2019-07-01 2020-06-30 0000875729 srt:PresidentMember us-gaap:CommonStockMember 2021-07-01 2021-12-31 0000875729 srt:PresidentMember 2021-12-31 0000875729 srt:PresidentMember us-gaap:RestrictedStockMember 2021-12-31 0000875729 srt:PresidentMember 2021-07-01 2021-12-31 0000875729 bnet:TwoConsultantsMember us-gaap:WarrantMember 2021-07-01 2021-12-31 0000875729 us-gaap:WarrantMember 2021-07-01 2021-12-31 0000875729 bnet:TwoConsultantsMember us-gaap:WarrantMember 2021-12-31 0000875729 us-gaap:WarrantMember 2020-07-01 2020-12-31 0000875729 us-gaap:WarrantMember 2021-12-31 0000875729 us-gaap:WarrantMember 2021-10-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2021-12-31 0000875729 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-07-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2021-10-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2020-10-01 2020-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-12-31 0000875729 us-gaap:OptionMember 2021-10-01 2021-12-31 0000875729 us-gaap:OptionMember 2021-07-01 2021-12-31 0000875729 us-gaap:OptionMember 2020-10-01 2020-12-31 0000875729 us-gaap:OptionMember 2020-07-01 2020-12-31 0000875729 2020-08-01 2021-07-31 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-10-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-10-01 2020-12-31 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-12-31 0000875729 us-gaap:GeneralAndAdministrativeExpenseMember 2021-10-01 2021-12-31 0000875729 us-gaap:GeneralAndAdministrativeExpenseMember 2020-10-01 2020-12-31 0000875729 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-12-31 0000875729 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-12-31 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-10-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-10-01 2020-12-31 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-12-31 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-12-31 0000875729 us-gaap:ResearchAndDevelopmentExpenseMember 2021-10-01 2021-12-31 0000875729 us-gaap:ResearchAndDevelopmentExpenseMember 2020-10-01 2020-12-31 0000875729 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-12-31 0000875729 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteMember 2021-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsIssusedSubscriptionReceivableMember 2021-12-31 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2021-12-31 0000875729 bnet:FormerEmployeeMember bnet:SecuredPromissoryNoteMember 2021-12-31 0000875729 bnet:FormerEmployeeMember bnet:WarrantsIssusedSubscriptionReceivableMember 2021-12-31 0000875729 bnet:ConsultantMember 2021-12-31 0000875729 srt:PresidentMember 2016-10-01 2016-10-10 0000875729 srt:PresidentMember bnet:WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember 2021-12-31 0000875729 srt:ChiefExecutiveOfficerMember 2015-02-03 2015-02-10 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2016-10-31 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2017-04-27 0000875729 bnet:BassaniMember 2018-02-28 0000875729 bnet:BassaniMember 2022-12-01 2022-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsExpiringOnDecember312025Member 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2021-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2021-07-01 2021-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2020-07-01 2020-12-31 0000875729 bnet:PennvestMember 2014-09-01 2014-09-25 0000875729 us-gaap:SubsequentEventMember 2022-01-01 2022-01-28 iso4217:USD shares iso4217:USD shares pure bnet:Decimal 0000875729 false --06-30 2022 Q2 10-Q true 2021-12-31 false 000-19333 Bion Environmental Technologies, Inc. CO 84-1176672 9 East Park Court Old Bethpage NY 11804 516 586-5643 Common Stock BNET Yes Yes Non-accelerated Filer true false false 43209511 4948282 4216321 46723 124049 1000 1000 4996005 4341370 171835 146895 541 5314735 4341911 513070 570050 0.01 0.01 50000 50000 0 0 200 200 0 40000 37400 477374 479208 9868495 990444 10955153 122605 5075586 4793097 6188635 15748250 0.01 0.01 50000 50000 0 0 0 0 0.01 0.01 60000 60000 0 0 0 0 0 0 100000000 100000000 43733820 41315986 43029511 40611677 123150676 121399067 504650 504650 -123558048 -132339873 -912022 -11445456 38122 39117 -873900 -11406339 5314735 4341911 617963 291682 1109096 594559 332 207 580 414 54404 155385 116213 246373 672699 447274 1225889 841346 -672699 -447274 -1225889 -841346 1269 47 2763 126 118365 303218 230545 407637 10234501 10234501 10117405 -303171 10006719 -407511 9444706 -750445 8780830 -1248857 -489 -524 -995 -1039 9445195 -749921 8781825 -1247818 0.23 -0.02 0.21 -0.04 41088992 31187645 40904342 30990639 31409005 114266683 -504650 -128891893 41902 -15087958 720000 360000 360000 -31000 -31000 8775 8775 188890 188890 2500 2500 141589 70794 70794 -1247818 -1039 -1248857 32270594 114866642 -504650 -130139711 40863 -15736856 41315986 121399067 -504650 -132339873 39117 -11406339 2315550 1736662 1736662 66860 -18601 -18601 35424 17711 17711 8337 8337 7500 7500 8781825 -995 8780830 43733820 123150676 -504650 -123558048 38122 -873900 8780830 -1248857 10234501 580 414 248409 425499 13125 36781 -77326 -3615 -49230 130628 8162 179867 245742 -852966 -528644 92134 -92134 1736662 18601 -41000 360000 -31000 1677061 329000 731961 -199644 4216321 560828 4948282 361184 28 17711 70794 50145 190000 54800 <p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zgITjaYSmdc2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>1.       <span id="xdx_82C_zDi5D28xpIZf">ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Organization and nature of business: </b></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Our patented and proprietary technology provides comprehensive environmental solutions to one of the greatest water air and water quality problems in the U.S. today: pollution from large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs").  Application of our technology and technology platform can simultaneously remediate environmental problems and improve operational/resource efficiencies by recovering value high-value co-products from the CAFOs’ waste stream that have traditionally been wasted or underutilized, including renewable energy, nutrients (including ammonia nitrogen) and water.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From 2016 to 2021 fiscal years, the Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“3G Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of organic ammonium bicarbonate products. The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. An application for our first solid ammonium bicarbonate product – AD Nitrogen – has been filed and is in the review process (which is likely to require an extended period of time and multiple procedural steps due to the novel nature of Bion’s 3G Tech in the context of organic certifications) See “Organic Fertilizer Listing/Certification Process” below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion is now focused primarily on: i) development/construction of its initial commercial-scale 3G Tech installation (see below and Note 10, “Subsequent Events”), ii) developing applications and markets for its organic fertilizer products and its sustainable (conventional and organic) animal protein products, and iii) initiation and development of joint ventures (“JVs” as discussed below) (and related projects) based on the augmented capabilities of our 3G Tech, while (iv) continuing to pursue development opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and ongoing R&amp;D activities.</p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns ranging including food safety, environmental impacts, and humane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company believes that its 3G Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a large production/marketing opportunity for Bion. Our 3G Tech will also produce (as co-products) biogas and valuable organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During late September 2021, Bion entered into a lease for the development site of its initial commercial scale 3G Tech project in September 2021(“Initial Project”), which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project will be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately <span id="xdx_90F_ecustom--CattlePerHead_uDecimal_c20210701__20211231_zx0CCs5n5et5" title="Cattle per head">300</span> head of beef cattle. The facility will include Bion’s 3G Tech platform including: i) covered barns (possibly including roof top solar photovoltaic generation), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion 3G Tech facilities capable of treating the waste from approximately <span id="xdx_900_ecustom--TechWastage_uDecimal_c20210701__20211231_z6Yn1OfioLB6" title="Tech wastage">1,500</span> head). The facility will be large enough to demonstrate engineering capabilities of Bion’s 3G Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly, with operations targeted to commence sometime late in 2022. 3G1 has been moving forward with the development process of the Initial Project. See Note 10 “Subsequent Events” for activities since the start of the 2022 calendar year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Specifically, the Initial Project is being developed to provide and/or accomplish the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">i.</span></td> <td><span style="font-size: 10pt">Proof of 3G Tech platform scalability</span></td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">-</span></td> <td><span style="font-size: 10pt">Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion 3G technology platform.</span></td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">-</span></td> <td><span style="font-size: 10pt">Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">ii.</span></td> <td><span style="font-size: 10pt">Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.</span></td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">iii.</span></td> <td><span style="font-size: 10pt">Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) for commercial testing by potential joint venture partners and/or purchasers and for university growth trials.</span></td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">iv.</span></td> <td><span style="font-size: 10pt">Produce sustainable beef products for initial test marketing efforts.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon achieving optimized and steady-state operations at the Initial Project (and especially of the core modules of our 3G Tech platform), coupled with obtaining organic certifications(s) ( OMRI listing and/or other organic listings/certifications) for its AD Nitrogen product, Bion expects to be ready to move forward with its plans for development of much larger facilities. The Company anticipates that discussions and negotiations regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will commence during the construction of the Initial Project with the goal of establishing JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef during 2023. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its 3G Tech platform.</p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/96% Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘<b><span style="text-decoration: underline">3G Tech Kreider 2 Poultry Project’</span></b> below as an example).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/ dairy/ egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a certain segment of consumers are choosing seemingly sustainable offering, and are also willing to pay a premium for it. Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is <span id="xdx_902_ecustom--PercentageOfSustainable_dp_c20210701__20211231_zhPqP3JiUdya" title="Percentage of sustainable">29.5</span> percent on average.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s 3G Tech platform, along with its business model, enables the cleanup of the ‘dirtiest’ part of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 retail value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef is 63% more expensive today, while pork and chicken, which are now primarily raised in covered barns, at CAFOs with highly integrated supply chains, are 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. Meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, are being heavily promoted by themselves and the media, and have enjoyed steady sales growth. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have recently entered the plant protein space. In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the only ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence). However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, which represents approximately 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost remains very uncertain at this point.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium sustainable beef products that satisfy these concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our 3G Tech platform, both sustainable and/or organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, but with the superior taste and texture those consumers have grown to prefer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Sustainable Beef</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s goal is to be first to market with meaningfully sustainable, and verified, beef products that can be produced at sufficient scale to service national market demand. The cattle produced at a Bion facility will enjoy a substantially lower carbon footprint, dramatically reduced nutrient impacts to water, and an almost total pathogen kill in the waste stream. A Bion sustainable beef facility will be comprised of covered barns with slotted floors, which allow the waste to pass through and be collected quickly and frequently to reduce ammonia volatilization and loss, as well as odors. Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns represent a very large roof surface area, which will be utilized in appropriate geographical locations for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. Waste treatment and resource recovery will be provided by Bion’s advanced 3G Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small scale livestock producers (largely in the grass fed beef category). The reach and extent of such efforts is limited to date and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ’cow-calf’ segment of the livestock chain) in procurement by major beef processing companies, but a closer look finds that most consist largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Sustainable Organic Beef</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion believes it has a unique opportunity to produce, at scale, affordable corn-fed organic beef that is certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the 3G Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. Stated directly, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap will put the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Organic Fertilizer Listing/Certification Process</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“3G Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of organically listed ammonium bicarbonate products. The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An application for our first solid ammonium bicarbonate product – AD Nitrogen – was filed during May 2021 and is currently actively proceeding through OMRI’s multi-stage review process ---which process has taken an extended period of time and multiple procedural steps due to the novel nature of Bion’s 3G Tech in the context of organic listings/certifications. OMRI’s Review Panel ‘…. voted to temporarily assign it to “Unresolved” status. This means that OMRI does not currently have the clarity necessary to decide whether the product meets OMRI standards which are based on the USDA National Organic Program regulations (NOP).’ Subsequently the application has gone through ‘Rebuttal’ (OMRI Review Panel) and ‘Appeal’ (Appeals Review Committee) stages which affirmed the “Unresolved” status. The Company has been informed that ‘…the product will remain Unresolved until July 22, 2022 or until resolution is reached by OMRI though consultation with the OMRI Advisory Council.’ The application is now beginning review by OMRI’s Advisory Council. The Company’s product is novel in part due to the fact that OMRI does not have a listing category for a solid form of concentrated and soluble nitrogen fertilizers and there is no clear guidance at present from OMRI internal policy on how to categorize this product and the process that produced it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives are involved in discussions regarding resolution of these matters at all three levels. The Company anticipates positive resolution of this manner well prior to operational dates for the Company’s initial large scale JV 3G projects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <b><span style="text-decoration: underline">3 Tech Kreider 2 Poultry Project</span></b></p> <p style="font: 10pt/96% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_905_ecustom--DescriptionOfKreider2PoultryProject_c20210701__20211231" title="Description of kreider 2 poultry project">Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 3G Tech) for 559,457 nutrient credits under the old EPA’s Chesapeake Bay model. The Company has been in ongoing discussions with the PADEP regarding the appropriate credit calculation methodology for large-scale technology-based nutrient reduction installations such as the KF2 Project utilizing our 3G Tech platform. Based on these discussions and the size of the Kreider 2 Project, we anticipate that if and when designs are finalized, the Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA</span>. Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). A review process to clarify certain issues related to credit calculation and verification commenced during 2014 based on Bion’s 2G Tech but was been placed on hold. The Company anticipates if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our 3G Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s 3G Tech for increased recovery of marketable by-products, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Note that while Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees related to a ‘sustainable brand’, the Covid-19 pandemic has delayed legislative efforts needed to commence its development. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.</p> <p style="font: 12pt/96% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Technology Deployment: Bion 3G Tech</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s 3G Tech has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The 3G Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts (see below and Note 10, “Subsequent Events”). and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion below), and d) payment for verified ecosystem services. The Company’s first patent on its 3G Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s 3G Tech coverage, and the Company has additional applications pending and/or planned.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s business model and technology platform can create the opportunity for JVs (in various contractual forms) between the Company and large livestock/food/fertilizer industry participants, based upon the supplemental cash flow generated by implementation of our 3G Tech business model, which will support the costs of technology implementation (including related debt). We anticipate this will result in long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) may expand to represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits, that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019. However, the Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry and its markets are already changing; with a commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its 3G Tech, during the current 2023 fiscal year. We believe that Bion’s 3G Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 4pt"><b><span style="text-decoration: underline">The Livestock Problem</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun - and policies have already begun to change, as well. Bion’s 3G Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21st Century consumer demands for meaningful sustainability.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition - it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source-- before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture and treat.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s 3G Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going concern and management’s plans:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and has incurred net losses (including significant non-cash expenses) of approximately $<span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pp0p0_c20200701__20210630_z9uXiGc7IR2g" title="Net Income (loss)">3,451,000</span> and $<span id="xdx_90F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pp0p0_c20190701__20200630_zzgUYn3TxuJ4" title="Net Income (loss)">4,553,000</span> during the years ended June 30, 2021 and 2020, respectively, and a net income of approximately $<span id="xdx_907_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pp0p0_c20210701__20211231_zRCw6EfEOCbc" title="Net Income (loss)">8,781,000</span> during the six months ended December 31, 2021. The net income for the six months is due to a one-time, non-cash event of the dissolution of PA-1 and a gain of approximately $<span id="xdx_903_eus-gaap--IncomeLossFromContinuingOperations_pp0p0_c20210701__20211231_zLqbvhzB4PYg" title="Net income">10,235,000</span>. There was an operating loss of approximately $<span id="xdx_90C_ecustom--OperatingLoss_c20210701__20211231_zsDgnJPYjphk" title="Operating loss">1,226,000</span> for the six months ended December 31, 2021. At December 31, 2021, the Company has working capital and a stockholders’ deficit of approximately $<span id="xdx_90A_ecustom--WorkingCapital_c20211231_pp0p0" title="Working Capital">4,006,000</span> and <span id="xdx_90C_eus-gaap--StockholdersEquity_iNI_pp0p0_di_c20211231_zF6nadxsTojd" style="display: none">912,022</span> $912,000, respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended June 30, 2021 and 2020, the Company received gross proceeds of approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20200701__20210630_pp0p0" title="Proceeds from Issuance or Sale of Equity">5,209,000</span> and $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20190701__20200630_pp0p0" title="Proceeds from Issuance or Sale of Equity">1,584,000</span>, respectively, from the sale of its debt and equity securities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the six months ended December 31, 2021, the Company received total proceeds of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20210701__20211231_zWqkv6XQmqf" title="Proceeds from Issuance or Sale of Equity">1,737,000</span> from the sale of its equity securities and paid approximately $<span id="xdx_902_eus-gaap--PaymentsForCommissions_c20210701__20211231_z8wT0pdVJaq5" title="Commissions paid">18,600</span> in cash commissions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During fiscal years 2021 and 2020, the Company has faced progressively less difficulty in raising equity funding (but substantial equity dilution has gone along with the larger amounts of equity financing during the periods) than was experienced in the prior 3 years. Note, however, that during the first six months of the current fiscal year, the Company raised equity funds at a rate less than the average rate during fiscal year 2021. The Company anticipates substantial increases in demands for capital and operating expenditures as it moves toward commercial implementation of its 3G Tech and development of JVs and, therefore, is likely to continue to face, significant cash flow management challenges due to limited capital resources and working capital constraints which have only recently begun to be alleviated. To partially mitigate these working capital constraints, the Company’s core senior management and several key employees and consultants have been deferring (and continue to defer) part of their cash compensation and/or are accepting compensation in the form of securities of the Company and/or converting portions of their compensation and deferred compensation to securities of the Company (Notes 5 and 7) and members of the Company’s senior management have made loans to the Company from time to time. During the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $<span id="xdx_90E_ecustom--DeferredCompensationLiabilityAmountCancelled_c20170701__20180630_pp0p0" title="Deferred Compensation Liability, Amount Cancelled">2,404,000</span>. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to continue its recent success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and curtailment of ongoing activities including research and development activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including the Initial Project, JV Projects, Integrated Projects and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $<span id="xdx_90D_eus-gaap--CapitalRequiredForCapitalAdequacy_c20211231__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Capital Required for Capital Adequacy">10,000,000 </span>to $<span id="xdx_90F_eus-gaap--CapitalRequiredForCapitalAdequacy_c20211231__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Capital Required for Capital Adequacy">50,000,000</span> or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us), that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Covid-19 pandemic related matters:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and are likely to delay and/or increase the cost of construction of the Company’s initial 3G Tech installation if equipment remains difficult to acquire in a timely manner, vi) due to the age and health of our core management team, all of whom are age 70 or older and have had one or more existing health issues, the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 300 1500 0.295 Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 3G Tech) for 559,457 nutrient credits under the old EPA’s Chesapeake Bay model. The Company has been in ongoing discussions with the PADEP regarding the appropriate credit calculation methodology for large-scale technology-based nutrient reduction installations such as the KF2 Project utilizing our 3G Tech platform. Based on these discussions and the size of the Kreider 2 Project, we anticipate that if and when designs are finalized, the Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA 3451000 4553000 8781000 10235000 1226000 4006000 -912022 5209000 1584000 1737000 18600 2404000 10000000 50000000 <p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zDNa3vSNmssf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2.       <span id="xdx_826_zzbAVvasSUHh">SIGNIFICANT ACCOUNTING POLICIES</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zFA9g6FQPv01" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_861_zGWu7OSJDNX3">Principles of consolidation</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc. (“Projects Group”), Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC; and its <span id="xdx_908_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20211231__srt--OwnershipAxis__custom--CenterpointMember_zL9tBu0zpyhb" title="Noncontrolling interest, ownership percentage by parent">58.9</span>% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). The operating loss are included in the consolidation through December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at December 31, 2021, and the results of operations of the Company for the three and six months ended December 31, 2021 and 2020 and the cash flows of the Company for the six months ended December 31, 2021 and 2020. Operating results for the three and six months ended December 31, 2021 are not necessarily indicative of the results that may be expected for the year ending June 30, 2022.</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zUnOfEkWUNh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zSvkLZ0iuKWb">Cash and cash equivalents</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zmgbewfm0Xfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86A_zifLQ6cJts4">Property and equipment</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zdte9i2W2xBc" style="font: 10pt/90% Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zAdxD3QMbF3f">Patents</span>: </b></p> <p style="font: 10pt/90% Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt/90% Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zNpPqylh71Vi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_zMDkVW5DAoFi">Stock-based compensation</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--DerivativesPolicyTextBlock_zAuuqys3GqTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_zgl29FK77sWg">Derivative Financial Instruments</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_ecustom--EquityIssuancesWarrantsPolicyPolicyTextBlock_zDlAzTMx7dWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86B_zW05JmF5XEjc">Warrants</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_z5yRxn28uf71" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_867_z8d4sOzUrMt8">Concentrations of credit risk</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_ecustom--MinorityInterestPolicyPolicyTextBlock_zq7empbJGqlg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_zkKfl11sx0Y3">Noncontrolling interests</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zLQTZqyWhWMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zpPFXYzUWo51">Fair value measurements</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 – assets and liabilities whose significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--LessorLeasesPolicyTextBlock_z80Nvp4IcL56" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_864_zVDpxj0oKaAf">Lease Accounting</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">The Company accounts for leases under ASC 842, <i>Leases</i> (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zwhEIN1n95E6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_z0TRx1NuVzL3">Revenue Recognition</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zTolzq2uwYEi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zWqoa44l78Hg">Loss per share</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic loss per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted loss per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the loss per share or increase the earnings per share. During the three and six months ended December 31, 2021 and 2020, the basic and diluted loss per share was the same, as the impact of potential dilutive common shares was anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents the warrants, options and convertible securities excluded from the calculation of basic loss per share:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zQx6cAdtd3Od" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_8BB_zjByibRmIEe3" style="display: none">Schedule of anti dilutive securities</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, <br/> 2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: justify">Warrants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; text-align: right" title="Antidilutive securities">19,726,777</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; text-align: right" title="Antidilutive securities">21,270,102</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Antidilutive securities">10,471,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zKZ2wHZppHOb" style="text-align: right" title="Antidilutive securities">9,511,600</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Convertible debt</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities">10,673,722</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities">11,215,175</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0678">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities">19,500</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AB_z4Hfe2iHZhB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a reconciliation of the denominators of the basic and diluted loss per share computations for the three and six months ended December 31, 2021 and 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zzOD2W37KCX2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 0in"><span id="xdx_8B2_zng47f5r2t4i" style="display: none">Schedule of earnings per share, basic and diluted</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20211001_20211231" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20201001_20201231" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20210701__20211231_zv6cUGsnm8d5" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20200701__20201231_zs7qfuYlPbwe" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Three months <br/>ended <br/>December 31, <br/>2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Three months <br/>ended <br/>December 31, <br/>2020</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Six months <br/>ended <br/>December 31, <br/>2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Six months <br/>ended <br/>December 31, <br/>2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_ecustom--SharesIssuedBeginningOfPeriod_zP4rnjCME6n5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; text-indent: 0in">Shares issued – beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">41,475,573</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">31,575,656</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">41,315,986</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">31,409,005</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SharesHeldBySubsidiaries_zYBm8cpWfID3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0in">Shares held by subsidiaries (Note 7)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--SharesOutstandingBeginningOfPeriod_z6iPfX8Ppqw9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in">Shares outstanding – beginning of period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,771,264</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,871,347</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,611,677</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,704,696</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--WeightedAverageNumberOfSharesIssuedDuringPeriod_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Weighted average shares issued <br/>    during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">317,728</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">316,298</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">292,665</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">285,943</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Diluted weighted average shares – <br/>    end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">41,088,992</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">31,187,645</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">40,904,342</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">30,990,639</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_8AF_zdkDu8WVaFre" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--UseOfEstimates_zvEenY1GWhni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86C_z9sxAI6qA469">Use of estimates</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zVnU1pMlXskf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_864_zsz62lzuVxL2">Recent Accounting Pronouncements</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s financial statements properly reflect the change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zFA9g6FQPv01" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_861_zGWu7OSJDNX3">Principles of consolidation</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc. (“Projects Group”), Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC; and its <span id="xdx_908_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20211231__srt--OwnershipAxis__custom--CenterpointMember_zL9tBu0zpyhb" title="Noncontrolling interest, ownership percentage by parent">58.9</span>% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). The operating loss are included in the consolidation through December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at December 31, 2021, and the results of operations of the Company for the three and six months ended December 31, 2021 and 2020 and the cash flows of the Company for the six months ended December 31, 2021 and 2020. Operating results for the three and six months ended December 31, 2021 are not necessarily indicative of the results that may be expected for the year ending June 30, 2022.</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 0.589 <p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zUnOfEkWUNh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zSvkLZ0iuKWb">Cash and cash equivalents</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zmgbewfm0Xfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86A_zifLQ6cJts4">Property and equipment</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zdte9i2W2xBc" style="font: 10pt/90% Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zAdxD3QMbF3f">Patents</span>: </b></p> <p style="font: 10pt/90% Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt/90% Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zNpPqylh71Vi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_zMDkVW5DAoFi">Stock-based compensation</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--DerivativesPolicyTextBlock_zAuuqys3GqTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_zgl29FK77sWg">Derivative Financial Instruments</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_ecustom--EquityIssuancesWarrantsPolicyPolicyTextBlock_zDlAzTMx7dWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86B_zW05JmF5XEjc">Warrants</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_z5yRxn28uf71" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_867_z8d4sOzUrMt8">Concentrations of credit risk</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_ecustom--MinorityInterestPolicyPolicyTextBlock_zq7empbJGqlg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_zkKfl11sx0Y3">Noncontrolling interests</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zLQTZqyWhWMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zpPFXYzUWo51">Fair value measurements</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 – assets and liabilities whose significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--LessorLeasesPolicyTextBlock_z80Nvp4IcL56" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_864_zVDpxj0oKaAf">Lease Accounting</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">The Company accounts for leases under ASC 842, <i>Leases</i> (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zwhEIN1n95E6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_z0TRx1NuVzL3">Revenue Recognition</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zTolzq2uwYEi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zWqoa44l78Hg">Loss per share</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic loss per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted loss per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the loss per share or increase the earnings per share. During the three and six months ended December 31, 2021 and 2020, the basic and diluted loss per share was the same, as the impact of potential dilutive common shares was anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents the warrants, options and convertible securities excluded from the calculation of basic loss per share:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zQx6cAdtd3Od" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_8BB_zjByibRmIEe3" style="display: none">Schedule of anti dilutive securities</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, <br/> 2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: justify">Warrants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; text-align: right" title="Antidilutive securities">19,726,777</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; text-align: right" title="Antidilutive securities">21,270,102</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Antidilutive securities">10,471,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zKZ2wHZppHOb" style="text-align: right" title="Antidilutive securities">9,511,600</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Convertible debt</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities">10,673,722</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities">11,215,175</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0678">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities">19,500</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AB_z4Hfe2iHZhB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a reconciliation of the denominators of the basic and diluted loss per share computations for the three and six months ended December 31, 2021 and 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zzOD2W37KCX2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 0in"><span id="xdx_8B2_zng47f5r2t4i" style="display: none">Schedule of earnings per share, basic and diluted</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20211001_20211231" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20201001_20201231" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20210701__20211231_zv6cUGsnm8d5" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20200701__20201231_zs7qfuYlPbwe" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Three months <br/>ended <br/>December 31, <br/>2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Three months <br/>ended <br/>December 31, <br/>2020</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Six months <br/>ended <br/>December 31, <br/>2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Six months <br/>ended <br/>December 31, <br/>2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_ecustom--SharesIssuedBeginningOfPeriod_zP4rnjCME6n5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; text-indent: 0in">Shares issued – beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">41,475,573</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">31,575,656</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">41,315,986</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">31,409,005</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SharesHeldBySubsidiaries_zYBm8cpWfID3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0in">Shares held by subsidiaries (Note 7)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--SharesOutstandingBeginningOfPeriod_z6iPfX8Ppqw9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in">Shares outstanding – beginning of period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,771,264</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,871,347</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,611,677</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,704,696</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--WeightedAverageNumberOfSharesIssuedDuringPeriod_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Weighted average shares issued <br/>    during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">317,728</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">316,298</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">292,665</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">285,943</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Diluted weighted average shares – <br/>    end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">41,088,992</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">31,187,645</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">40,904,342</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">30,990,639</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_8AF_zdkDu8WVaFre" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zQx6cAdtd3Od" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_8BB_zjByibRmIEe3" style="display: none">Schedule of anti dilutive securities</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, <br/> 2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: justify">Warrants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; text-align: right" title="Antidilutive securities">19,726,777</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; text-align: right" title="Antidilutive securities">21,270,102</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Antidilutive securities">10,471,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zKZ2wHZppHOb" style="text-align: right" title="Antidilutive securities">9,511,600</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Convertible debt</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities">10,673,722</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities">11,215,175</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0678">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="text-align: right" title="Antidilutive securities">19,500</td><td style="text-align: left"> </td></tr> </table> 19726777 21270102 10471600 9511600 10673722 11215175 19500 <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zzOD2W37KCX2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 0in"><span id="xdx_8B2_zng47f5r2t4i" style="display: none">Schedule of earnings per share, basic and diluted</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20211001_20211231" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20201001_20201231" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20210701__20211231_zv6cUGsnm8d5" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20200701__20201231_zs7qfuYlPbwe" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Three months <br/>ended <br/>December 31, <br/>2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Three months <br/>ended <br/>December 31, <br/>2020</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Six months <br/>ended <br/>December 31, <br/>2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Six months <br/>ended <br/>December 31, <br/>2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_ecustom--SharesIssuedBeginningOfPeriod_zP4rnjCME6n5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; text-indent: 0in">Shares issued – beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">41,475,573</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">31,575,656</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">41,315,986</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">31,409,005</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SharesHeldBySubsidiaries_zYBm8cpWfID3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0in">Shares held by subsidiaries (Note 7)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--SharesOutstandingBeginningOfPeriod_z6iPfX8Ppqw9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in">Shares outstanding – beginning of period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,771,264</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,871,347</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,611,677</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,704,696</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--WeightedAverageNumberOfSharesIssuedDuringPeriod_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Weighted average shares issued <br/>    during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">317,728</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">316,298</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">292,665</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">285,943</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Diluted weighted average shares – <br/>    end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">41,088,992</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">31,187,645</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">40,904,342</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">30,990,639</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 41475573 31575656 41315986 31409005 -704309 -704309 -704309 -704309 40771264 30871347 40611677 30704696 317728 316298 292665 285943 41088992 31187645 40904342 30990639 <p id="xdx_845_eus-gaap--UseOfEstimates_zvEenY1GWhni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86C_z9sxAI6qA469">Use of estimates</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zVnU1pMlXskf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_864_zsz62lzuVxL2">Recent Accounting Pronouncements</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s financial statements properly reflect the change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_801_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zC7AtuMXBzNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>3.  <span id="xdx_827_zA4jd86y1lMg">PROPERTY AND EQUIPMENT</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--PropertyPlantAndEquipmentTextBlock_zckzo2Rkl984" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BC_zsHKMHuiPm3b" style="display: none">Schedule of property and equipment</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20211231_zGk0TXZf4ot3" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20210630_zlsIqTyN9r6d" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br/> 2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAEGz0BL_zZQ1U5SAAKu3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Machinery and equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0720">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,222,670</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BuildingsAndImprovementsGross_iI_pp0p0_maPPAEGz0BL_zxP3iN3LRyM6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Buildings and structures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0723">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">401,470</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--ComputersAndOfficeEquipmentGross_iI_pp0p0_maPPAEGz0BL_zkBXmLV0nU2a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computers and office equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171,485</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConstructionInProgressGross_iI_pp0p0_maPPAEGz0BL_z9qlqb6cGfW2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">3G project construction in process</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">145,439</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0730">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_mtPPAEGz0BL_maPPAENzL89_zT5OA05SG1od" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 12pt"><span style="color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">Property and equipment, gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">156,576</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,795,625</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzL89_zcbFWJhLFBkf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(9,681</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,795,084</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentOtherNet_iTI_pp0p0_mtPPAENzL89_ztMGhYYx6qnf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 12pt; padding-bottom: 2.5pt"><span style="color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">Property and equipment, net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">146,895</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">541</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has reviewed the remaining property and equipment for impairment as of December 31, 2021 and believes that <span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20210701__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--PropertyPlantAndEquipmentOfPA1Member_z3zF90yT5s08" title="Impairment of Long-Lived Assets Held-for-use">no</span> impairment exists.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense was $<span id="xdx_908_eus-gaap--Depreciation_pp0p0_c20211001__20211231_zw5OV3iho65d" title="Depreciation expense">332</span> and $<span id="xdx_90E_eus-gaap--Depreciation_pp0p0_c20201001__20201231_zzqvgVEVcz5" title="Depreciation expense">207</span> for the three months ended December 31, 2021 and 2020, respectively, and $<span id="xdx_90B_eus-gaap--Depreciation_c20210701__20211231_pp0p0" title="Depreciation expense">580</span> and $<span id="xdx_90D_eus-gaap--Depreciation_c20200701__20201231_pp0p0" title="Depreciation expense">414</span> for the six months ended December 31, 2021 and 2020, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 29, 2021 Bion PA1 LLC was dissolved which removed all items which were listed under ‘Machinery and equipment’ and Buildings and structures’ plus almost all of the items which were listed under ‘Computers and office equipment’ at June 30, 2021 resulting in the elimination of almost the entire balance of ‘accumulated depreciation’. See Note 5, “LOANS PAYABLE: Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution” below.</p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--PropertyPlantAndEquipmentTextBlock_zckzo2Rkl984" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BC_zsHKMHuiPm3b" style="display: none">Schedule of property and equipment</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20211231_zGk0TXZf4ot3" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20210630_zlsIqTyN9r6d" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br/> 2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAEGz0BL_zZQ1U5SAAKu3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Machinery and equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0720">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,222,670</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BuildingsAndImprovementsGross_iI_pp0p0_maPPAEGz0BL_zxP3iN3LRyM6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Buildings and structures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0723">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">401,470</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--ComputersAndOfficeEquipmentGross_iI_pp0p0_maPPAEGz0BL_zkBXmLV0nU2a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computers and office equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171,485</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConstructionInProgressGross_iI_pp0p0_maPPAEGz0BL_z9qlqb6cGfW2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">3G project construction in process</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">145,439</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0730">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_mtPPAEGz0BL_maPPAENzL89_zT5OA05SG1od" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 12pt"><span style="color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">Property and equipment, gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">156,576</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,795,625</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzL89_zcbFWJhLFBkf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(9,681</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,795,084</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentOtherNet_iTI_pp0p0_mtPPAENzL89_ztMGhYYx6qnf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 12pt; padding-bottom: 2.5pt"><span style="color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">Property and equipment, net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">146,895</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">541</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2222670 401470 11137 171485 145439 156576 2795625 9681 2795084 146895 541 0 332 207 580 414 <p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zmuDOYN7tPW7" style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify"><b>4.       <span id="xdx_822_zzWpDspylcG1">DEFERRED COMPENSATION</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">The Company owes deferred compensation to various employees, former employees and consultants totaling $<span id="xdx_907_eus-gaap--DeferredCompensationLiabilityCurrent_c20211231_pp0p0" title="Deferred compensation liability">477,374</span> and $<span id="xdx_90C_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20201231_zhO74CUxWdkg" title="Deferred compensation liability">998,474</span> as of December 31, 2021 and 2020, respectively. Included in the deferred compensation balances as of December 31, 2021, are $<span id="xdx_909_eus-gaap--DeferredCompensationLiabilityCurrent_c20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Deferred compensation liability">374,015</span> and nil owed Dominic Bassani (“Bassani”), the Company’s Chief Executive Officer, and Mark A. Smith (“Smith”), the Company’s President<span style="font-family: Arial, Helvetica, Sans-Serif">, </span>respectively, pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at <span id="xdx_906_ecustom--InterestRateOnDeferredCompensation_iI_dp_c20201231_z5RN7Whu0xQl" title="Interest Rate on Deferred Compensation">4</span>% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last <span id="xdx_901_ecustom--DeferredCompensationConsecutiveTradingDays_dtD_c20210701__20211231_zdBykWWb9Wm3" title="Deferred Compensation Consecutive Trading Days (Day)">10</span> trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of December 31, 2020 was $<span id="xdx_906_eus-gaap--DeferredCompensationLiabilityCurrent_c20201231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Deferred compensation liability">307,260</span> and $<span id="xdx_901_eus-gaap--DeferredCompensationLiabilityCurrent_c20201231__srt--TitleOfIndividualAxis__srt--PresidentMember_pp0p0" title="Deferred compensation liability">71,699</span>, respectively. The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $<span id="xdx_909_eus-gaap--DeferredCompensationLiabilityCurrent_c20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_pp0p0" title="Deferred compensation liability">30,859</span> and $<span id="xdx_908_eus-gaap--DeferredCompensationLiabilityCurrent_c20201231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_pp0p0" title="Deferred compensation liability">512,432</span> as of December 31, 2021 and 2020, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at <span id="xdx_909_ecustom--InterestRateOnDeferredCompensation_iI_dp_c20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zoKI7XrJMRWg" title="Interest Rate on Deferred Compensation">3</span>% per annum. The Company also owes a former employee $<span id="xdx_906_eus-gaap--DeferredCompensationLiabilityCurrent_c20211231__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember_pp0p0" title="Deferred compensation liability">72,500</span>, which is not convertible and is non-interest bearing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">Bassani and Smith have each been granted the right to convert up to $<span id="xdx_90F_ecustom--DeferredCompensationConvertibleToCommonStock_c20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Deferred Compensation, Convertible to Common Stock">300,000</span> of deferred compensation balances at a price of $<span id="xdx_904_ecustom--DeferredCompensationConvertibleToCommonStockPricePerShare_c20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pdd" title="Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share)">0.75</span> per share until December 31, 2022 (to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_90C_eus-gaap--InterestExpense_pp0p0_c20211001__20211231__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_z9IGN9RYGlpg" title="Interest Expense">4,268</span> ($<span id="xdx_906_eus-gaap--InterestExpenseRelatedParty_pp0p0_c20211001__20211231__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_z7qzk2l0C4Z9" title="Interest Expense, Related Party">4,095</span> with related parties) and $<span id="xdx_904_eus-gaap--InterestExpense_pp0p0_c20201001__20201231__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zc0HI04tetK4" title="Interest Expense">6,693</span> ($<span id="xdx_90C_eus-gaap--InterestExpenseRelatedParty_pp0p0_c20201001__20201231__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zwkwklaxQsW8" title="Interest Expense, Related Party">2,950</span> with related parties) for the three months ended December 31, 2021 and 2020, respectively, and $<span id="xdx_90F_eus-gaap--InterestExpense_c20210701__20211231__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_pp0p0" title="Interest Expense">8,300</span> ($<span id="xdx_90A_eus-gaap--InterestExpenseRelatedParty_c20210701__20211231__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_pp0p0" title="Interest Expense, Related Party">8,044</span> with related parties) and $<span id="xdx_90D_eus-gaap--InterestExpense_c20200701__20201231__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_pp0p0" title="Interest Expense">12,476</span> ($<span id="xdx_908_eus-gaap--InterestExpenseRelatedParty_c20200701__20201231__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_pp0p0" title="Interest Expense, Related Party">5,159</span> with related parties) for the six months ended December 31, 2021 and 2020, respectively.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 477374 998474 374015 0.04 P10D 307260 71699 30859 512432 0.03 72500 300000 0.75 4268 4095 6693 2950 8300 8044 12476 5159 <p id="xdx_808_eus-gaap--DebtDisclosureTextBlock_zPIiIeIJaVOi" style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b>5.       <span id="xdx_82F_z2R0lpyjijYl">LOANS PAYABLE</span>:</b></p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b>Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution</b></p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed $<span id="xdx_903_eus-gaap--ConstructionLoan_c20211231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Construction Loan">10,009,802</span> under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $<span id="xdx_904_ecustom--AccruedInterestAndLateChargesPayable_c20211231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Accrued Interest and Late Charges Payable">2,255,802</span> as of that date. The terms of the Pennvest Loan provided for funding of up to $<span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_c20211231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Line of Credit Facility, Maximum Borrowing Capacity">7,754,000</span> which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210701__20211231__srt--StatementScenarioAxis__custom--YearsOneThroughFiveMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zuoC5s1FBl4f" title="Debt Instrument, Interest Rate During Period">2.547</span>% per annum for years 1 through 5 and <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210701__20211231__srt--StatementScenarioAxis__custom--YearsSixThroughMaturityMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_z7XboYsMuCsf" title="Debt Instrument, Interest Rate During Period">3.184</span>% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $<span id="xdx_90D_eus-gaap--DebtInstrumentAnnualPrincipalPayment_c20211231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Debt Instrument, Annual Principal Payment">5,886,000</span> in fiscal years 2013 through 2021, and $<span id="xdx_903_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c20211231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Long-Term Debt, Maturity, Year Two">846,000</span> in fiscal year 2022, $<span id="xdx_90A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c20211231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Long-Term Debt, Maturity, Year Three">873,000</span> in fiscal year 2023 and $<span id="xdx_907_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c20211231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Long-Term Debt, Maturity, Year Four">149,000</span> in fiscal year 2024. The Pennvest Loan is collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $<span id="xdx_907_eus-gaap--InterestExpenseDebt_pp0p0_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_z8V0Jd8i3vW9" title="Interest Expense, Debt"><span id="xdx_907_eus-gaap--InterestExpenseDebt_pp0p0_c20201001__20201231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_z5QTckdqU4q2" title="Interest Expense, Debt">61,722</span></span> for both the three months ended December 31, 2021 and 2020, respectively, and $<span id="xdx_90C_eus-gaap--InterestExpenseDebt_c20210701__20211231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Interest Expense, Debt"><span id="xdx_90E_eus-gaap--InterestExpenseDebt_c20200701__20201231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Interest Expense, Debt">123,444</span></span> for both the six months ended December 31, 2021 and 2020, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 has not made any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $<span id="xdx_909_eus-gaap--DebtDefaultLongtermDebtAmount_c20140925__dei--LegalEntityAxis__custom--PA1Member_pp0p0" title="Debt Instrument, Debt Default, Amount">8,137,117</span> (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business. PA 1 is prepared to transfer to Pennvest all of PA1’s right, title and interest in its property (by a bill of sale or other acceptable agreement) or alternatively, with Pennvest’s approval and direction, arrange for the sale of its property and deliver all proceeds (net of commissions and customary costs of sale) to Pennvest. PA1 and Pennvest have entered into communication/exchanges to determine how Pennvest would like PA1 to proceed with this process. The Company’s personnel will assist PA1 with this process as needed at no cost to PA1.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PA 1 has made no payments to vendors or other creditors in connection with the dissolution. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $<span id="xdx_905_eus-gaap--Assets_iI_pp0p0_c20210930_zWnASnSddr6g" title="Total assets">297</span> and its total liabilities were $<span id="xdx_903_eus-gaap--Liabilities_iI_pp0p0_c20210930_zdWpiluv4XK7" title="Total liabilities">10,154,334</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_905_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_c20210930_z2jI6npJIIUa" title="Accounts payable and accrued liabilities">9,939,148</span>, accounts payable of $<span id="xdx_90D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20210930_zeTaXZ4C50R2" title="Accounts payable">214,235</span> and accrued liabilities of $<span id="xdx_907_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20210930_z0kQHe7YCImf">950</span>) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities will no longer be consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $<span id="xdx_90B_eus-gaap--Liabilities_iI_pp0p0_c20211229_zjUC6t71v2Bi">10,234,501</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_900_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_c20211229_zj2Pvd4iJxS2" title="Accounts payable and accrued liabilities">10,009,802</span>, accounts payable of $<span id="xdx_902_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20211229_zSE5kXE84Oej">212,263</span> and accrued liabilities of $<span id="xdx_90C_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20211229_zkOU949vKJGe">12,436</span>. The net amount of $<span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20210701__20211231_pp0p0" title="Gain on legal dissolution of subsidiary">10,234,501</span> was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 10009802 2255802 7754000 0.02547 0.03184 5886000 846000 873000 149000 61722 61722 123444 123444 8137117 297 10154334 9939148 214235 950 10234501 10009802 212263 12436 10234501 <p id="xdx_80E_ecustom--ConvertibleDebtTextBlock_zBkcR2A08Rzi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>6.       <span id="xdx_82D_zzOtTd5U9cG">CONVERTIBLE NOTES PAYABLE - AFFILIATES</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2020 Convertible Obligations </b></p> <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2020 Convertible Obligations, which accrue interest at either <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zF1uk0fsn7ub" title="Debt Instrument, Interest Rate, Stated Percentage">4</span>% per annum or <span id="xdx_90A_ecustom--DebtInstrumentInterestRateStatedPercentageQuarterly_iI_dp_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zHql9HHuVyzf" title="Debt Instrument, Interest Rate, Stated Percentage, Quarterly">4</span>% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $<span id="xdx_907_ecustom--ConversionPricePerUnit_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pdd" title="Conversion Price Per Unit (in dollars per share)">0.50</span> per Unit until July 1, 2024. The warrant contained in the Unit was originally exercisable at $<span id="xdx_903_ecustom--NumberOfWarrantsPerUnit_c20200630__srt--TitleOfIndividualAxis__srt--PresidentMember_pdd" title="Number of Warrants Per Unit (in shares)">1.00</span> per unit but was modified to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200630__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pdd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> during the year ended June 30, 2020 and is exercisable until a date three years after the date of the conversion. During the year ended June 30, 2021, the Company approved the increase of warrants by one-third to be received by the noteholder if a conversion takes place. The original conversion price of $0.50 per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2021, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani (and his donees), Smith and Edward Schafer (“Schafer”), the Company’s Vice Chairman, were $<span id="xdx_90C_eus-gaap--ConvertibleLongTermNotesPayable_c20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Convertible Notes Payable, Noncurrent">2,550,104</span>, $<span id="xdx_90A_eus-gaap--ConvertibleLongTermNotesPayable_c20211231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Convertible Notes Payable, Noncurrent">1,302,049</span> and $<span id="xdx_904_eus-gaap--ConvertibleLongTermNotesPayable_c20211231__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Convertible Notes Payable, Noncurrent">490,197</span>, respectively. As of December 31, 2020, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani, Smith and Schafer were $<span id="xdx_90F_eus-gaap--ConvertibleLongTermNotesPayable_c20201231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Convertible Notes Payable, Noncurrent">2,455,656</span>, $<span id="xdx_90B_eus-gaap--ConvertibleLongTermNotesPayable_c20201231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Convertible Notes Payable, Noncurrent">1,163,862</span> and $<span id="xdx_905_eus-gaap--ConvertibleLongTermNotesPayable_c20201231__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Convertible Notes Payable, Noncurrent">472,041</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2021, Smith elected to add $<span id="xdx_90E_eus-gaap--SalariesAndWages_c20210701__20211231__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_pp0p0" title="Salary paid">90,000</span> of his salary to his 2020 Convertible Obligations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_906_eus-gaap--InterestExpense_pp0p0_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zXEGAwwjJX79" title="Interest Expense">40,864</span> and $<span id="xdx_907_eus-gaap--InterestExpense_pp0p0_c20201001__20201231__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z0WqLfIRA1Lk" title="Interest Expense">65,468</span> for the three months ended December 31, 2021 and 2020, respectively. The Company recorded interest expense of $<span id="xdx_90E_eus-gaap--InterestExpense_c20210701__20211231__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Interest Expense">81,424</span> and $<span id="xdx_908_eus-gaap--InterestExpense_c20200701__20201231__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Interest Expense">96,428</span> for the six months ended December 31, 2021 and 2020, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>September 2015 Convertible Notes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani, Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at <span id="xdx_901_ecustom--FinancingReceivableInterestRateStatedPercentage_iI_dp_c20211231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zQR2GDZ0ZCc5" title="Financing Receivable, Interest Rate, Stated Percentage">4</span>% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $<span id="xdx_90B_ecustom--ConversionPricePerUnit_c20201231__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pdd" title="Conversion Price Per Unit (in dollars per share)">0.60</span> per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The balances of the September 2015 Convertible Notes as of December 31, 2021, including accrued interest owed Bassani, Schafer and Shareholder, are $<span id="xdx_904_eus-gaap--ConvertibleNotesPayable_c20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_pp0p0" title="Convertible Notes Payable">274,521</span>, $<span id="xdx_900_eus-gaap--ConvertibleNotesPayable_c20211231__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_pp0p0" title="Convertible Notes Payable">20,517</span> and $<span id="xdx_90E_eus-gaap--ConvertibleNotesPayable_c20211231__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_pp0p0" title="Convertible Notes Payable">438,198</span>, respectively. The balances of the September 2015 Convertible Notes as of December 31, 2020, including accrued interest, were $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_c20201231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_pp0p0" title="Convertible Notes Payable">168,498</span>, $<span id="xdx_901_eus-gaap--ConvertibleNotesPayable_c20201231__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_pp0p0" title="Convertible Notes Payable">19,862</span> and $<span id="xdx_90F_eus-gaap--ConvertibleNotesPayable_c20201231__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_pp0p0" title="Convertible Notes Payable">423,081</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2021, Bassani elected to transfer $<span id="xdx_900_eus-gaap--DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_pp0p0_c20210701__20211231__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_zcAyvX9MNnTa" title="Deferred compensation">100,000</span> from deferred compensation to his 2015 convertible note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_905_eus-gaap--InterestExpense_pp0p0_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zWhC1EcZVXkk" title="Interest Expense">5,698</span> and $<span id="xdx_904_eus-gaap--InterestExpense_pp0p0_c20201001__20201231__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zazhmNxmpPt2" title="Interest Expense">5,365</span> for the three months ended December 31, 2021 and 2020, respectively. The Company recorded interest expense of $<span id="xdx_904_eus-gaap--InterestExpense_c20210701__20211231__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Interest Expense">11,064</span> and $<span id="xdx_906_eus-gaap--InterestExpense_pp0p0_c20200701__20201231__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zMIUGsGE3ePi">10,731</span> for both the six months ended December 31, 2021 and 2020, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> 0.04 0.04 0.50 1.00 0.75 2550104 1302049 490197 2455656 1163862 472041 90000 40864 65468 81424 96428 0.04 0.60 274521 20517 438198 168498 19862 423081 100000 5698 5365 11064 10731 <p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zT4EV8jhVa9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>7.       <span id="xdx_825_zqgWEZCmuOl5">STOCKHOLDERS' EQUITY</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Series B Preferred stock:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since July 1, 2014, the Company had <span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_c20140702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z2XSNpE8A8J9" title="Preferred Stock, Shares Outstanding, Ending Balance (in shares)">200</span> shares of Series B redeemable convertible Preferred stock outstanding with a par value of $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20140702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9QW2dhzNJa6" title="Preferred Stock, Par or Stated Value Per Share (in dollars per share)">0.01</span> per share, convertible at the option of the holder at $<span id="xdx_905_ecustom--PreferredStockConvertibleOptionPerShare_iI_c20140703__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zEz8GFnHewRg" title="Preferred Stock, Convertible Option Per Share (in dollars per share)">2.00</span> per share, with dividends accrued and payable at <span id="xdx_909_eus-gaap--PreferredStockDividendRatePercentage_dp_c20140625__20140701__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBHCydcQalq" title="Preferred Stock, Dividend Rate, Percentage">2.5</span>% per quarter. The Series B Preferred stock is mandatorily redeemable at $<span id="xdx_90E_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20140702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFBvnahX1uF1" title="Preferred Stock, Redemption Price Per Share (in dollars per share)">100</span> per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares have reached their maturity date and the Company approved the redemption of the Series B preferred stock during the quarter ended December 31, 2021. 200 shares of Series B redeemable convertible Preferred stock were redeemed for $<span id="xdx_905_ecustom--RedemptionOfConvertiblePreferredStock_c20210701__20211231_z2J8cZrwAc75" title="Redemption of convertible Preferred stock">41,000</span>, which included the $<span id="xdx_902_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_pdp0_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKg2buejOedl" title="Dividends Payable">21,000</span> in accrued dividend payable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended June 30, 2021, and 2020, the Company declared dividends of $<span id="xdx_90F_eus-gaap--DividendsPreferredStock_c20200701__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pp0p0" title="Dividends, Preferred Stock">2,000</span> and $<span id="xdx_900_eus-gaap--DividendsPreferredStock_pp0p0_c20190701__20200630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zxk50pr5ppG6" title="Dividends, Preferred Stock">2,000</span> respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common stock:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Centerpoint holds <span id="xdx_90B_ecustom--SharesHeldBySubsidiaries_iN_di_c20210701__20211231_zYUcxEN7lx96" title="Shares Held by Subsidiaries (in shares)">704,309</span> shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2021, Smith elected to convert accounts payable (based on his unreimbursed expenses) of $<span id="xdx_90F_ecustom--ConvertedToUnitsAmount_c20210701__20211231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" title="Converted to Units, Amount">17,711</span> into <span id="xdx_904_ecustom--AccountsPayableConvertedToUnitsShares_c20210701__20211231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Accounts Payable Converted to Units, Shares">35,424</span> units at $<span id="xdx_90B_ecustom--AccountsPayableConvertedToUnitsPricePerUnit_c20211231__srt--TitleOfIndividualAxis__srt--PresidentMember_pdd" title="Accounts Payable Converted to Units, Price Per Unit">0.50</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> per share until December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">During the six months ended December 31, 2021, <span id="xdx_90B_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20210701__20211231_pdd" title="Class of Warrant or Right, Exercised During Period (in shares)">2,315,550</span> warrants were exercised to purchase <span id="xdx_901_ecustom--CommonStockSharesIssuedUponExerciseOfWarrants_c20210701__20211231_pdd" title="Common Stock Shares Issued upon Exercise of Warrants (in shares)">2,315,550</span> shares of the Company’s common stock at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> per share for total proceeds of $<span id="xdx_90E_ecustom--WarrantExercisedForCommonStock_pp0p0_c20210701__20211231_zjMgxKSl38U2" title="Warrant Exercised for Common Stock">1,736,662</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the six months ended December 31, 2021, the Company issued <span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesCommissionOnSaleOfUnitsAndWarrantExercises_c20210701__20211231_pdd" title="Stock Issued During Period, Shares, Commission on Sale of Units and Warrant Exercises (in shares)">66,860</span> shares of the Company’s common stock to three FINRA brokers as commissions for the warrant exercises. As the issuance was both a reduction and addition to additional paid in capital there was no impact to the financial statements. The Company also paid a FINRA broker $<span id="xdx_904_ecustom--PaymentsOfCommissionsOnExerciseOfWarrants_c20210701__20211231_pp0p0" title="Payments of Commissions on Exercise of Warrants">18,601</span> in commissions for the warrant exercises.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> <b>Warrants:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2021, the Company had approximately <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pp0n3_dm_c20211231_zp0ZK6LFfnw2" title="Class of Warrant or Right, Outstanding (in shares)">19.7</span> million warrants outstanding, with exercise prices from $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211231__srt--RangeAxis__srt--MinimumMember_pdd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.60</span> to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211231__srt--RangeAxis__srt--MaximumMember_pdd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">1.50</span> and expiring on various dates through June 30, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted-average exercise price for the outstanding warrants is $<span id="xdx_90B_ecustom--WeightedAverageExercisePriceForOutstandingWarrants_c20210701__20211231_pdd" title="Weighted Average Exercise Price for Outstanding Warrants (in dollars per share)">0.73</span>, and the weighted-average remaining contractual life as of December 31, 2021 is <span id="xdx_908_ecustom--WeightedAverageRemainingContractualLifeForOutstandingWarrants_dtY_c20210701__20211231_zTqispjxbp8c" title="Weighted Average Remaining Contractual Life for Outstanding Warrants (Year)">2.7</span> years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2021, Smith elected to convert accounts payable of $<span id="xdx_90B_ecustom--ConvertedToUnitsAmount_pp0p0_c20210701__20211231__srt--TitleOfIndividualAxis__srt--PresidentMember_zZCDQWhCJNka" title="Converted to Units, Amount">17,711</span> into <span id="xdx_902_ecustom--AccountsPayableConvertedToUnitsShares_c20210701__20211231__srt--TitleOfIndividualAxis__srt--PresidentMember_pdd" title="Accounts Payable Converted to Units, Shares">35,424</span> units at $<span id="xdx_90D_ecustom--AccountsPayableConvertedToUnitsPricePerUnit_iI_c20211231__srt--TitleOfIndividualAxis__srt--PresidentMember_zsa3oxY3MPFc" title="Accounts Payable Converted to Units, Price Per Unit">0.50</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211231__srt--TitleOfIndividualAxis__srt--PresidentMember_pdd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> per share until December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the six months ended December 31, 2021, the Company approved the issuance of <span id="xdx_902_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20210701__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zyOg65mUNRmg" title="Class of Warrant or Right, Exercised During Period (in shares)">75,000</span> warrants for two consultants for consulting services of $<span id="xdx_907_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c20210701__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeuXKOsOLPmi" title="Issuance of warrants">7,500</span>. The warrants are exercisable at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zo9iLf8y51fl" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">1.50</span> and expire in November 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">During the six months ended December 31, 2020, the Company approved the modification of existing warrants held by one former consultants and four investors, which extended certain expiration dates. The modifications resulted in incremental non-cash compensation of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pdp0_c20200701__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoYorKQxeG81" title="Share-based Payment Arrangement, Plan Modification, Incremental Cost">5,625</span> and interest expenses of $<span id="xdx_904_eus-gaap--InterestExpense_c20200701__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNAO9cCYUtu7" title="Interest expenses">2,712</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">During the six months ended December 31, 2021, <span id="xdx_900_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20210701__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Class of Warrant or Right, Exercised During Period (in shares)">2,315,550</span> warrants were exercised to purchase <span id="xdx_909_ecustom--CommonStockSharesIssuedUponExerciseOfWarrants_c20210701__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Common Stock Shares Issued upon Exercise of Warrants (in shares)">2,315,550</span> shares of the Company’s common stock at $0.75 per share for total proceeds of $<span id="xdx_906_ecustom--WarrantExercisedForCommonStock_pp0p0_c20210701__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWzgm9mMUVG" title="Warrant Exercised for Common Stock">1,736,662</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">During the 2021 calendar year, <span id="xdx_90B_ecustom--WarrantsIssued_c20210701__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJe9tVn35wRa" title="Warrants issued">6,431,538</span> warrants scheduled to expire on December 31, 2021, in aggregate, were exercised by their holders at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9IsCpUa4pG9">.75</span> per share of which <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210701__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpCFeiY2WkI4" title="Warrant exercised">2,176,216</span> warrants were exercised during the quarter ended December 31, 2021. The Company issued, in aggregate, <span id="xdx_907_ecustom--CommonStockShareRestricted_c20210701__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUXhffc95Ej" title="Common stock share restricted">6,431,538</span> share of its restricted and legended common stock in connection with these warrant exercises, of which <span id="xdx_909_ecustom--WarrantsIssued_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znxvipcQ6dZ2">2,226,216</span> shares were issued during the quarter ended December 31, 2021. The Company received, in aggregate, $<span id="xdx_90D_eus-gaap--ProceedsFromWarrantExercises_c20210701__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztXiwBhK5Bud" title="Proceeds from warrant">4,823,651</span> of gross processed from such warrant exercises, of which $<span id="xdx_908_eus-gaap--ProceedsFromWarrantExercises_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpkjNCDkodvh">1,632,162</span> was received in the quarter ended December 31, 2021 (these sums do not reflect expenses and commissions related to these warrant exercises). In aggregate, <span id="xdx_907_ecustom--WarrantUnexercised_c20210701__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5aeXexJeKL5" title="Warrant unexercised">648,142</span> warrants expired unexercised on December 31. 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the six months ended December 31, 2021, the Company issued <span id="xdx_900_ecustom--CommissionsOnWarrantExercisesShares_c20210701__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Commissions on warrant exercises, shares">66,860</span> shares of the Company’s common stock to three FINRA brokers as commissions for the warrant exercises. As the issuance was both a reduction and addition to additional paid in capital there was no impact to the financial statements. The Company also paid a FINRA broker $<span id="xdx_90F_ecustom--CommissionsOnWarrantExercises_iN_pp0p0_di_c20210701__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zsa54DEuXA1i" title="Commissions on warrant exercises">18,601</span> in commissions for the warrant exercises.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Stock options: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Stock options, authorized (in shares)">36,000,000</span> shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20210701__20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCzGfVvrlGS5" style="display: none" title="Options expiration period (Year)">10</span> years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded compensation expense related to employee stock options of nil <span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBccesiMFiha" title="Share-based Payment Arrangement, Expense"><span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVUXFtxsLmdj" title="Share-based Payment Arrangement, Expense"><span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20201001__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zIqxzYrgufm2" title="Share-based Payment Arrangement, Expense"><span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOdNlY79W8wl" style="display: none" title="Share-based Payment Arrangement, Expense">0</span></span></span></span> for both the three and six months ended December 31, 2021 and 2020, respectively. The Company granted nil <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zWvwaHBXP1Kj" title="Share-based Compensation, Granted"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zLmFccbvJK4k" title="Share-based Compensation, Granted"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zw8dHYfQeaZk" title="Share-based Compensation, Granted"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200701__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zLr9eIne0Y5d" style="display: none" title="Share-based Compensation, Granted">0</span></span></span></span> options during both the three and six months ended December 31, 2021 and 2020, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt">A summary of option activity under the 2006 Plan for the six months ended December 31, 2021 is as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zxvZIJqqVvQ1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Stock Options Activity (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"><span id="xdx_8BC_zZxNKMIrnQ3f" style="display: none">Schedule of option activity</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1pt; font-size: 12pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- <br/> Average <br/> Remaining <br/> Contractual <br/> Life</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td style="width: 39%; text-align: left"><span style="font-size: 10pt">Outstanding at July 1, 2021</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20211231_zi3UrmjuEum8" style="width: 12%; text-align: right" title="Options outstanding, beginning (in shares)">10,471,600</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20211231_zy6GwdtJav43" style="width: 12%; text-align: right" title="Options outstanding, beginning weighted-average exercise price">0.77</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200801__20210731_zEZ2oNzuW4Zi" title="Outstanding, weighted-average remaining contractual life (Year)">3.7</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20210701__20211231_zSPNryoc3Xx9" style="width: 12%; text-align: right" title="Outstanding, aggregate intrinsic value beginning">6,064,335</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"><span style="font-size: 10pt">  Granted</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20211231_zyjXFEjWPsgk" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1028">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20211231_zwk2UHPwtWpc" title="Granted, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1030">—</span></span>  </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: left"><span style="font-size: 10pt">  Exercised</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210701__20211231_pdd" style="text-align: right" title="Exercised, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1032">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210701__20211231_zfgVxqeUeHC2" title="Exercised, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1034">—</span></span>  </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"><span style="font-size: 10pt">  Forfeited</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210701__20211231_pdd" style="text-align: right" title="Forfeited, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1036">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210701__20211231_zAStuXg3VKOg" title="Forfeited, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1038">—</span></span>  </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">  Expired</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210701__20211231_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Expired, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1040">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20211231_zazVj3JdxpM3" title="Expired, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1042">—</span></span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="font-size: 12pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Outstanding at December 31, 2021</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20211231_zVAZkN7qxNph" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending (in shares)">10,471,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20211231_zNve8IOA71ol" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, beginning weighted-average exercise price">0.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20211231_zHtICFHpuTU3" title="Outstanding, weighted-average remaining contractual life (Year)">3.2</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20210701__20211231_zZsYVSgpQs4a" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding, aggregate intrinsic value ending">9,624,679</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Exercisable at December 31, 2021</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable, options (in shares)">10,471,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231_zKi3NXd4Pye6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, beginning weighted-average exercise price">0.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210701__20211231_zXoARUbuxoZ" title="Exercisable, weighted-average remaining contractual life (Year)">3.2</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20211231_zJCvjY4lQKU4" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable, aggregate intrinsic value">9,624,679</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_z7XH2szHgJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents information relating to nonvested stock options as of December 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_zemmdgkZwAt4" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Nonvested Share Activity (Details)"> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span id="xdx_8BC_zvqFrJxgHc4g" style="display: none">Schedule of non vested stock options</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">Options</span></td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">Weighted Average <br/> Grant-Date Fair <br/> Value</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td><span style="font-size: 10pt">Nonvested at July 1, 2021</span></td> <td> </td> <td> </td> <td/> <td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20210701__20211231_zLUxxo4NVEdb" style="text-align: right" title="Nonvested options, beginning (in shares)"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1062">—</span>  </span></td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20210701__20211231_zIClwBHsRkP9" title="Nonvested, weighted-average grant-date fair value beginning"><span style="-sec-ix-hidden: xdx2ixbrl1064">—</span></span>  </span></td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 1%"> </td> <td style="width: 64%"><span style="font-size: 10pt">Granted</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20211231_zwdoScSU2Efg" style="width: 15%; text-align: right" title="Granted, options (in shares)"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1066">—</span>  </span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210701__20211231_zBnUrosCExDg" title="Granted, weighted-average grant-date fair value"><span style="-sec-ix-hidden: xdx2ixbrl1068">—</span></span>  </span></td> </tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Vested</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20210701__20211231_pdd" style="border-bottom: black 1pt solid; text-align: right" title="Vested (in shares)"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1070">—</span>  </span></td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20210701__20211231_zgX3DBjqkJf3" title="Vested, weighted-average grant-date fair value"><span style="-sec-ix-hidden: xdx2ixbrl1072">—</span></span>  </span></td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Nonvested at December 31, 2021</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"/> <td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20210701__20211231_zPqo67Kf6c41" style="border-bottom: black 2.25pt double; text-align: right" title="Nonvested options, ending (in shares)"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1074">—</span>  </span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20210701__20211231_zUW2Nf0xhWAl" title="Nonvested, weighted-average grant-date fair value, ending"><span style="-sec-ix-hidden: xdx2ixbrl1076">—</span></span>  </span></td> </tr> </table> <p id="xdx_8A1_zlgpoawFbXY9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total fair value of stock options that vested during both the three and six months ended December 31, 2021 and 2020 was nil. As of December 31, 2021, the Company had no unrecognized compensation cost related to stock options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt">Stock-based employee compensation charges in operating expenses in the Company’s financial statements for the three and six months ended December 31, 2021 and 2020 are as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_89F_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zkqxm3Gyobb7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Financial Statements (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt; padding-left: 5.4pt"><span id="xdx_8BD_z7JSxZqi6318" style="display: none">Condensed Financial Statement</span></td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Three <br/>months <br/>ended <br/>December 31, <br/>2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Three <br/>months <br/>ended <br/>December 31, <br/>2020</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Six months <br/>ended <br/>December 31, <br/>2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Six months <br/>ended <br/>December 31, <br/>2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">General and administrative:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 5.4pt">  Change in fair value from modification of <br/>    option terms</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pdp0_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zEWji7G3ZKpe" style="width: 12%; text-align: right" title="Change in fair value from modification of option terms"><span style="-sec-ix-hidden: xdx2ixbrl1083">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pdp0_c20201001__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zpd6xBdmQ3Pg" style="width: 12%; text-align: right" title="Change in fair value from modification of option terms">8,775</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pdp0_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zOiegPzWPP8l" style="width: 12%; text-align: right" title="Change in fair value from modification of option terms"><span style="-sec-ix-hidden: xdx2ixbrl1087">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pdp0_c20200701__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zrwCLvypkE27" style="width: 12%; text-align: right" title="Change in fair value from modification of option terms">8,775</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Change in fair value from modification of <br/>    warrant terms</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms_pdp0_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zR9MkW8Bm3k7" style="text-align: right" title="Change in fair value from modification of warrant terms">5,625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms_pdp0_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zNBKELHfmIP3" style="text-align: right" title="Change in fair value from modification of warrant terms">25,506</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms_pdp0_c20210701__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZfqBBWIFGIg" style="text-align: right" title="Change in fair value from modification of warrant terms">5,625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms_pdp0_c20200701__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zOCGNJQaQVg2" style="text-align: right" title="Change in fair value from modification of warrant terms">25,506</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">  Fair value of stock options expensed</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zGMRu510HqO" style="border-bottom: Black 1pt solid; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1099">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20201001__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zjss6WAdYzBf" style="border-bottom: Black 1pt solid; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1101">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPRXeKqOGU7c" style="border-bottom: Black 1pt solid; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1103">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20200701__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zi3BUQT6F3lb" style="border-bottom: Black 1pt solid; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1105">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">     Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zuNqaBFoDmu4" style="border-bottom: Black 2.5pt double; text-align: right" title="Allocated Share-based Compensation Expense">5,625</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zorfSHCe5j4a" style="border-bottom: Black 2.5pt double; text-align: right" title="Allocated Share-based Compensation Expense">34,281</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20210701__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zDJSC1hMKdS7" style="border-bottom: Black 2.5pt double; text-align: right" title="Allocated Share-based Compensation Expense">5,625</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20200701__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ztRUWUejUBO9" style="border-bottom: Black 2.5pt double; text-align: right" title="Allocated Share-based Compensation Expense">34,281</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt; padding-left: 5.4pt"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Research and development:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">  Fair value of stock options expensed</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zG8jtkiCtsva" style="border-bottom: Black 1pt solid; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1115">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20201001__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zcqOY7XuWrb" style="border-bottom: Black 1pt solid; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1117">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pdp0" style="border-bottom: Black 1pt solid; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1119">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20200701__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znlmObFBteE6" style="border-bottom: Black 1pt solid; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1121">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">     Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zB9xYthkLOP1" style="border-bottom: Black 2.5pt double; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1123">—</span>  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zLvdOPU4O0S" style="border-bottom: Black 2.5pt double; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1125">—</span>  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20210701__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z1ftQXt2ohA6" style="border-bottom: Black 2.5pt double; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1127">—</span>  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20200701__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zI93hNDfGap4" style="border-bottom: Black 2.5pt double; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1129">—</span>  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zKrE0ahMqp94" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 200 0.01 2.00 0.025 100 41000 21000 2000 2000 -704309 17711 35424 0.50 0.75 2315550 2315550 0.75 1736662 66860 18601 19700000 0.60 1.50 0.73 P2Y8M12D 17711 35424 0.50 0.75 75000 7500 1.50 5625 2712 2315550 2315550 1736662 6431538 0.75 2176216 6431538 2226216 4823651 1632162 648142 66860 -18601 36000000 P10Y 0 0 0 0 0 0 0 0 <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zxvZIJqqVvQ1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Stock Options Activity (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"><span id="xdx_8BC_zZxNKMIrnQ3f" style="display: none">Schedule of option activity</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1pt; font-size: 12pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- <br/> Average <br/> Remaining <br/> Contractual <br/> Life</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td style="width: 39%; text-align: left"><span style="font-size: 10pt">Outstanding at July 1, 2021</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20211231_zi3UrmjuEum8" style="width: 12%; text-align: right" title="Options outstanding, beginning (in shares)">10,471,600</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20211231_zy6GwdtJav43" style="width: 12%; text-align: right" title="Options outstanding, beginning weighted-average exercise price">0.77</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200801__20210731_zEZ2oNzuW4Zi" title="Outstanding, weighted-average remaining contractual life (Year)">3.7</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20210701__20211231_zSPNryoc3Xx9" style="width: 12%; text-align: right" title="Outstanding, aggregate intrinsic value beginning">6,064,335</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"><span style="font-size: 10pt">  Granted</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20211231_zyjXFEjWPsgk" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1028">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20211231_zwk2UHPwtWpc" title="Granted, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1030">—</span></span>  </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: left"><span style="font-size: 10pt">  Exercised</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210701__20211231_pdd" style="text-align: right" title="Exercised, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1032">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210701__20211231_zfgVxqeUeHC2" title="Exercised, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1034">—</span></span>  </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"><span style="font-size: 10pt">  Forfeited</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210701__20211231_pdd" style="text-align: right" title="Forfeited, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1036">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210701__20211231_zAStuXg3VKOg" title="Forfeited, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1038">—</span></span>  </td><td style="text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">  Expired</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210701__20211231_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Expired, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1040">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20211231_zazVj3JdxpM3" title="Expired, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1042">—</span></span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="font-size: 12pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 1pt; font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Outstanding at December 31, 2021</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20211231_zVAZkN7qxNph" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending (in shares)">10,471,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20211231_zNve8IOA71ol" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, beginning weighted-average exercise price">0.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20211231_zHtICFHpuTU3" title="Outstanding, weighted-average remaining contractual life (Year)">3.2</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20210701__20211231_zZsYVSgpQs4a" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding, aggregate intrinsic value ending">9,624,679</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Exercisable at December 31, 2021</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable, options (in shares)">10,471,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231_zKi3NXd4Pye6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, beginning weighted-average exercise price">0.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210701__20211231_zXoARUbuxoZ" title="Exercisable, weighted-average remaining contractual life (Year)">3.2</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20211231_zJCvjY4lQKU4" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable, aggregate intrinsic value">9,624,679</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 10471600 0.77 P3Y8M12D 6064335 10471600 0.77 P3Y2M12D 9624679 10471600 0.77 P3Y2M12D 9624679 <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_zemmdgkZwAt4" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Nonvested Share Activity (Details)"> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td><span id="xdx_8BC_zvqFrJxgHc4g" style="display: none">Schedule of non vested stock options</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">Options</span></td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">Weighted Average <br/> Grant-Date Fair <br/> Value</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td><span style="font-size: 10pt">Nonvested at July 1, 2021</span></td> <td> </td> <td> </td> <td/> <td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20210701__20211231_zLUxxo4NVEdb" style="text-align: right" title="Nonvested options, beginning (in shares)"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1062">—</span>  </span></td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20210701__20211231_zIClwBHsRkP9" title="Nonvested, weighted-average grant-date fair value beginning"><span style="-sec-ix-hidden: xdx2ixbrl1064">—</span></span>  </span></td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 1%"> </td> <td style="width: 64%"><span style="font-size: 10pt">Granted</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20211231_zwdoScSU2Efg" style="width: 15%; text-align: right" title="Granted, options (in shares)"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1066">—</span>  </span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210701__20211231_zBnUrosCExDg" title="Granted, weighted-average grant-date fair value"><span style="-sec-ix-hidden: xdx2ixbrl1068">—</span></span>  </span></td> </tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Vested</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20210701__20211231_pdd" style="border-bottom: black 1pt solid; text-align: right" title="Vested (in shares)"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1070">—</span>  </span></td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20210701__20211231_zgX3DBjqkJf3" title="Vested, weighted-average grant-date fair value"><span style="-sec-ix-hidden: xdx2ixbrl1072">—</span></span>  </span></td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Nonvested at December 31, 2021</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"/> <td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20210701__20211231_zPqo67Kf6c41" style="border-bottom: black 2.25pt double; text-align: right" title="Nonvested options, ending (in shares)"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1074">—</span>  </span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20210701__20211231_zUW2Nf0xhWAl" title="Nonvested, weighted-average grant-date fair value, ending"><span style="-sec-ix-hidden: xdx2ixbrl1076">—</span></span>  </span></td> </tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_89F_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zkqxm3Gyobb7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Financial Statements (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt; padding-left: 5.4pt"><span id="xdx_8BD_z7JSxZqi6318" style="display: none">Condensed Financial Statement</span></td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Three <br/>months <br/>ended <br/>December 31, <br/>2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Three <br/>months <br/>ended <br/>December 31, <br/>2020</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Six months <br/>ended <br/>December 31, <br/>2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Six months <br/>ended <br/>December 31, <br/>2020</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">General and administrative:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 5.4pt">  Change in fair value from modification of <br/>    option terms</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pdp0_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zEWji7G3ZKpe" style="width: 12%; text-align: right" title="Change in fair value from modification of option terms"><span style="-sec-ix-hidden: xdx2ixbrl1083">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pdp0_c20201001__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zpd6xBdmQ3Pg" style="width: 12%; text-align: right" title="Change in fair value from modification of option terms">8,775</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pdp0_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zOiegPzWPP8l" style="width: 12%; text-align: right" title="Change in fair value from modification of option terms"><span style="-sec-ix-hidden: xdx2ixbrl1087">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pdp0_c20200701__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zrwCLvypkE27" style="width: 12%; text-align: right" title="Change in fair value from modification of option terms">8,775</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Change in fair value from modification of <br/>    warrant terms</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms_pdp0_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zR9MkW8Bm3k7" style="text-align: right" title="Change in fair value from modification of warrant terms">5,625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms_pdp0_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zNBKELHfmIP3" style="text-align: right" title="Change in fair value from modification of warrant terms">25,506</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms_pdp0_c20210701__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZfqBBWIFGIg" style="text-align: right" title="Change in fair value from modification of warrant terms">5,625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms_pdp0_c20200701__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zOCGNJQaQVg2" style="text-align: right" title="Change in fair value from modification of warrant terms">25,506</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">  Fair value of stock options expensed</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zGMRu510HqO" style="border-bottom: Black 1pt solid; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1099">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20201001__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zjss6WAdYzBf" style="border-bottom: Black 1pt solid; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1101">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zPRXeKqOGU7c" style="border-bottom: Black 1pt solid; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1103">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20200701__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zi3BUQT6F3lb" style="border-bottom: Black 1pt solid; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1105">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">     Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zuNqaBFoDmu4" style="border-bottom: Black 2.5pt double; text-align: right" title="Allocated Share-based Compensation Expense">5,625</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zorfSHCe5j4a" style="border-bottom: Black 2.5pt double; text-align: right" title="Allocated Share-based Compensation Expense">34,281</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20210701__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zDJSC1hMKdS7" style="border-bottom: Black 2.5pt double; text-align: right" title="Allocated Share-based Compensation Expense">5,625</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20200701__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ztRUWUejUBO9" style="border-bottom: Black 2.5pt double; text-align: right" title="Allocated Share-based Compensation Expense">34,281</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt; padding-left: 5.4pt"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Research and development:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">  Fair value of stock options expensed</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zG8jtkiCtsva" style="border-bottom: Black 1pt solid; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1115">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20201001__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zcqOY7XuWrb" style="border-bottom: Black 1pt solid; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1117">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pdp0" style="border-bottom: Black 1pt solid; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1119">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20200701__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znlmObFBteE6" style="border-bottom: Black 1pt solid; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1121">—</span>  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">     Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zB9xYthkLOP1" style="border-bottom: Black 2.5pt double; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1123">—</span>  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zLvdOPU4O0S" style="border-bottom: Black 2.5pt double; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1125">—</span>  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20210701__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z1ftQXt2ohA6" style="border-bottom: Black 2.5pt double; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1127">—</span>  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pdp0_c20200701__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zI93hNDfGap4" style="border-bottom: Black 2.5pt double; text-align: right" title="Allocated Share-based Compensation Expense"><span style="-sec-ix-hidden: xdx2ixbrl1129">—</span>  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 8775 8775 5625 25506 5625 25506 5625 34281 5625 34281 <p id="xdx_80E_ecustom--SubscriptionReceivableTextBlock_zDcaHUe3uqXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>8.       <span id="xdx_82A_zSly4GRpw7Dc">SUBSCRIPTION RECEIVABLE - AFFILIATES</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2021, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $<span id="xdx_901_eus-gaap--NotesReceivableNet_c20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_pp0p0" title="Financing Receivable, after Allowance for Credit Loss, Total">428,250</span> ($<span id="xdx_904_ecustom--NotesReceivableInterest_iI_c20211231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zcvQMjeY9j4g" title="Notes receivable interest">491,975</span>, including interest) from Bassani which were received as consideration for purchases of warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_pdd" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">5,565,000</span> shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211231_pdd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> and have expiry dates ranging from December 31, 2024 to December 31, 2025. The promissory notes bear interest at 4% per annum, and are secured by portions of Bassani’s 2020 Convertible Obligation and Bassani’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2021, the Company has an interest bearing, secured promissory note for $<span id="xdx_90C_ecustom--FinancingReceivablePrincipalAmount_c20211231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_pp0p0" title="Financing Receivable, Principal Amount">30,000</span> ($<span id="xdx_909_eus-gaap--NotesReceivableNet_c20211231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_pp0p0" title="Financing Receivable, after Allowance for Credit Loss, Total">34,093</span> including interest) from Smith as consideration to purchase warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20211231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_pdd" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">300,000</span> shares of the Company’s restricted common stock, which warrants are exercisable at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_pdd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.60</span> and have expiry dates of December 31, 2024. The warrants have a 75% exercise bonus and the promissory note bears interest at <span id="xdx_906_ecustom--FinancingReceivableInterestRateStatedPercentage_iI_pp2d_dp_c20211231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember__srt--TitleOfIndividualAxis__srt--PresidentMember_zOtpuSUw3ACl" title="Financing Receivable, Interest Rate, Stated Percentage">4</span>% per annum, and is secured by $<span id="xdx_905_ecustom--FinancingReceivablePrincipalAmount_iI_c20211231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember__srt--TitleOfIndividualAxis__srt--PresidentMember_zDYmqOKUEa" title="Financing Receivable, Principal Amount">30,000</span> ($<span id="xdx_907_eus-gaap--NotesReceivableNet_iI_c20211231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember__srt--TitleOfIndividualAxis__srt--PresidentMember_z19OjNt9sauf" title="Financing Receivable, after Allowance for Credit Loss, Total">34,093</span>, including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">As of December 31, 2021, the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $<span id="xdx_90C_ecustom--FinancingReceivablePrincipalAmount_c20211231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember_pdn2" title="Financing Receivable, Principal Amount">46,400</span> ($<span id="xdx_909_eus-gaap--NotesReceivableNet_iI_pdn2_c20211231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember_zxFtRQNXZRFd" title="Financing Receivable, after Allowance for Credit Loss, Total">54,088</span> including interest) from two former employees as consideration to purchase warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember_pdd" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">928,000</span> shares of the Company’s restricted common stock, which warrants are exercisable at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember_zfBizfUWz9hl" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> and have expiry dates of December 31, 2024. These warrants have a <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_dp_c20211231__srt--TitleOfIndividualAxis__custom--ConsultantMember_zh5YP5DWZ4L8" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">90</span>% exercise bonus. The promissory notes bear interest at <span id="xdx_903_ecustom--FinancingReceivableInterestRateStatedPercentage_iI_dp_c20211231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember_z3FpF1w7ww71" title="Financing Receivable, Interest Rate, Stated Percentage">4</span>% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.</p> 428250 491975 5565000 0.75 30000 34093 300000 0.60 0.04 30000 34093 4640000 5408800 928000 0.75 0.90 0.04 <p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zXcD1jf2R6y6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>9.       <span id="xdx_828_zkRiIn6nN0ah">COMMITMENTS AND CONTINGENCIES</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Employment and consulting agreements:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Smith has held the positions of Director, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month to month contract extension with Smith which includes provisions for i) a monthly salary of $<span id="xdx_902_ecustom--MonthlyOfficersCashCompensation_c20161001__20161010__srt--TitleOfIndividualAxis__srt--PresidentMember_pp0p0" title="Monthly Officers' Cash Compensation">18,000</span> until the Board of Directors re-instates cash payments to all employees and consultants who are deferring compensation, ii) the right to convert up to $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_zvv5h0jgSLLi" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">300,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember_zFKWS5TdzNu9" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> per share, until December 31, 2022), and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since March 31, 2005, the Company has had various agreements with Brightcap and/or Bassani, through which the services of Bassani are provided (any reference to Brightcap or Bassani for all purposes are the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017, (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($<span id="xdx_907_ecustom--MonthlyOfficersCashCompensation_c20150203__20150210__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Monthly Officers' Cash Compensation">31,000</span> per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation. During October 2016 Bassani was granted the right to convert up to $<span id="xdx_90A_ecustom--DeferredCompensationMaximumConvertibleAmount_c20161031__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_pp0p0" title="Deferred Compensation, Maximum Convertible Amount">125,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_90C_ecustom--DeferredCompensationStockConversionPricePerShare_c20161031__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_pdd" title="Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)">0.75</span> per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $<span id="xdx_902_ecustom--DeferredCompensationMaximumConvertibleAmount_c20170427__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_pp0p0" title="Deferred Compensation, Maximum Convertible Amount">300,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_906_ecustom--DeferredCompensationStockConversionPricePerShare_c20170427__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_pdd" title="Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)">0.75</span> per share, and subsequently extended until December 31, 2022). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $<span id="xdx_90F_eus-gaap--AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent_iI_c20180228__srt--TitleOfIndividualAxis__custom--BassaniMember_z5IbhxTYoxJl" title="Salaries and wages">31,000</span> per month, which sum would continue to be accrued until the Company there is adequate cash available at which point re-instatement of a least a partial cash payment would be instituted. Additionally, the Company has agreed to pay him $<span id="xdx_904_eus-gaap--OtherAdditionalCapital_iI_c20180228__srt--TitleOfIndividualAxis__custom--BassaniMember_zrKdjmXN8IEh" title="Additional paid amount">2,000</span> per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $<span id="xdx_905_ecustom--InterestBearingSecuredPromissoryNote_c20221201__20221231__srt--TitleOfIndividualAxis__custom--BassaniMember_zqsiEgU0CJ4k" title="Interest bearing secured promissory note">300,000</span> from Bassani as consideration to purchase warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20180801__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsExpiringOnDecember312025Member_pdd" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">3,000,000</span> shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of <span id="xdx_900_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20210701__20211231_zjh9Q6L4cc6c" title="Expiration date">June 30, 2025</span>. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of December 31, 2021, the principal and accrued interest was $<span id="xdx_90A_eus-gaap--NotesReceivableNet_c20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_pp0p0" title="Financing Receivable, after Allowance for Credit Loss, Total">340,093</span>. For the six months ended December 31, 2021 and 2020, Brightcap was paid $<span id="xdx_900_eus-gaap--RepaymentsOfLongTermDebt_c20210701__20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_pp0p0" title="Repayments of Long-term Debt, Total">120,000</span> and $<span id="xdx_904_eus-gaap--RepaymentsOfLongTermDebt_pp0p0_c20200701__20201231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_zWuHTLRcaUw4" title="Repayments of Long-term Debt, Total">55,000</span>, respectively, of cash compensation earned during the period. For the last 2 years, portions of Bassani’s compensation (determined by the Company’s President and the Board of Directors from time to time) has been paid in cash with the balance of his compensation accrued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Execution/exercise bonuses:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise bonus which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the bonus shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock bonuses, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods have been reduced to $.01 per option or warrant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2021, the Company added a <span id="xdx_90B_ecustom--ExerciseBonus_iI_dp_c20210630_zsh0iwtXSN74" title="Exercise bonus">75</span>% execution/exercise bonus to the terms of <span id="xdx_901_ecustom--WarrantsHeldByTrustOwned_c20200701__20210630_zeNtQm2ogGEe" title="Warrants held by trust owned">3,000,000</span> warrants held by a trust owned by Bassani.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2021, the execution/exercise bonuses ranging from <span id="xdx_90E_ecustom--ExerciseBonus_iI_dp_c20211231__srt--RangeAxis__srt--MinimumMember_zaKVSAQjYQe7" title="Exercise bonus">50</span>-<span id="xdx_908_ecustom--ExerciseBonus_iI_dp_c20211231__srt--RangeAxis__srt--MaximumMember_zLsRyeiXoxt3" title="Exercise bonus">90</span>% were applicable to 10,326,600 of the Company’s outstanding options and <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstanding_iI_c20211231_zqMrirQfLKIg">16,778,213</span> of the Company’s outstanding warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Litigation:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">A: Website</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the &lt;biontech.com&gt; domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and &lt;biontech.com&gt;, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name &lt;biontech.com&gt; ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and &lt;biontech.com&gt;, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name &lt;biontech.com&gt; to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>B: Dissolution of Bion PA1, LLC (“PA1”)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20140901__20140925__us-gaap--InvestmentTypeAxis__custom--PennvestMember_zXgkOPr7Tei6" title="Principal, interest">8,137,117</span> (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 29, 2021, the Company approved and executed a Consent of the Sole Member of Bion PA 1 (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business. PA 1 is prepared to transfer to Pennvest all of PA1’s right, title and interest in its property (by a bill of sale or other acceptable agreement) or alternatively, with Pennvest’s approval and direction, arrange for the sale of its property and deliver all proceeds (net of commissions and customary costs of sale) to Pennvest. PA1 and Pennvest have entered into communication/exchanges to determine how Pennvest would like PA1 to proceed with this process. The Company’s personnel will assist PA1 with this process as needed at no cost to PA1.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon the complete distribution of all assets of PA1, whether by transfer or sale as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PA 1 has made no payments to vendors or other creditors in connection with the dissolution. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $<span id="xdx_90C_eus-gaap--Assets_iI_pp0p0_c20210930_z9rdYEsSbj86" title="Assets">297</span> and its total liabilities were $<span id="xdx_90A_eus-gaap--Liabilities_iI_pp0p0_c20210930_zGCpQEDY2Hme" title="Total liabilities">10,154,334</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_901_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_c20210930_zHRntgTP2Dtb" title="Accounts Payable And Accrued Liabilities">9,939,148</span>, accounts payable of $<span id="xdx_90E_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20210930_zN0AvprPPVL8" title="Accounts payable">214,235</span> and accrued liabilities of $<span id="xdx_906_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20210930_zmDJKa4srgEb" title="Accrued liabilities">950</span>) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities will no longer be consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets where nil and its total liabilities were $<span id="xdx_909_eus-gaap--Liabilities_iI_pp0p0_c20211229_zLgYP5Kxo3v4">10,234,501</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_90C_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_c20211229_zivmYjxDvr22" title="Accounts Payable And Accrued Liabilities">10,009,802</span>, accounts payable of $<span id="xdx_90F_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20211229_zgQRZj47bIrg" title="Accounts payable">212,263</span> and accrued liabilities of $<span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20211229_zRseky3aW9e6">12,436</span>. The net amount of $<span id="xdx_90A_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_c20210701__20211231_zeVrz4T52YRi" title="Gains Losses On Extinguishment Of Debt">10,234,501</span> was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The Company currently is not involved in any other material litigation or similar events.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Lease:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarized the supplemental cash flow information for the six months ended December 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zOURuSW1l419" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: white"> <td><span id="xdx_8B2_zsC6tgp3dkwh" style="display: none">Schedule Of Cash Flow Supplemental Disclosure</span></td> <td> </td> <td> </td> <td id="xdx_499_20211231_zlk5R1tFwFPj" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">December 31, 2021</span></td></tr> <tr id="xdx_404_ecustom--CashPaidForNoncancelableOperatingLeaseIncludedInOperatingCashFlow_iI_zusv9LbOudT" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%"><span style="font-size: 10pt">Cash paid for noncancelable operating lease included in the operating cash flows</span></td> <td style="width: 10%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 17%; text-align: right"><span style="font-size: 10pt">60,000</span></td> <td style="width: 1%"> </td></tr> <tr id="xdx_40A_ecustom--RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities_iI_zb9vL7h948n5" style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Right of use assets obtained in exchange for operating lease liabilities</span></td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt">180,586</span></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The future minimum lease payment under noncancelable operating lease with terms greater than one year as of December 31, 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--ScheduleOfFutureMinimumLeasePaymentTableTextBlock_zjX5dyvwenF8" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details1)"> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify"><span id="xdx_8B0_zbjC7qey9ZG2" style="display: none">Schedule Of Future Minimum Lease Payment</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears_iI_zC8l2NskCWS5" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%; padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">From January 2022 to December 2022</span></td> <td style="width: 10%; padding-bottom: 1pt"> </td> <td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 10pt">$</span></td> <td style="width: 17%; padding-bottom: 1pt; text-align: right">—  </td> <td style="width: 1%; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears_iI_zZEtFiDJZpef" style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">From January 2023 to December 2023</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt">75,000</span></td> <td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInFourYears_iI_zrBERUQkmL77" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">From January 2024 to December 2024</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt">75,000</span></td> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_ecustom--UndiscountedCashFlow_iI_zYR894FZ9rPl" style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Undiscounted cash flow</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt">150,000</span></td> <td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_ecustom--ImputedInterest_iI_ziZJjSVku4qe" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">   Less imputed interest</span></td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(27,395</span></td> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_403_eus-gaap--CapitalLeasesContingentRentalPaymentsDue_iI_zLswS1EXC1pg" style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Total</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$ </span></td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">122,605</span></td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_907_ecustom--WeightedAverageRemainingLeaseTermDescription_c20210701__20211231_zunOU8SRmPcb" title="Weighted average remaining lease term">The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of December 31, 2022 were 3 years and 10%, respectively</span>. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> 18000 300000 0.75 31000 125000 0.75 300000 0.75 31000 2000 300000 3000000 2025-06-30 340093 120000 55000 0.75 3000000 0.50 0.90 16778213 8137117 297 10154334 9939148 214235 950 10234501 10009802 212263 12436 10234501 <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zOURuSW1l419" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: white"> <td><span id="xdx_8B2_zsC6tgp3dkwh" style="display: none">Schedule Of Cash Flow Supplemental Disclosure</span></td> <td> </td> <td> </td> <td id="xdx_499_20211231_zlk5R1tFwFPj" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">December 31, 2021</span></td></tr> <tr id="xdx_404_ecustom--CashPaidForNoncancelableOperatingLeaseIncludedInOperatingCashFlow_iI_zusv9LbOudT" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%"><span style="font-size: 10pt">Cash paid for noncancelable operating lease included in the operating cash flows</span></td> <td style="width: 10%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 17%; text-align: right"><span style="font-size: 10pt">60,000</span></td> <td style="width: 1%"> </td></tr> <tr id="xdx_40A_ecustom--RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities_iI_zb9vL7h948n5" style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Right of use assets obtained in exchange for operating lease liabilities</span></td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt">180,586</span></td> <td> </td></tr> </table> 60000 180586 <table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--ScheduleOfFutureMinimumLeasePaymentTableTextBlock_zjX5dyvwenF8" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details1)"> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify"><span id="xdx_8B0_zbjC7qey9ZG2" style="display: none">Schedule Of Future Minimum Lease Payment</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears_iI_zC8l2NskCWS5" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%; padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">From January 2022 to December 2022</span></td> <td style="width: 10%; padding-bottom: 1pt"> </td> <td style="width: 1%; padding-bottom: 1pt"><span style="font-size: 10pt">$</span></td> <td style="width: 17%; padding-bottom: 1pt; text-align: right">—  </td> <td style="width: 1%; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears_iI_zZEtFiDJZpef" style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">From January 2023 to December 2023</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt">75,000</span></td> <td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInFourYears_iI_zrBERUQkmL77" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">From January 2024 to December 2024</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt">75,000</span></td> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_ecustom--UndiscountedCashFlow_iI_zYR894FZ9rPl" style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Undiscounted cash flow</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt">150,000</span></td> <td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_ecustom--ImputedInterest_iI_ziZJjSVku4qe" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">   Less imputed interest</span></td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(27,395</span></td> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_403_eus-gaap--CapitalLeasesContingentRentalPaymentsDue_iI_zLswS1EXC1pg" style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Total</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$ </span></td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">122,605</span></td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of December 31, 2022 were 3 years and 10%, respectively <p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zCXCosszJZtf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>10.       <span id="xdx_825_z3mNCAaW1gae">SUBSEQUENT EVENTS</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated events that occurred subsequent to December 31, 2021 for recognition and disclosure in the financial statements and notes to the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 26, 2022 OMRI’s Appeals Review Committee affirmed the prior “unresolved’ determination by OMRI’s Review Panel. The OMRI process has now moved to OMRI’s Advisory Council. See Note 1 subsection “Organic Fertilizer Listing/Certification Process” above for related disclosure.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $<span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220101__20220128__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ziKRSO3zkeb8" title="Debt instrument paid amount">2,665,500</span> (and made the initial <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220101__20220128__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ziwss4ZO3km2" title="Debt instrument rate">25</span>% payment ($<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20220101__20220128__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zB1G6TAx59Ac" title="Debt instrument principal payment">665,375</span>)) for the core of the ‘Bion System’ portion (without the crystallization modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete and procurement/fabrication has now been initiated. 3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, etc.) for work related to the Initial Project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Initial Project is designed to be installed primarily in two targeted primary phases which approach has been adopted to enable more rapid deployment of our 3G technology given pandemic-induced supply chain constraints. The first phase includes procurement and deployment of Bion’s core 3G technology. The modules in this phase include evaporation, distillation, absorption and crystallization modules, along with supporting mechanical/electrical equipment, controls, instrumentation, and facilities, many of which include components with ‘long lead times’ for manufacture and delivery. These items have now been ordered and procurement/manufacturing, as applicable, is underway.  This phase also includes installing a process building to house the system components, full utility installation (electrical, water, internet, natural gas, etc.), tankage to hold process and waste product liquids, facility access, and other items. The second phase, which will require additional permitting, planning and logistics, will consist primarily of design and construction of a 300 head beef cattle feed barn and an anaerobic digester, which items have shorter construction and fabrication/installation lead times than many of the components of the first phase.  The barn will include an innovative slatted floor livestock and an automated manure collection system.  Support structures will include manure collection basins, pumping stations, and automated controls integrated with the 3G system control system. The design and installation for both phases will include adaptive spaces that allow the integration of Initial Project expansions and the refinement of equipment operations that enhance system productivity and reduce energy demand.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-right: 0; margin-left: 0"> </p> 2665500 0.25 665375 EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

\0RZ.Z]CA M'N7>TG^U46\T^:TFOU?3F[.F=?X,+3GKEN,?RG$]U_?VY!R&67[H>M:1+0A: MND$OW<]@,O2?I,S*%$LRA[8!?B04JXWHHAL<\#@/O<#<8]L1I>@:@=---VSI MAO_E;DXZ'^[PX+PP'2\(W3VVAV&N8^X1U7?ZDOHFN,5\27.!4K( E''A@UA> M]]EZ(EE1M:H9D]#XJN$*/DT(5P%P?\&8W$Y4]VL_=J(_4$L#!!0 ( $50 M3E2E#_CBPP( /\' 9 >&PO=V]R:W-H965TTY3L?.,:'6H&?68C[HL;7,"(68(['.<\S?1I"Q3=]RK>W" MC"Q74B_8@UZ!EW /\K&(N9K9-4M*!'PCL!$[8Z2= MS!E[UI-)VK<M^1*6"?-%FS*V[5LH60O)\@JL3I 36O[Q M:Y6''8#B.0[P*H#W'A"< /@5P/^H0E !@H\JM"N L6Z7WDWB0BSQH,?9!G$= MK=CTP&3?H%6^"-7OY%YRM4L43@[BV9XPYUC?Y3EJHU;6]K>^0U$H:07"+?O4">X[E'SC/^.-PY9N??U*._5M]+AE^_ =_P M^:?> %=EA\NW"Q1GF$J$:8JB7VM2J'H@T=.M"D<3";GXV2 6U&*!$0M.'E[5 MLX1@4R;@5=4[ <<>5,G2,2RZV+T,?-_KV2^[EW08XSG=_9CP,*9]Y>S'1(KH2G2[]9'[O78/;(>JNY6-J,_]&5KG&*^)%2@#!9*RKGLJHOF9;LI M)Y(5II[.F535V0Q7JD,#UP%J?\&8W$ZT0-WS![\!4$L#!!0 ( $503E3P ME243# 4 )$7 9 >&PO=V]R:W-H965T E"N/DIK,68G-M&,EB32*<7+$-B>63 M)>,1%O*6KXQDPPD.4J >4.J.Y@GW"P<@>K[0QV[F"WG<')'9RV M#F[ND"ZFD14KK?08"SSH<[8#7%E+-'61+E?J+0M,8\6LF>#R*95^8C#V[_SI MU!^#T=/#Q'^[_[[9[YK=OVQCZ6[J9C^HI54PR$KQK)/A+ GG) C%LE^ ME^"T8]Q*WL0K(GN0D(P6:W ?!_29!EL<7@+_91%N QJOP&R-.?FL6D, )GBO MS!. 8WG#$L&)H#R#&)*8+*E\]OU/.3VX%R1*_FD(WBZ"M]/@[7/!+ZK!AQ3/ M:4C%7D?U#-!- 57??A[8GF=Y=M]XKC+HV*S7Z]IULW$[-+\=VIT.K8?,;F%V M4"2G*)+36*3[6!!.$@&F6! @ZZ-=\;-\\"31!(]X9XO2)>K]TR^"\J7*(C M9X;@5 @ 8==RG1HYO2.>6*:%8+=&SF,S9)F.74/SC\ULTW,M3\^Z;I%N]TWI MGB0>>)J'=)5=?G\@T9SPIM;0*^;O?;R^!LU2U\UWLR6'J-+%1FZ-!2.-E>OV MK!I7-%9=RS1K5-%8061[KIXJL/(6 ]^4[268DE!V*U5]KN_C.>)!\F:OOE,T M5JCGF/7DCZVZIEUOXAHK!SJ]$[FC,G?4F/MH3@*7( MPP^H\K"4>?C+=3Y'K*Z6U&43'C%$8V=ZR#WB2#L\_SS>80U*%8?-NJE=PDLE M>,^$"SH/"1!,/8QD:6:"+7YHR^)HM$/]U=,]:W>81JG:\"=DNS&-2S#A MB=P4*17!!8U!P,(0\P1LY&BB1O4?-EDP7B4-\\ISZLF>L3I,M11\V*SX$]G2 M:*!V1IN]7 HK['[ O5SJ,NS]XKT\RA&K>\J#;J]7WWKGS X_-DLM1LU:K-XI MMZ' JE0M5A*5LH?@QUM)5"H7:E:NG^C*.>)A6^DZM94<: K1/?5N.W^QVF5DHN:I9<=? G6ZL?;4*V)Z05\4LM M0\X')'ZI8:BEAKV!^.X1!3WD',GN6;,L8J-R8BA7:96>[28RG&TLLJ.?8K0X M/[Y-3TUKXT-X/8*:\3&\]K/3X1(^.ZQ^P'Q%XP2$9"FG4C+9 3P[_\UN!-ND MYY5S)@2+TLLUP0'ARD ^7S(F7F_4!,4I_. _4$L#!!0 ( $503E2R79B8 MH 4 -\7 9 >&PO=V]R:W-H965T3SG;O.=\3>CO$?8D.(!,]QE(B;SD;*[76W*Y8;$F-QQ;8D4;\\,AYCJ6[Y MNBNVG.!5!HJC+K(LKQMCFG3ZO>S9G/=[+)4138O0Q*QW4T'=EX? M?*;KC=0/NOW>%J_) Y%?MW.N[KJEEA6-22(H2P GCS>= ;R^0X$&9!)_4K(3 M>]= A[)@[(>^N5O=="SM$8G(4FH56/U[(B,215J3\N.?0FFGM*F!^]>OVJ=9 M\"J8!19DQ**_Z$IN;CI!!ZS((TXC^9GM;DD1D*OU+5DDLK]@E\MZRN(R%9+% M!5C=QS3)_^/G(A%[ *7'#$ % !T#G!, NP#8;2TX! 1M> M &0A:/!GU!YNF<+Y->N37[,^;0%'X4GK'YKA#V2KK%LGX;?-\#_2I!%^U\(Z M^JX-'=]V>]VG_7YJ*?>A+H="_U#FMB[CV X, M(2SE#D)URU#=%J%&%"]H1"4EQGAS%>Z>;0\&@5>+MZ78GL%RR=)$"K#%+W@1$8"3E6+X)4_) MZES6O)I/+K0MWSI*6CNQ:5T,6I85!A8ZREE=, SM$#K!4G/ZEG4J87Z9 M,/^G$F8:='[-0P01\NRC0$QB#MIKI@,'@]+!X)R#6?%F5?$NP"CEG"32Y&Q0 M[U7DV-Z1KW6I\%0FP]+1L-'1#VK5!6J?C,A:O:$K*@2+TFS#9(]JN5T(NJ)J MOS7Q6&CH%=/[-6GT0"_JUV*+E^2FHS9Q0?@3Z?1!PWR%5K6V6(W!S0>7$'R_ M)_&"\*:)#?<6(?@6E !190 UNIQIO4N$Y*GZ6I 7N9EQOIA?@$&L^]Y$C87> M_>8(H.U#Z)L;!%8L".WF+)(D>2)"@AG#2:MT5@P(G3=)9\4[L)EX1BQ+9?[- MI/TW[J\-#_:B+#YI&<54[-C!$G*RK!%"_UW'NY /?XF<9I#(:,*Z4T M68,15J^[^LT827T>^[[KJ"0?1W)>\#"2:G3#YME=>P4'29*JX3CG-%G2K;[" M+[%YD \+W0=$JY83@__G!0_]KR8Z;![I,Y:L+[^\OE.Z #+E62F^$Q=+T!4_I$VE >JB@/O0GE MH8KR4#/EU<976>?/FDW&JC?5#)X33IGQM.6,>G3E.O[O39Y6E(>:*>],'1[H MJ52TJSD+^F]2BHA+TDU3RL[5H5F]?P< QUJ*[=]@7$[4^Z)-B ;*O MIOP I'Q:GD8/LC/8H^=#>#V"AN=C>#W)SYHK]?G1][W:5F@BU!?%HS)E7?FJ MGWA^FIS?2+;-CAH73$H69Y<;@E>$:P'U^R-C\O5&&RC/]/O_ 5!+ P04 M" !%4$Y4-YK0/*D& !L(P &0 'AL+W=OE2&_T3X]7](%-F?BTFG#9ZI+' M$>!L<=([@T>7Q$T5,HG//GM**M<@->4^CK^EC:OY2<]*1\0"-A,I!)4_CVS$ M@B!%DN/XIP#ME7VFBM7K'^@7F?'2F'N:L%$F*T3$8>%LAQ!Z$?Y+_U>3$1%0>)T*Z!" 345R 8% M7"A@TQY(H4!,>[ +!=M4P2D4'%.%0:$P,%5P"X4L7/JY.S)?CJF@I\<\?@(\ ME99HZ446$)FV=*$?I;$[%5P^]:6>.!W=WGSV[CY>G5][X.;VHS<%D[._SM+6 M.W!V<7%U?766WGPS9H+Z00)N*.W4N#3= S>_/;VN"_D2%*\_JSH]3SO M%6WH%8,/<226"?"B.9MWZ(_U^HY&OR]GH)P&]&,:SI$6<,QFAP## X L!#O& M,S)7M[K,>5WOWNMZO]"K_[&.I+JUL??WYNI=O5]N4:=2W>HY :^Y$ MVNK/IKN(\N&)?Q0.^:;=3K06@I-9/M3Y(LL@[*L2;K2 MYGT.;%<]USU_T%(4:?TB.5\,9$O2;Y.JFUE9"< = P7\"Z9,)CR;2_OBT$^2 MF#]G-<$DEB!2/:-]1!-4G "QUK0+/Z+1S(\>P!V;,?\QKV9E(;BC0C:G0O[, MTT";R4F0"_=.#^D[(H>6]7OG>F9GO;JIBI^@GJ ^+EE&I:!:QF_O _^!IIN% MQ,ASBBJ@O1?/J5H-]<5Z2F7:/(,5];N7B>V:.;3DWX9<4#43ZHNF\2S*%*F* MY)-@,,.JT,*]5%JH2BW4U]H,]2I*!%_+/:EX45I<;NEC6W@C58N1OA;O/-H# M\.>:J^B+T M:]#;^V(@9L2%5'5'^N)ILJ K(.J+*]X&@U6-1S^IQNNJDWRVT](0*5) >R$%I$@!Z4GAQ3N4 K>V.L1R(LFP M&0<=@M#!KH.:D6"(Z!D@UF=#<17Z'[@J?;;TV2)-^=DZ/> !MXN%3'IN%!N* MSM!>Z PI.D-ZJGEY;+1W#LBV+6BU:D2'(+%MQV[NW,-U+8Z/ K3J(#"U8.8G(0Z-+ M;B"+ 6Q$AB&>MQVO/A.50S(]94[92F2>D]$!;=">&!/'*K["9"^.58R#]4=6 M8[9@/-VFSN(P70)DP=VU7RAP:E78VKQAP(J2\)9]BNF$OJ[08L4*>+"7.5>5 M'+LO2Z;.!'+;%6Y ; 2;"=26@XY+ALT%F"&>MQVO;KVB&:RGF5W\_8KB252E M)]9>SKU5=28F&QA#?Q=8M<*%7=CTXZA+#F'+;19,0SQO.U[=>D4=1$\=.^6W M)-9U(+)MDHF/5=4F^WFW47FYL>7MQDX^)NTJ#Y\Q3M$ MSSLFN_T"HO:*R6D7GPZIUCN><8<4A%;SY,#K$K,&N%EX^I57]2'C#]EG&XE< MMZPCD;_D+.^6GX:<91]$-.Z?PZ,1[+@_AD=>_N&'@L^_0_E ^8,OE_P!6\BN MTH.7'N#YIQUY0\2K[$.!^UB(.,PNEXS.&4\%Y/-%+#.A:*0=E!_8G/X'4$L# M!!0 ( $503E2W7.=@0@0 &X2 9 >&PO=V]R:W-H965T]]ZS_1GWMXP_B26 1,]IDHF!LY1R=>VZ M(EI"2L0%6T&FOLP93XE43;YPQ8H#B8U1FKC8\T(W)31SAGW3=\^'?;:6"0L.W \9U]QP-=+*7N<(?]%5G %.3CZIZKEENBQ#2%3%"6(0[S M@3/RK\<8:P,SXG<*6U%[1SJ4&6-/NO$I'CB>9@0)1%)#$/78P!B21",I'M\* M4*?TJ0WK[WOT'TWP*I@9$3!FR1\TELN!<^F@&.9DG<@'MOT(14!=C1>Q1)A? MM"W&>@Z*UD*RM#!6#%*:Y4_R7"2B9A#T#AC@P@#_RP!W#Q@$A4%@ LV9F;!N MB23#/F=;Q/5HA:9?3&Z,M8J&9KJ,4\G55ZKLY'#ZY6[\R\>[7V\G#],?T.2W MQT]?OJ)S-)4L>D)W*YUJ@48ZUU3NT,DM2$(3<=IWI7*N(=RH<'23.\(''(7H M,\OD4J!)%D/<8#^VV_O8 N"JJ,O0\3[T&VQ%O(7H @7^&<(>]A^GM^CDP^D' MY"*Q)!Q$_MO$TX[Z\SJI4"TL@[) @<$+#N!-OJUUYO\^BUVNF'):40SOE.M7_$.2@-U3-/5)36%=Q31*4T#F@DZ] >.-RLCL,T$X9 M"H11FJ\*M3YBLFND>;0F/S_8[Y!GZ25E(H4)#]\ IBW4/$\*Z?JSLM'Y?BQ6) M8. H@1; -^ ,D:4J5V785]:P#56(&^;I&Q>2UI5F>-8))P5/%P(J] MHNV>94<^@G1-:/VVI-^;>+NG(X+ 51#8&H0Z.LV!RJ,R;T4^@G2EH'[0EO2[ M,V_U=$00E63[=LV>/*\H/RKO5MPC*%"(LT'S@2%C_JAX"K$ MG;!W=8!>)8^^71^+C9K,$CABM5V]L=BX4CUL5[WO7.S">[MBXTKV<"O9R[/Y M_YR,7_'8[FC\,IQ* +%= %^$&ULK59M3]LP$/XKIVC20 *2IM " M:BNUM!N(,1@%IFG:!S>Y-A:)'6RG!8D?/]M)TTZBH9GXDMB.[WDYQ_9U%EP\ MR@A1P7,2,]EU(J724]>5080)D0<\1::_3+E(B-)=,7-E*I"$-BB)7=_S6FY" M*'-Z'3MV(WH=GJF8,KP1(+,D(>)E@#%?=)V&LQRXI;-(F0&WUTG)#,>H[M,; MH7MNB1+2!)FDG(' :=?I-TX'#1M@9SQ07,BU-A@K$\X?3>480Q!LI M$/V:XQG&L4'2.IX*4*?D-('K[27Z%VM>FYD0B6<\_DE#%76=8P="G)(L5K=\ M<8Z%H2.#%_!8VBWX,XQ^ MW%_<_8)]^,[9'*7"$,81$0A]DSRJ7F!GB(K06.YV7*7I#8@;%%2#G,K?0-6" M*\Y4)&'$0@S_C7>U[%*[O]0^\"L!AQ@<0+.Q![[G-SZ!"])HE?FS K]9YJ9I M\9L;\$=/F;'\NS^12NC?YT\%YF&)>6@Q#S=@KA++4_-;RCV8X(PR1MD,=B@K M/.S"*[SE(T]+)879QZ+.S?CN$^F:/0 MNQ=F@C"U'Q*%,"54P)S$&:Y9>X75 KUEJ9*YOJ56::E5:>FKD6T,%:NQ]1)4 MPM;7VR[UMK?3N^4"O)?V2K;Z-HY+&\>5-A[R+;!MLBO!ZJL\*56>;*'RPW)= M25;?1<-;'?%>W3,'65CGP*DF^ _M:]=3XV//G-+;>\M135S#D[MV^R8H9K;& MD!#PC*G\(BY'RSJFG]_>J^EY$71%A#XP)<0XU:'>05L?BR*O*_*.XJF]RR=< MZ=JV3$$9777^PM02P,$% @ 15!.5-(4?[_Y P MT1, !D !X;"]W;W)K&ULS5A1;]I($/XK*^ND MME(;>PT&$@$2P>XUND9)0W.G4W4/&WO J]I>;G>!1+H??[MKQP8*!EI'RDNP MUS/?-S,[NS.9_HKQ[R(&D.@Q33(QL&(IYQ>V+<(84B+.V!PR]67*>$JD>N4S M6\PYD,@HI8GM.D['3@G-K&'?K-WR89\M9$(SN.5(+-*4\*=+2-AJ8&'K>>&. MSF*I%^QA?TYF, %Y/[_EZLTN42*:0B8HRQ"'Z< :X8L GVL%(_$GA958>T;: ME0?&ONN7JVA@.=HB2""4&H*HGR6,(4DTDK+CWP+4*CFUXOKS,_I'X[QRYH$( M&+/D+QK)>&#U+!3!E"P2><=6GZ!PR--X(4N$^8M6A:QCH7 A)$L+965!2K/\ MESP6@5A34#B[%=Q"P=U6:.]1:!4*K6,9VH5"^U@&KU PKMNY[R9P/I%DV.=L MA;B65FCZP43?:*MXT4PGRD1R]94J/3FH.#+_=77O]$' M])%F) LI2=!$$@DJ,Z1 ;WV0A";BG1*XG_CH[6_O^K941F@H.RP(+W-"=P]A M"UVS3,8"!5D$T0Y]OUZ_4Z-O*^?+"+C/$;AT:P%]",]0"[]'KN/B'?:,CU=W M=KGS:^S!3[-O!*-5ID/+X+7WX/T.&7"UZR2+T"A2^4:%Y$2?910\JLM) /IV M#>D#\']JV-HE6]NPM?8E7TPX?-#G/$)CEFI\8JZ/$>KJ?6CT*NYSF=32G_&*C@$-1& M/#IE/#JU\1@E"5,^J[#OW:HB+7:%(,?VZD/PHU"K[?;P5@B.@0H.06V$H%N& MH%L;@CL00'@8FR/APU*5UKE)P!/.0Z_DZKV.\W!>&G3^@OM?BZT[H LQ)R$, M+-7B".!+L(9HUP7<$([?$$[PZS@;FX&=JE8[M=NQ<]^KU'B/;N9F3XY(2;S6 M(.#7D938K4QR7S M"_#U>\+9NI0.B_B'18):D4W7J_J,ZPOTJ2F _D/-U'1< M%77\2JHZKLHZ;JJNLSQ\>\MZ/=$)EUH!M)X/@JLG!KZ3+P56;@U^RSZD' M/R6-F^ITF@(*&@#*M\1>&U&DP&=F-B10R!:9S/\]+5?+^=/(3%VVUB_QQ1CO M6/?UO,J,1"KX?-AU3?B,9@(E,%54SEE778(\GQ_E+Y+-S8#D@4G)4O,8 XF M:P'U?&PO=V]R:W-H965TQ6-P'QF(2H;+DD^2\'/;''RG)HEXH4D[J_9+8U@PY,YQY M9CBDCI_CY$?ZR%@&7E9AE)Z,'K-L_6D\3I>/;$73PWC-(O[D/DY6-.-?DX=Q MNDX8]7.F53B&EH7'*QI$H]/C_+=YEFM:+)ZSD+X^>3D3W: M_G ;/#QFXH?QZ?&:/K %R[ZOYPG_-JY&\8,5B](@CD#"[D]&9_:G:\\1##G% MKP%[3FN?@5#E+HY_B"]7_LG($A*QD"TS,03E_Y[8A(6A&(G+\=]RT%$UIV"L M?]Z.?I$KSY6YHRF;Q.%O@9\]GHR\$?#9/=V$V6W\?,E*A9 8;QF':?X7/)>T MU@@L-VD6KTIF+L$JB(K_]*4T1(W!=GL88,D AS(X)8,SE,$M&=P6 T0]#*AD M0$-GP"4#'LI 2@8RE,$K&;RA#$U"QY+F_3&E&3X^3^!DD M@IZ/)S[D3I?SK;[^# M#U.6T2!,P;]HDE#AP+^ C^#[8@H^_.V7XW'&YQ7Q0Q3[F;EKY*JQ\%>;C.3WC34*:IB"^!XLL7OX ?WSAS\%5 MQE;I?S2C.]7H3CZZVS/Z+?/9:IV#-I]B&4=/+,F"NY"!.8=LEB3,!ZF86.5# MQ= X'UJDI*=3U[8L;O(GA41N)9&KE6CQ2!.6@DL6^N#N%2PV=VG@!S0)^(\? M@@BD^7-50$Z*@5%-'F*YCG54"51$SC"RV3"R"R-9PPJHL@+26J%:]=\$&$49 MB!.0I_$#,'MAR3)(Q0H%2U:C22NB5&6=8D)2$]0Z)*BEM(&HH0NN=,'OU<4' MTTT21 ]@SI(@]@T+/<,=FT/'1@CUN!ZI!"5Z0>/5B@="$6BE'UZEZ8:+MUGS M!Y7EZS8WB$IV$]6K1/6THFY-*0W(JT905T EC-<)6)LX&&.H%N:H$N9('[*Y MP4I+-1;RH#3C02Y:D.8%II"0AKD5OTT6M%BOS6.OFZR-.-F%)8W@&0Y M2=UP]A&QK#IPEWH,H&RJ(G.:#?7NFU?PW%O.>+[A.Y(VJ EGKNO4B#8_#D.: MI&#-DD)1I7^4$K2@S.F17.9+6Y\P.Y+?,K$A$T).XBA+^-9G0T/P);C7:?$[ MHXE::OWL$+PRH;H'>)QGCRFP(?#I:ZJI!&R9>&U]YA4!3*,BI3SK_-OM^#=! M;>^Y4%!!U.LY,B_:^L1X%66,NW8&V O?+7.<4/HXZD:@[3FXE>VF"CK'[]FA?O9;W\QPU;W;%$ MMS& ,A-":P\;#RC3&=2GL[<8>@*[.:D%/%,SRXR3X'_,M)6=E./6<<;!EJH<'T+9E%Y" ML3,EMQ'93#(SDUQH29J*2T1V](B\JR^"/\$.".+4NG#[ M '%'@KBC!_%ME<"+YB#)LZS8/>6=EMZMB&%(VRKV(CKY)"P[AG97O?,RQ+(2 MFYU]8+,CL=GYR['9Z<*NHE-GHFKJ(]'9T:/ST$V@?IA!%6\9UC^Y='9D3G#T MI7.KO?/^NO8<8<"6*NGH4W4,, MN,KN33L&3%1-?20:N_HNR\]O6)<3#FX#N[73$D-YOH>>M=L]T]!+*W'>U>/\ MV]K6KJ*=H^M;NS([N/J^RE"T*X?I;7DUIY?)P]4G#V/Y,0]I!&YB/[@/EN7F M^"I:)OE3&G+#I:HVRX7;/75 &/;%AA@U'.P@B3>(T-/OURU3:1?MRZ(8]>SW1[?1A+#D1[#SWP_$,'-(WI. M _\C1^<)70755 MGU+@+IYJ3O20!%2D!]0YC\[ 9\/J/22Q$NVCV8$ERF$]RDV*:R(\:65Q<81[ M ,Y6\4;=\\>*XU!"[![C80EV6 ]V9\NEF#(5F9.*&RLJL1:]%3SN0I^#7.CV MB"6!#^N!;Y!8137,:\?\!Q4L8E5IVZY_#41-#207O[N6\^6,GKZ<-U$U M]9'PBO7PVHTR\">XK?+B\*X#EDB+]X&TN':CYMU7:G9>(CQHB? N%X0D*&/3 M :)BB79M"F&)N]C;Q_)( ,:FSL). 'FT"T 2"=-$#]/O!$BBZ#?W R21N$WT MN/WM.1:2I)LPR[VRMN([=#^(!&2RCPN41,(E^!U'EZ[J3H8*HA$6K*/_C&I73DT(E]=^&U MUN\-<";&LKAIDSE- MA!\N,BK ZU<:;HKB*;?5\#MADW+>9O:JE?&E<890?1Y$=6VB:EI()ABB3S = M"TUJ-[?+,ZLW&.B*=%-1S^[6DVG(,]RH;,LZ#9Y$KO?!+5_. R'G4K2S'E3' MB^>&P>$ALOZN"41/IB5/GY8Z8M:NQLMR?4>#7GO=0TN[+T \F=(\_1YC:\$J MM:NOV2Z#=/58VDC5EE&G1TZ?%2L:#-D"K7@CQNN\2P(ZLER:J0M1Q[<4@ M\;K;#4T> K[;#]D]9Q/EZ@@DQ1MDQ9&PO M=V]R:W-H965T)(@%M M=9&Z#D&[O9CVPB0.6'-BKNV45MJ'OW:2)=R5I!W=[LH;B!/;YW\>G!\V_8V0 M7]6*4@WW$8_566.E]?J=XRA_12.B3L6:QN9)*&1$M&G*I:/6DI(@'11Q![MN MVXD(BQN#?GIO*@=]D6C.8CJ5H)(H(O)A1+G8G#50X_N-&5NNM+WA#/IKLJ1S MJF_74VE:3C%+P"(:*R9BD#0\:PS1NY'7M /2'A\9W:BM:["N+(3X:AN3X*SA M6D644U_;*8CYNJ-CRKF=R>CX)Y^T4=BT [>OO\]^F3IOG%D01<>"?V*!7ITU MN@T(:$@2KF=B\S?-'6K9^7S!5?H)F[ROVP _45I$^6"C(&)Q]DWN\T!L#? Z M%0-P/@"GNC-#JCJPMX"\/+R\G59'AS,8>C.@$L(O1[?P)5F0BHE#6 L(E.ZBJ3)'QK=\9*:<* 4BA$\VT,:0D) N%"N22I\I"E/)?+K51Q6=%!RQ& +!.9$*UE1F ML3V&;U &>E?B,E&=5)1=QG<#][33ZCMW.UQI%JXTZUU9,1I:U7YB"P8^A*'1 M+>'S>QHMJ/QB1!4.3)1*3,A/8)XLE"_9.LW9C/J4W9$%I\6@FA"W"EVMPZN/ M=B&^O6]]7"!= I?.B\MD-03&VHI(J:4D ]P+?2SRJ%;J.@>7CGT"O&]VA!>LIC$OE52 MKI43(*$V81QR USSE()!-XR-BTS#E5#J!&Z$)GQ7IC-K[:U,-W$7MRH2C=R2 M,6ZM3ILT91A>K&<6&XE4Z9T4<1^KZ*%>U?L(;9$.U:J8&HLLL/EX1OV@DC?H M (N*@5XD<]#/,025T4#UU'N?X5W,&E:!!!T@:5*(&O4+6H,>P\5RWDC6H MA UZ@C9_J,P[.\J\7>%,R2S4_?DJ?P$L40D>JZ?]4ENR0;KB>;W;6;O%Y$:RX>*/UM1, E MG7#S %=/"33<>GU$R#5M$Z&'N]457?(-[\VWWTF$7-7S?OC@DF^XGF\UQ?X" M,. 22?@ ]U&XY!K^?W=2^/%6JM5TN]VJLO5*A'G[(.PY:/!V;*S:S6HX>"6N MO'UPM0\/6;&(E8)U^1YNT%OZP#/.[QUX)6$\IXXM?M#!Y#- M'2_%W@]EZ6R=KB@) MJ+0=S/-0F-=@WK!GZ<5?(8-_ 5!+ P04 " !%4$Y4QJ3_8U8" #,! M&0 'AL+W=OVADZ9" M2)I5%4%JDV[+0]*J2;>':0\&CF#5V,PV3?OM=S8415E3'L!G^_[W._N.9*_T MDZD0+;S40II94%G;7(6AR2NLF3E7#4I:*96NF253[T+3:&2%=ZI%&$?1-*P9 MET&:^+E[G2:JM8)+O-=@VKIF^O4&A=K/@E'P-O' =Y5U$V&:-&R'&[2/S;TF M*QQ4"EZC-%Q)T%C.@NO1U2 4&!NG0*C MSS/.40@G1!A_>\U@".D<#\=OZM]\[I1+Q@S.E?C%"UO-@LL "BQ9*^R#VO_ M/I\+IY*("\-5;5O3,1U%QV7_;2G\.!0SPZX1#W#K'G[@)YR@6S M+$VTVH-VNTG-#7RJWIO@N'27LK&:5CGYV71^MUHMMZO;]78#U^L%S._6V^7Z M^^UZOKS=P-D"+>/"?$Y"2\&<2YCWPC>=<'Q">('Y.8Q'7R".XM'C9@%GGXY4 M0D(=>..!-_:RXU.\JJZYI:JP!I@L8*ZDY7*',N=H8,%-+I1I-<+OZ\Q839?^ MYX.HXR'JV$>=G(K*3 4-XP50&X!4,F,CL_G=9R)X"SC@ELZV?> )_\!CRZCB\OI$7%X4)RNSU=,[[@T M%*,DQ^C\ZT4 NNN=SK"J\?6:*4O5[X<5_6Y0NPVT7BIEWPS7 L,/+/T'4$L# M!!0 ( $503E3,-O&^GP@ *8I 9 >&PO=V]R:W-H965T>YX&,#FB5-$@2MYHS':>/L MQ'QWGY^=9 N5Q*FXSY%#&YHN/\>-4Z2^:9R=S_B@&0GV: MW^?PU-Q*&<-<_RVS]H:8$;\,Q9+N?,9Z:4,L^R+?NB-3QN! MUD@D8J2T" Y_GD17)(F6!'K\IQ#:V,ZI@;N?-]*OS.)A,4,N13=+/L=C-3UM MM!MH+"9\D:B/V?*]*!;$M+Q1EDCS/UH68X,&&BVDRF8%Q>GZ+W\N-F(' M@,,* "D I"Z %@!:%Q 6@+ N@!4 ]@I0N>A6 6C5G2$J %%=0+L M.L".@6@ M4Q> @XWE@MJ0K;%K6QMOS(UKVQMO#(YK6QQO3(Z-S9MK]S6^?\$5/SO)LR7* M]7B0IS^8 V3PX/)QJL_Z0.7P-@:<.NO>W=[V'FXO^P\#=-Z_0-V[_D.O?WW9 M[_8N!^C-A5 \3B3J\SSG^E3^BGY#GP87Z,U??SUI*E! BVF.BLG>K2!=/_Q*#+=PYH!?^.$78G2,*-9P0ASP2S]\(.;'B# S>^B M7]6?'3O@U_7A@0/^W@__L$@!'E3.WJLQ.^E4PC_4V#K/[+_[X>>+QV,4F+7C MM@-^4\-M2+L2?KMG]GD.\,C (P>\7\/GUX9[[?--.*O; TNV!Y88>;1"WDTF M)>IFJ8K31Y&.8B'1'SV:@VQFHF2&LHH2$PQ39!'W6ASY5*,N1 MR0&.T.6SR$>Q%.@^CT=B9XS<#I+H39RB<98D/)=H+B"OF/)#65; ME=@>E8I=&V;I0KH.KQ\?L>,@^,6C2&NK2,LK:&NLJ4C&:+A"*H<8@[)E*L8N MM=;26COVH8'YYS91M%4CJJ<&3\<;I[E;**G@&;S:9;*HI EN15&;8.I6I;U5 MI>U5Y5Q*H5PFN5KCV,Z,C.(PHM8]UWM4'A?2$'GI%\+M]NMTCK*XS"+PC9AP MK]@A$>)V2&GH7C8.;,X2^*TV&F4+[4#W?,6'B4#GX$CP9;X08W3CWX]"] O# M8AI$KY;YOABWNTX6!4%I.QSR,)R03CL@K_;#,;+3H1T'P_7V8[[> M#V> QZ79"2:D15]KZ1H7$EI!R]C&+4SV*6GLX_?77B'EA7^1D+9>JUD>UF$5 MO(1MY,/^T'<-Q;%$.L1"6+U+(=[I,+N(Y13*6X7N)NA"#)73K6C-8W'M5T'7 M]F_EG(_$:0.*=RGR)]$X0Q[RQS8R8G]D^VP*7S !?Q(Y%/)0J^MN *P0)0+J M9:1$/G,NSB_W82K0LHYL0_CC6!IO%>.?(4[K@0G70)4A!8*ZV6S.T]7?_@+D M'OU#%NB-TZP0-ZD))*1B-H3D8I//@P*Y0!2MA$X[]#PX^.4(A,NY,.V$9.7; M0QO*L3\6WXLT?1(0-/^X-0KX$BYLXS)N'2BIPS;H8G_4A90-),]Y"#^\+ W_[S:(X %>Q)0LE.]^*/ +7^NZP3$TC:AAW("2Y[$ M3W(_T G"DA/@XXKP2RQQD6\L0J[V".CL=0)+=\1?A]P#^<1C'5'KN(%E.!(= MR@TLB9$]) ;BI\D*4H$)V#J7?T==+J M:& _Y)$F&Y2!;\8NTIW [!5*C:II\%$;2B@ M_F3W!_8PH_HI&[5AAOK#S'ZG@RT''<$7TN+6=!FK*1KPQ"SI4QK#N%A7L*,I M!V=!$U@Y+R/?L*A\8P M%1R6^SR;Q5)FX/_]3(DCO5/ZB!5W!?IX;#W'W"'HU@6\>-UI8+6,9AD]/!2C MAY;10S^C7\4I!]&P'AN7CA"?*%C5>9)D2WB[)H@N[%2L3 /L")GVLO.0..X% MPB#H5/3B0\O:H9^U/XHY7^E/XW: E%.@:\S0W$ZLYS.OOJ^]WL;\/="E7+"5V5 &PJ8/Q2\@T7P-*ZU_3L7MX=B M9V;9F?G9V21E6K)N6B_YH_-:Y(8Y.+=C('R@()Z@.8_'B%<5 MFC>LS)ZD6@%+GLQ/GKVB%XV&@IM#)8N /;&PO=V]R M:W-H965TJ2@% :B=).8UH1 M(RO[,/'!3:Z-A5^"[;3P[V<[;=:-MA)?'-_Y[KGGGN@N74OUI"L @UXX$WH8 M5,;4EV&HBPHXT3U9@[ O"ZDX,=94RU#7"DCIDS@+<10E(2=4!%GJ?7.F' :1(P0,"N,0B/VLX!H8Y9@8DJ5*KI%RT1;- M77RK/MN2H\+]E-PH^TIMGLGRV2B?_)A-;G^BR8,]L#;'D;X*. W(GH(7WQ".,)XEH_1R8?3(["#3IJ!AQTUC$'8OX72SL+X=]Y8^CX+@711^/B))T=)+WB:*H*&A-F)7GU7GV<4O> M2&.5&9S'_RD3[HP)![7TRT"CPBG>3DSG[?;-53MF?\/;934E:FE9(@8+FQKU MSJT\JET K6%D[8=N+HT=87^M[,X$Y0+L^T)*LS5<@6X+9W\ 4$L#!!0 ( M $503E0\&U7!! , "T0 - >&PO MWSW/G8\8==KH-:>W2TJUMZJX:%)_J77],0B:Q9)6I#F7-14&*:2JB#93509- MK2C)&W"J># >C>*@(DSXLZEHJZM*-]Y"MD*G_G@P>?;V)4_],'[O>S9<)G.: M^O>G;W^T4E^^\>S]Y-W)R>C^[/+0?MH!9W[@#'KQ@J#G(SRNP;K009_#;%I( ML4TE\JW!<).*>@^$IWY&.)LK!EX%J1A?6_,8# O)I?*TJ:$1$X*E>;1P:&=0 MWCY.Q814';=EL-_S?OD!L)F!0,;Y7JW!,)O61&NJQ)69=(L[XQ/(Z\=WZ]HH M+!59A^,+?^O0W0S)7*JFV933 N0H5B[AKF4= *BUK,P@9Z24@G0: M-A[]P(1=4,YOH?>^%WNQ5\7.KHY@3\4P-(+ZH0UC)Q!_-YJ-O1,V>558KV8/ M4G]N33:BFT.OT!M%"[;JYJMBX,>BAWAT4M=\_8FS4E34YOYBPMF4;/R\I53L MT;!!IRR,@2K?>Z!*L\6NY:'+_(*#E*C4'_>[YS:.P=&8/5@Z,Y];_! M:P#?DGKSEG'-1#];LCRGXLG)8<)K,C?O0GOQS?J<%J3E^FX 4W\[OJ8Y:ZMD M6'4#A>A7;<=?(;TP'MX+#!<3.5W1/.NGJIQW0\\,#&M_@<,A"#*M;',.?.QJF#3PP'F#ZO5KCNXUWR/-]@.WI2!$.@%]T]&L=(=6+X MN/<'>TJB*$G<"&!N!5&$(? TX@BF #1@2!1UY^#!>11LSJE@^P^"V2]02P,$ M% @ 15!.5)>*NQS $P( L !?3T\$MP>:4#M.*2V MBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YV MX$G1H2)8%II%R=.B':5_'/A%LY#RV\?N\-I]?I'IZE/()_55733OV-EIO;P:#MMSP MFK6_RRUO3,U:JIIIP*EH*_M&_UW2W:B58\BDKHO\=>_[OB'JI%(VKQ@Z_&WM!#[4:^S*02 M/V2C645+):MJ[/G[BB576I3_*J8=9,$>V[Y$L\><&9"Q-QJ:!M="M;I_HF^? M&<8=-P_O[YZUG(I*N&=.+@=6-?AP.U_T@WJC_,HQRO18E MG\CRN>:-WH^CXE4'V+0;L6T]U+":C[U8[KCJ^F/^(%GM^Z8-E#52ZD:8"I6L M>CR'*"FAZ3R91 6>H-MH'I$8(SK#N*#H8M%8D $ &9P1\EM@088 9/@_0M+" M7.XQ,8#I%*49SBW(*P#RZFR0\2PB%N0U 'E]/LB(SBS($0 Y<@N9YG<12?Z, MBB0EOR$2%8L<=X2W"YH03"W(#P#D![>0-+DCR32)(U*@*([3!2D2(KSW+R&<7J?84+[ MZ;8C]Q *W4.W^B"R8_A18?4HGOV"7=6)K9-9 (+SM4&PS2A^_8 M'V!H/LII?$@@_CD-\BVT,2&%^&=Q"+HPR7_%VU]M3,@FOF.=G(HZIR #2"N! M8ZV ZQI=V)B0: +'H@$3L*,%%(!;%]>B 1?0E8T).2=P[1P0\]K&A)P3.'8. MC#FR,2'K!(ZM\TXXND29,LW:6_\ 4EJ\I,H>ZR/R*YNNXV+.OGJHI-6=K,)5L= MOED]PDN! 0 *1< !H !X;"]?1/L:O"[1N%1?A0%]T@SRJRHXS?U:/(VR]7Y>'2-KZ\=#ZYU57C,U.&T'U8 MZXO2U;F?M9UKAC>GMJ_S,"S[L^WRXIJ?G>4T7=K^>8;9;9]G)H=[Y_XSL3V= M+H7[;(OOVC7AC\'VI^VOOG0NF.20]V<7,F-OU;3M[?B@V3#9)/MC9OK]D8R- M'<00Q/&#!((D?M <@N;Q@Q80M(@?M(2@9?R@%02MX@>M(6@=/V@#09OX092B MC*F"I!>L%6A-R#4I\)H0;%(@-B'9I,!L0K1)@=J$;),"MPGA)@5R$])-"NPF MQ)L4Z,VH-RO0FU%O5J WO_QL*]";46]6H#>CWJQ ;T:]68'>C'JS KT9]68% M>C/JS0KT9M2;%>@MJ+HD!O>;DL4:"WH-ZB0&]!O46!WH)Z MBP*]!?46!7H+ZBWOU-N'>^7\U/-8X_GOI#H,W[KI^''YV$0)YR/.%F[&=[]0 M2P,$% @ 15!.5&/6BA2; 0 E!< !, !;0V]N=&5N=%]4>7!E&ULS9C-;L(P$(1?)^@)ML2$026[:A\/9UPH_4BD8@ M*G4NL1+OSHR]TG?(Y'UKR$6;NFK<-"Z\-X^,N;2@6KE$&VK"3JYMK7QXM0MF M5+I4"V)B-!JS5#>>&C_TK48\FSQ3KE:5CUXVX;,K=3.-+54NCIYVA:W7-%;& M5&6J?-AGZR;[X3+<.R2ALZMQ16G<(!3$[*1#N_.[P;[O;4W6EAE%=YF5*FTU4=6A)G+*G,%42^KI*=Z*#?V8<;IMV37^W? MR?09ALJYU<:%B5FZW.XPDK9[:((065_V'_'H&*2O/A^UT\XH.],[7.^GMLMN M'HYUR_5W_'W&1_T+Y!&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( $503E0;X-*^" 4 +\4 M 8 " @0X( !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ 15!.5/2D4J3+ M P IQ !@ ("!K1, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 15!.5"8!@ X1H !@ M ("!2B4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0# M% @ 15!.5'A%KF'T P M0@ !@ ("!ZVX 'AL+W=O M&UL M4$L! A0#% @ 15!.5%!I<$VX!P A!$ !D ("!+G8 M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M15!.5-3!H>FB @ 7 8 !D ("!18H 'AL+W=O&UL4$L! A0#% @ 15!.5)$P,<@_$P M0CD !D ("!;*, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 15!.5&AJU_:2 P P@D !D M ("!O[T 'AL+W=O&PO=V]R:W-H M965T/$ !X;"]W;W)K&UL4$L! M A0#% @ 15!.5&Y AD _ P _PH !D ("!3,P 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 15!. M5-30C+L0 P ^ @ !D ("!Q-4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 15!.5+)=F)B@!0 WQ< M !D ("!2.$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 15!.5$[ZWSW, @ Z0D !D M ("!>/( 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ 15!.5+Y?E9V\! %AD !D ("!K0,! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 15!.5*B^ MJ>=: @ D04 !D ("! Q0! 'AL+W=O&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !% M4$Y48]:*%)L! "4%P $P @ %'( $ 6T-O;G1E;G1?5'EP =97-=+GAM;%!+!08 +@ N 'D, 3(@$ ! end XML 51 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 180 358 1 false 48 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://biontech.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://biontech.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://biontech.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) Sheet http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://biontech.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS Sheet http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS Notes 7 false false R8.htm 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://biontech.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://biontech.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 9 false false R10.htm 00000010 - Disclosure - DEFERRED COMPENSATION Sheet http://biontech.com/role/DeferredCompensation DEFERRED COMPENSATION Notes 10 false false R11.htm 00000011 - Disclosure - LOANS PAYABLE Sheet http://biontech.com/role/LoansPayable LOANS PAYABLE Notes 11 false false R12.htm 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES Notes http://biontech.com/role/ConvertibleNotesPayable-Affiliates CONVERTIBLE NOTES PAYABLE - AFFILIATES Notes 12 false false R13.htm 00000013 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://biontech.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 13 false false R14.htm 00000014 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES Sheet http://biontech.com/role/SubscriptionReceivable-Affiliates SUBSCRIPTION RECEIVABLE - AFFILIATES Notes 14 false false R15.htm 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://biontech.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 15 false false R16.htm 00000016 - Disclosure - SUBSEQUENT EVENTS Sheet http://biontech.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 16 false false R17.htm 00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://biontech.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 00000018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://biontech.com/role/SignificantAccountingPoliciesTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://biontech.com/role/SignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://biontech.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://biontech.com/role/PropertyAndEquipment 19 false false R20.htm 00000020 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://biontech.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://biontech.com/role/StockholdersEquity 20 false false R21.htm 00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://biontech.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://biontech.com/role/CommitmentsAndContingencies 21 false false R22.htm 00000022 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS (Details Narrative) Sheet http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS (Details Narrative) Details http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans 22 false false R23.htm 00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) Sheet http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) Details 23 false false R24.htm 00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) Sheet http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) Details 24 false false R25.htm 00000025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://biontech.com/role/SignificantAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details) Sheet http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails PROPERTY AND EQUIPMENT - Property and Equipment (Details) Details 26 false false R27.htm 00000027 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://biontech.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://biontech.com/role/PropertyAndEquipmentTables 27 false false R28.htm 00000028 - Disclosure - DEFERRED COMPENSATION (Details Narrative) Sheet http://biontech.com/role/DeferredCompensationDetailsNarrative DEFERRED COMPENSATION (Details Narrative) Details http://biontech.com/role/DeferredCompensation 28 false false R29.htm 00000029 - Disclosure - LOANS PAYABLE (Details Narrative) Sheet http://biontech.com/role/LoansPayableDetailsNarrative LOANS PAYABLE (Details Narrative) Details http://biontech.com/role/LoansPayable 29 false false R30.htm 00000030 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative) Notes http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative) Details http://biontech.com/role/ConvertibleNotesPayable-Affiliates 30 false false R31.htm 00000031 - Disclosure - STOCKHOLDERS' EQUITY - Stock Options Activity (Details) Sheet http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails STOCKHOLDERS' EQUITY - Stock Options Activity (Details) Details 31 false false R32.htm 00000032 - Disclosure - STOCKHOLDERS' EQUITY - Nonvested Share Activity (Details) Sheet http://biontech.com/role/StockholdersEquity-NonvestedShareActivityDetails STOCKHOLDERS' EQUITY - Nonvested Share Activity (Details) Details 32 false false R33.htm 00000033 - Disclosure - STOCKHOLDERS' EQUITY - Financial Statements (Details) Sheet http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails STOCKHOLDERS' EQUITY - Financial Statements (Details) Details 33 false false R34.htm 00000034 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) Sheet http://biontech.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS' EQUITY (Details Narrative) Details http://biontech.com/role/StockholdersEquityTables 34 false false R35.htm 00000035 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative) Sheet http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative) Details http://biontech.com/role/SubscriptionReceivable-Affiliates 35 false false R36.htm 00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://biontech.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://biontech.com/role/CommitmentsAndContingenciesTables 36 false false R37.htm 00000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://biontech.com/role/CommitmentsAndContingenciesTables 37 false false R38.htm 00000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://biontech.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://biontech.com/role/SubsequentEvents 38 false false All Reports Book All Reports bion_10q-123121.htm bnet-20211231.xsd bnet-20211231_cal.xml bnet-20211231_def.xml bnet-20211231_lab.xml bnet-20211231_pre.xml ex31x1.htm ex31x2.htm ex32x1.htm ex32x2.htm http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 55 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bion_10q-123121.htm": { "axisCustom": 0, "axisStandard": 20, "contextCount": 180, "dts": { "calculationLink": { "local": [ "bnet-20211231_cal.xml" ] }, "definitionLink": { "local": [ "bnet-20211231_def.xml" ] }, "inline": { "local": [ "bion_10q-123121.htm" ] }, "labelLink": { "local": [ "bnet-20211231_lab.xml" ] }, "presentationLink": { "local": [ "bnet-20211231_pre.xml" ] }, "schema": { "local": [ "bnet-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 434, "entityCount": 1, "hidden": { "http://biontech.com/20211231": 51, "http://fasb.org/us-gaap/2021-01-31": 107, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 163 }, "keyCustom": 74, "keyStandard": 284, "memberCustom": 25, "memberStandard": 21, "nsprefix": "bnet", "nsuri": "http://biontech.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://biontech.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - DEFERRED COMPENSATION", "role": "http://biontech.com/role/DeferredCompensation", "shortName": "DEFERRED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - LOANS PAYABLE", "role": "http://biontech.com/role/LoansPayable", "shortName": "LOANS PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:ConvertibleDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES", "role": "http://biontech.com/role/ConvertibleNotesPayable-Affiliates", "shortName": "CONVERTIBLE NOTES PAYABLE - AFFILIATES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:ConvertibleDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://biontech.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:SubscriptionReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES", "role": "http://biontech.com/role/SubscriptionReceivable-Affiliates", "shortName": "SUBSCRIPTION RECEIVABLE - AFFILIATES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:SubscriptionReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://biontech.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - SUBSEQUENT EVENTS", "role": "http://biontech.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://biontech.com/role/SignificantAccountingPoliciesPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://biontech.com/role/SignificantAccountingPoliciesTables", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "role": "http://biontech.com/role/PropertyAndEquipmentTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)", "role": "http://biontech.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://biontech.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://biontech.com/role/CommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "bnet:CattlePerHead", "reportCount": 1, "unique": true, "unitRef": "Decimal", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS (Details Narrative)", "role": "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "shortName": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "bnet:CattlePerHead", "reportCount": 1, "unique": true, "unitRef": "Decimal", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-012021-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)", "role": "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-012021-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-10-012021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "bnet:SharesIssuedBeginningOfPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)", "role": "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-10-012021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "bnet:SharesIssuedBeginningOfPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-12-31_custom_CenterpointMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-12-31_custom_CenterpointMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:MachineryAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)", "role": "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails", "shortName": "PROPERTY AND EQUIPMENT - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:MachineryAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-10-012021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "role": "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-012021-12-31_custom_PropertyPlantAndEquipmentOfPA1Member", "decimals": "0", "lang": null, "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationLiabilityCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - DEFERRED COMPENSATION (Details Narrative)", "role": "http://biontech.com/role/DeferredCompensationDetailsNarrative", "shortName": "DEFERRED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "lang": "en-US", "name": "bnet:DeferredCompensationConsecutiveTradingDays", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - LOANS PAYABLE (Details Narrative)", "role": "http://biontech.com/role/LoansPayableDetailsNarrative", "shortName": "LOANS PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2014-09-25_custom_PA1Member", "decimals": "0", "lang": null, "name": "us-gaap:DebtDefaultLongtermDebtAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "role": "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "bnet:SubscriptionReceivableTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative)", "role": "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "shortName": "CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "bnet:ConvertibleDebtTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2020-06-30_srt_PresidentMember", "decimals": "INF", "lang": null, "name": "bnet:NumberOfWarrantsPerUnit", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - STOCKHOLDERS' EQUITY - Stock Options Activity (Details)", "role": "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails", "shortName": "STOCKHOLDERS' EQUITY - Stock Options Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - STOCKHOLDERS' EQUITY - Nonvested Share Activity (Details)", "role": "http://biontech.com/role/StockholdersEquity-NonvestedShareActivityDetails", "shortName": "STOCKHOLDERS' EQUITY - Nonvested Share Activity (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-10-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember", "decimals": "0", "first": true, "lang": null, "name": "bnet:SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - STOCKHOLDERS' EQUITY - Financial Statements (Details)", "role": "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails", "shortName": "STOCKHOLDERS' EQUITY - Financial Statements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-10-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember", "decimals": "0", "first": true, "lang": null, "name": "bnet:SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "bnet:RedemptionOfConvertiblePreferredStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)", "role": "http://biontech.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS' EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "bnet:RedemptionOfConvertiblePreferredStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "bnet:SubscriptionReceivableTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative)", "role": "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative", "shortName": "SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "bnet:SubscriptionReceivableTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-12-31_srt_ChiefExecutiveOfficerMember_custom_SecuredPromissoryNoteMember", "decimals": "0", "lang": null, "name": "us-gaap:NotesReceivableNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "bnet:CashPaidForNoncancelableOperatingLeaseIncludedInOperatingCashFlow", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://biontech.com/role/CommitmentsAndContingenciesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "bnet:CashPaidForNoncancelableOperatingLeaseIncludedInOperatingCashFlow", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "bnet:SubscriptionReceivableTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2022-01-012022-01-28_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://biontech.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2022-01-012022-01-28_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-10-012021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "role": "http://biontech.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-10-012021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)", "role": "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "role": "http://biontech.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:OtherNoncashExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS", "role": "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans", "shortName": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "role": "http://biontech.com/role/SignificantAccountingPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - PROPERTY AND EQUIPMENT", "role": "http://biontech.com/role/PropertyAndEquipment", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-123121.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 48, "tag": { "bnet_AccountsPayableConvertedToUnitsPricePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable Converted to Units, Price Per Unit" } } }, "localname": "AccountsPayableConvertedToUnitsPricePerUnit", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_AccountsPayableConvertedToUnitsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable Converted to Units, Shares" } } }, "localname": "AccountsPayableConvertedToUnitsShares", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_AccruedInterestAndLateChargesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of accrued interest and late charges payable to lender.", "label": "Accrued Interest and Late Charges Payable" } } }, "localname": "AccruedInterestAndLateChargesPayable", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_AdjustmentToAdditionalPaidInCapitalModificationOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This item represents the adjustment to additional paid in capital as a result of modification of warrants.", "label": "Modification of warrants" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalModificationOfWarrants", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_AdjustmentToAdditionalPaidInCapitalModificationOfoptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This item represents the adjustment To additional paid in capital as a result of modification of options.", "label": "Modification of options" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalModificationOfoptions", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_BassaniMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bassani [Member]" } } }, "localname": "BassaniMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_BionsStockholdersEquityDeficitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bion's stockholders' equity (deficit):" } } }, "localname": "BionsStockholdersEquityDeficitAbstract", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "bnet_CashPaidForNoncancelableOperatingLeaseIncludedInOperatingCashFlow": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cash paid for noncancelable operating lease included in the operating cash flows" } } }, "localname": "CashPaidForNoncancelableOperatingLeaseIncludedInOperatingCashFlow", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bnet_CattlePerHead": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cattle per head" } } }, "localname": "CattlePerHead", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "decimalItemType" }, "bnet_CenterpointMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents the separate legal entity of Centerpoint.", "label": "Centerpoint [Member]" } } }, "localname": "CenterpointMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ClassOfWarrantOrRightExercisedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights exercised during period.", "label": "Class of Warrant or Right, Exercised During Period (in shares)" } } }, "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_CommissionsOnExerciseOfWarrants": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "CommissionsOnExerciseOfWarrants", "negatedLabel": "Commissions on exercise of warrants" } } }, "localname": "CommissionsOnExerciseOfWarrants", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_CommissionsOnSaleOfUnits": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "CommissionsOnSaleOfUnits", "verboseLabel": "Commissions on sale of units" } } }, "localname": "CommissionsOnSaleOfUnits", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_CommissionsOnWarrantExercises": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Commissions on warrant exercises [Default Label]", "negatedLabel": "Commissions on warrant exercises" } } }, "localname": "CommissionsOnWarrantExercises", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_CommissionsOnWarrantExercisesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commissions on warrant exercises, shares" } } }, "localname": "CommissionsOnWarrantExercisesShares", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_CommonStockShareRestricted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock share restricted" } } }, "localname": "CommonStockShareRestricted", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_CommonStockSharesIssuedUponExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents warrants exercised for common stock shares.", "label": "Common Stock Shares Issued upon Exercise of Warrants (in shares)" } } }, "localname": "CommonStockSharesIssuedUponExerciseOfWarrants", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_ComputersAndOfficeEquipmentGross": { "auth_ref": [], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the gross amount computers and office equipment held by the Company.", "label": "Computers and office equipment" } } }, "localname": "ComputersAndOfficeEquipmentGross", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "bnet_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to a consultant.", "label": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultants of the Company.", "label": "Consultants [Member]" } } }, "localname": "ConsultantsMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ConversionOfDebtAndLiabilitiesIntoCommonUnits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of debt and liabilities into common units" } } }, "localname": "ConversionOfDebtAndLiabilitiesIntoCommonUnits", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_ConversionOfDeferredCompensationToNotePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of deferred compensation to note payable" } } }, "localname": "ConversionOfDeferredCompensationToNotePayable", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_ConversionPricePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the conversion price on a per Unit basis of convertible debt instruments.", "label": "Conversion Price Per Unit (in dollars per share)" } } }, "localname": "ConversionPricePerUnit", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_ConvertedToUnitsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Converted to Units, Amount" } } }, "localname": "ConvertedToUnitsAmount", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_ConvertibleDebtTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE NOTES PAYABLE - AFFILIATES" } } }, "localname": "ConvertibleDebtTextBlock", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-Affiliates" ], "xbrltype": "textBlockItemType" }, "bnet_ConvertiblePreferredStockAntidilutiveSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents the convertible preferred stock securities that have been excluded from the computation of earnings per share.", "label": "Convertible Preferred Stock Antidilutive Securities [Member]" } } }, "localname": "ConvertiblePreferredStockAntidilutiveSecuritiesMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "bnet_DebtInstrumentInterestRateStatedPercentageQuarterly": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents quarterly stated percentage of debt instrument.", "label": "Debt Instrument, Interest Rate, Stated Percentage, Quarterly" } } }, "localname": "DebtInstrumentInterestRateStatedPercentageQuarterly", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_DeferredCompensationConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of specified trading days during the end of a month for which the share price of common stock during that period will be applied to deferred compensation if converted.", "label": "Deferred Compensation Consecutive Trading Days (Day)" } } }, "localname": "DeferredCompensationConsecutiveTradingDays", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "bnet_DeferredCompensationConvertibleToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of deferred compensation liability convertible to shares of the entity's common stock as of the balance sheet date.", "label": "Deferred Compensation, Convertible to Common Stock" } } }, "localname": "DeferredCompensationConvertibleToCommonStock", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_DeferredCompensationConvertibleToCommonStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the price per share at which the deferred compensation liability is convertible to shares of the entity's common stock as of the balance sheet date.", "label": "Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share)" } } }, "localname": "DeferredCompensationConvertibleToCommonStockPricePerShare", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_DeferredCompensationLiabilityAmountCancelled": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of deferred compensation liability cancelled during the period.", "label": "Deferred Compensation Liability, Amount Cancelled" } } }, "localname": "DeferredCompensationLiabilityAmountCancelled", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_DeferredCompensationMaximumConvertibleAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The maximum amount of deferred compensation that is deemed to be convertible.", "label": "Deferred Compensation, Maximum Convertible Amount" } } }, "localname": "DeferredCompensationMaximumConvertibleAmount", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_DeferredCompensationStockConversionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The price per share in which an individual can convert their deferred compensation.", "label": "Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)" } } }, "localname": "DeferredCompensationStockConversionPricePerShare", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_DeficitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deficit:" } } }, "localname": "DeficitAbstract", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "bnet_DescriptionOfKreider2PoultryProject": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of kreider 2 poultry project" } } }, "localname": "DescriptionOfKreider2PoultryProject", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "bnet_DisclosureConvertibleNotesPayableAffiliatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable - Affiliates" } } }, "localname": "DisclosureConvertibleNotesPayableAffiliatesAbstract", "nsuri": "http://biontech.com/20211231", "xbrltype": "stringItemType" }, "bnet_DisclosureSubscriptionReceivableAffiliatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subscription Receivable - Affiliates" } } }, "localname": "DisclosureSubscriptionReceivableAffiliatesAbstract", "nsuri": "http://biontech.com/20211231", "xbrltype": "stringItemType" }, "bnet_EquityIssuancesWarrantsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "localname": "EquityIssuancesWarrantsPolicyPolicyTextBlock", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bnet_ExecutiveViceChairmanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Executive Vice Chairman.", "label": "Executive Vice Chairman [Member]" } } }, "localname": "ExecutiveViceChairmanMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ExerciseBonus": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise bonus" } } }, "localname": "ExerciseBonus", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_ExtensionBonusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Extension Bonus [Member]" } } }, "localname": "ExtensionBonusMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_FinancingReceivableInterestRateStatedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for financing receivable, under the agreement.", "label": "Financing Receivable, Interest Rate, Stated Percentage" } } }, "localname": "FinancingReceivableInterestRateStatedPercentage", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_FinancingReceivablePrincipalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The principal amount of financing receivable.", "label": "Financing Receivable, Principal Amount" } } }, "localname": "FinancingReceivablePrincipalAmount", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_FormerEmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents former employee.", "label": "Former Employee [Member]" } } }, "localname": "FormerEmployeeMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_Fy2016ExtensionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FY2016 Extension Agreement [Member]" } } }, "localname": "Fy2016ExtensionAgreementMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_GainOnLegalDissolutionOfSubsidiary": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "GainOnLegalDissolutionOfSubsidiary", "negatedLabel": "Gain on legal dissolution of subsidiary" } } }, "localname": "GainOnLegalDissolutionOfSubsidiary", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "bnet_ImputedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Less imputed interest" } } }, "localname": "ImputedInterest", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "bnet_InterestBearingSecuredPromissoryNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Interest bearing secured promissory note" } } }, "localname": "InterestBearingSecuredPromissoryNote", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_InterestExpenseOnDeferredCompensationObligationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents the obligation accrued for interest expense of deferred compensation.", "label": "Interest Expense on Deferred Compensation Obligation [Member]" } } }, "localname": "InterestExpenseOnDeferredCompensationObligationMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_InterestRateOnDeferredCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents the interest rate that is accrued on deferred compensation.", "label": "Interest Rate on Deferred Compensation" } } }, "localname": "InterestRateOnDeferredCompensation", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_LoansPayableCurrentIncludingAccruedInterestAndLateCharges": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Loan payable and accrued interest (Note 5)" } } }, "localname": "LoansPayableCurrentIncludingAccruedInterestAndLateCharges", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "bnet_MinorityInterestPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncontrolling interests" } } }, "localname": "MinorityInterestPolicyPolicyTextBlock", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bnet_MonthlyOfficersCashCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents information about monthly officers' cash compensation.", "label": "Monthly Officers' Cash Compensation" } } }, "localname": "MonthlyOfficersCashCompensation", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_NetIncomeLossApplicableToBionsCommonStockholders": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "NetIncomeLossApplicableToBionsCommonStockholders", "totalLabel": "Net income (loss) applicable to Bion's common stockholders" } } }, "localname": "NetIncomeLossApplicableToBionsCommonStockholders", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "bnet_NotesReceivableInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Notes receivable interest" } } }, "localname": "NotesReceivableInterest", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_NumberOfWarrantsPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants per unit.", "label": "Number of Warrants Per Unit (in shares)" } } }, "localname": "NumberOfWarrantsPerUnit", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_OperatingLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Operating loss" } } }, "localname": "OperatingLoss", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_PA1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Depicts the subsidiary PA-1.", "label": "PA-1 [Member]" } } }, "localname": "PA1Member", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_PaymentsOfCommissionsOnExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow of commissions on exercise of warrants.", "label": "Payments of Commissions on Exercise of Warrants" } } }, "localname": "PaymentsOfCommissionsOnExerciseOfWarrants", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_PennvestLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents the Pennvest Loan.", "label": "Pennvest Loan [Member]" } } }, "localname": "PennvestLoanMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_PennvestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pennvest [Member]" } } }, "localname": "PennvestMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_PercentageOfSustainable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage of sustainable" } } }, "localname": "PercentageOfSustainable", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_PreferredStockConvertibleOptionPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is convertible to an option.", "label": "Preferred Stock, Convertible Option Per Share (in dollars per share)" } } }, "localname": "PreferredStockConvertibleOptionPerShare", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_ProceedsFromSaleOfUnits": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from sale of units" } } }, "localname": "ProceedsFromSaleOfUnits", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_PropertyPlantAndEquipmentOfPA1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Property, Plant and Equipment of PA1.", "label": "Property, Plant and Equipment of PA1 [Member]" } } }, "localname": "PropertyPlantAndEquipmentOfPA1Member", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_PurchaseOfPropertyAndEquipmentForAccountsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Purchase of property and equipment for accounts payable" } } }, "localname": "PurchaseOfPropertyAndEquipmentForAccountsPayable", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_RedemptionOfConvertiblePreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Redemption of convertible Preferred stock" } } }, "localname": "RedemptionOfConvertiblePreferredStock", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_RedemptionOfPreferredSeriesBSharesAndInterest": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Redemption of Preferred Series B shares and interest" } } }, "localname": "RedemptionOfPreferredSeriesBSharesAndInterest", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Right of use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bnet_SaleOfUnitsNumberOfUnitsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of units issued pursuant to a subscription agreement.", "label": "Sale of units (in shares)" } } }, "localname": "SaleOfUnitsNumberOfUnitsIssued", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "bnet_SaleOfUnitsValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the equity impact of units issued during the period.", "label": "Sale of units" } } }, "localname": "SaleOfUnitsValue", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_ScheduleOfFutureMinimumLeasePaymentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Future Minimum Lease Payment" } } }, "localname": "ScheduleOfFutureMinimumLeasePaymentTableTextBlock", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "bnet_SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information concerning the secured promissory note that was received as consideration toward the Bassani Warrants that expire on December 31, 2025.", "label": "Secured Promissory Note, Consideration for Warrants Expiring on December 31, 2025 [Member]" } } }, "localname": "SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SecuredPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to a secured promissory note.", "label": "Secured Promissory Note [Member]" } } }, "localname": "SecuredPromissoryNoteMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_September2015ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about the September 2015 convertible notes.", "label": "September 2015 Convertible Notes [Member]" } } }, "localname": "September2015ConvertibleNotesMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of change in fair value of share-based payment awards due to modifications in warrants terms.", "label": "Change in fair value from modification of warrant terms" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "bnet_SharesHeldBySubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares held by subsidiaries.", "label": "Shares held by subsidiaries (Note 7)", "negatedLabel": "Shares Held by Subsidiaries (in shares)" } } }, "localname": "SharesHeldBySubsidiaries", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_SharesIssuedBeginningOfPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued \u2013 beginning of period" } } }, "localname": "SharesIssuedBeginningOfPeriod", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "bnet_SharesIssuedForWarrantExerciseCommissions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued for warrant exercise commissions" } } }, "localname": "SharesIssuedForWarrantExerciseCommissions", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_SharesOutstandingBeginningOfPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares outstanding \u2013 beginning of period" } } }, "localname": "SharesOutstandingBeginningOfPeriod", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "bnet_StockIssuedDuringPeriodSharesCommissionOnSaleOfUnitsAndWarrantExercises": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period for commissions on sale of units and warrant exercises.", "label": "Stock Issued During Period, Shares, Commission on Sale of Units and Warrant Exercises (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesCommissionOnSaleOfUnitsAndWarrantExercises", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_StockIssuedDuringPeriodValueCommissionOnSaleOfUnitsAndWarrantExercises": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of stock issued during the period for commissions on sale of units and warrant exercises.", "label": "Commissions on warrant exercises" } } }, "localname": "StockIssuedDuringPeriodValueCommissionOnSaleOfUnitsAndWarrantExercises", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_StockIssuedDuringPeriodValueCommissionsOnSaleOfUnits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the value of stock issued during the period for commissions on sale of units.", "label": "Commissions on sale of units" } } }, "localname": "StockIssuedDuringPeriodValueCommissionsOnSaleOfUnits", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_SubscriptionReceivableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSCRIPTION RECEIVABLE - AFFILIATES" } } }, "localname": "SubscriptionReceivableTextBlock", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-Affiliates" ], "xbrltype": "textBlockItemType" }, "bnet_SubscriptionsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subscriptions Receivable [Member]" } } }, "localname": "SubscriptionsReceivableMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "bnet_TechWastage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tech wastage" } } }, "localname": "TechWastage", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "decimalItemType" }, "bnet_The2020ConvertibleObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents 2020 Convertible Obligations (formerly January 2015 Convertible Notes) and 2019 Convertible Note.", "label": "The 2020 Convertible Obligations [Member]" } } }, "localname": "The2020ConvertibleObligationsMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_TwoConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Consultants [Member]" } } }, "localname": "TwoConsultantsMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_UndiscountedCashFlow": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Undiscounted cash flow" } } }, "localname": "UndiscountedCashFlow", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantExercisedForCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrant Exercised for Common Stock" } } }, "localname": "WarrantExercisedForCommonStock", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantUnexercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant unexercised" } } }, "localname": "WarrantUnexercised", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_WarrantsExercisedForCommonSharesShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercised for common shares, shares" } } }, "localname": "WarrantsExercisedForCommonSharesShare", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "bnet_WarrantsExercisedForCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the equity impact of the warrants exercised for common stock.", "label": "Warrants exercised for common shares" } } }, "localname": "WarrantsExercisedForCommonStock", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantsExpiringOnDecember312025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information concerning warrants that expire on December 31, 2025.", "label": "Warrants Expiring on December 31, 2025 [Member]" } } }, "localname": "WarrantsExpiringOnDecember312025Member", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_WarrantsHeldByTrustOwned": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Warrants held by trust owned" } } }, "localname": "WarrantsHeldByTrustOwned", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants issued" } } }, "localname": "WarrantsIssued", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about warrants issued in connection with sale of units in exchange for salary.", "label": "Warrants Issued in Connection with Sale of Units in Exchange for Salary [Member]" } } }, "localname": "WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_WarrantsIssusedSubscriptionReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The warrants issued in exchange for promissory notes.", "label": "Warrants Issused, Subscription Receivable [Member]" } } }, "localname": "WarrantsIssusedSubscriptionReceivableMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_WeightedAverageExercisePriceForOutstandingWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price for Outstanding Warrants (in dollars per share)" } } }, "localname": "WeightedAverageExercisePriceForOutstandingWarrants", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_WeightedAverageNumberOfSharesIssuedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the weighted average number of additional shares issued during period.", "label": "Weighted average shares issued \u00a0\u00a0\u00a0\u00a0during the period" } } }, "localname": "WeightedAverageNumberOfSharesIssuedDuringPeriod", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "bnet_WeightedAverageRemainingContractualLifeForOutstandingWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents weighted average remaining contractual life for outstanding warrants.", "label": "Weighted Average Remaining Contractual Life for Outstanding Warrants (Year)" } } }, "localname": "WeightedAverageRemainingContractualLifeForOutstandingWarrants", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "bnet_WeightedAverageRemainingLeaseTermDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average remaining lease term" } } }, "localname": "WeightedAverageRemainingLeaseTermDescription", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "bnet_WorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the capital available for operations for the Company.", "label": "Working Capital" } } }, "localname": "WorkingCapital", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_YearsOneThroughFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents events that will occur during years one through five.", "label": "Years One Through Five [Member]" } } }, "localname": "YearsOneThroughFiveMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_YearsSixThroughMaturityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents events that occur during years six through loan maturity.", "label": "Years Six Through Maturity [Member]" } } }, "localname": "YearsSixThroughMaturityMember", "nsuri": "http://biontech.com/20211231", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r472", "r474", "r475" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Person with designation of chief executive officer.", "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r212", "r251", "r284", "r286", "r380", "r381", "r382", "r383", "r384", "r385", "r404", "r429", "r430", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r212", "r251", "r284", "r286", "r380", "r381", "r382", "r383", "r384", "r385", "r404", "r429", "r430", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_PresidentMember": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Person with designation of president.", "label": "President [Member]" } } }, "localname": "PresidentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r212", "r251", "r282", "r284", "r286", "r380", "r381", "r382", "r383", "r384", "r385", "r404", "r429", "r430", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r212", "r251", "r282", "r284", "r286", "r380", "r381", "r382", "r383", "r384", "r385", "r404", "r429", "r430", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r97", "r101", "r285" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.", "label": "Condensed Financial Statement" } } }, "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r97", "r101", "r185", "r285", "r372" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r149", "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals." } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses", "terseLabel": "Accounts Payable And Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r30", "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to underwriters, promoters, and employees excluding salaries, wages and amount to related party, classified as current.", "label": "Salaries and wages" } } }, "localname": "AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r28", "r175" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r20", "r313", "r369" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r89", "r90", "r91", "r310", "r311", "r312", "r342" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r208", "r265", "r273" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Issuance of warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r288", "r307", "r314" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "verboseLabel": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r85", "r135", "r138", "r144", "r157", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r323", "r329", "r344", "r367", "r369", "r407", "r422" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total assets", "totalLabel": "Total assets", "verboseLabel": "Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r45", "r85", "r157", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r323", "r329", "r344", "r367", "r369" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r289", "r309" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r8", "r174" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and structures" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesContingentRentalPaymentsDue": { "auth_ref": [ "r358" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount due based upon the occurrence of an event specified in the contractual terms.", "label": "Total" } } }, "localname": "CapitalLeasesContingentRentalPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalRequiredForCapitalAdequacy": { "auth_ref": [ "r418", "r419" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of minimum total risk-based capital required for capital adequacy as defined by regulatory framework.", "label": "Capital Required for Capital Adequacy" } } }, "localname": "CapitalRequiredForCapitalAdequacy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r25", "r369", "r436", "r437" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r9", "r72" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r64", "r71", "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r64", "r345" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r82", "r85", "r105", "r106", "r111", "r114", "r116", "r121", "r122", "r123", "r157", "r196", "r200", "r201", "r202", "r205", "r206", "r249", "r250", "r254", "r258", "r344", "r477" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r274", "r287" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)", "verboseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r181", "r182", "r183", "r191", "r454" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r89", "r90", "r342" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable": { "auth_ref": [ "r18" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of subscription receivable from investors who have been allocated common stock.", "label": "Common Stock, Share Subscribed but Unissued, Subscriptions Receivable", "negatedLabel": "Subscription receivable - affiliates (Note 8)" } } }, "localname": "CommonStockShareSubscribedButUnissuedSubscriptionsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18", "r369" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, no par value, 100,000,000 shares authorized, 43,733,820 and 41,315,986 shares issued, respectively; 43,029,511 and 40,611,677\u00a0shares outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r18" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r126", "r420" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentrations of credit risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r78", "r325" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r174" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "3G project construction in process" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionLoan": { "auth_ref": [ "r12" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the carrying value of a short-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project, usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property. Note that there are separate concepts for the current and noncurrent portions of long-term construction loans.", "label": "Construction Loan" } } }, "localname": "ConstructionLoan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r207", "r209", "r210", "r212", "r222", "r223", "r224", "r228", "r229", "r230", "r231", "r232", "r238", "r239", "r240", "r241" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r38" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes payable - affiliates (Note 6)", "verboseLabel": "Convertible Notes Payable, Noncurrent" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r14", "r410", "r424", "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r74", "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt instrument paid amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDefaultLongtermDebtAmount": { "auth_ref": [ "r81" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.", "label": "Debt Instrument, Debt Default, Amount" } } }, "localname": "DebtDefaultLongtermDebtAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r81", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r226", "r233", "r234", "r236", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "LOANS PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/LoansPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "auth_ref": [ "r14" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the total principal payments made during the annual reporting period.", "label": "Debt Instrument, Annual Principal Payment" } } }, "localname": "DebtInstrumentAnnualPrincipalPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r12", "r13", "r14", "r84", "r87", "r209", "r210", "r211", "r212", "r213", "r214", "r216", "r222", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r231", "r232", "r238", "r239", "r240", "r241", "r356", "r408", "r410", "r421" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r37", "r229", "r354" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "verboseLabel": "Debt instrument rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r37", "r210" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r38", "r84", "r87", "r209", "r210", "r211", "r212", "r213", "r214", "r216", "r222", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r231", "r232", "r238", "r239", "r240", "r241", "r356" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r38", "r417" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Principal, interest", "verboseLabel": "Debt instrument principal payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).", "label": "Deferred compensation" } } }, "localname": "DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationLiabilityCurrent": { "auth_ref": [ "r279", "r281" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred compensation (Note 4)", "verboseLabel": "Deferred compensation liability" } } }, "localname": "DeferredCompensationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Deposits" } } }, "localname": "DepositsAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r69", "r173" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows", "http://biontech.com/role/ConsolidatedStatementsOfOperations", "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r86", "r336", "r337", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivative Financial Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "DEFERRED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/DeferredCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r13", "r15", "r409", "r423" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r273", "r416" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Preferred Stock" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net income (loss) applicable to Bion's common stockholders per basic and diluted common share" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r117", "r118" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Loss per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r48", "r49", "r50", "r89", "r90", "r91", "r93", "r98", "r100", "r120", "r158", "r265", "r273", "r310", "r311", "r312", "r317", "r318", "r342", "r346", "r347", "r348", "r349", "r350", "r351", "r431", "r432", "r433", "r489" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair value measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r152", "r153", "r154", "r155", "r156", "r159", "r160", "r161", "r162", "r164", "r165", "r166", "r167", "r168", "r235", "r263", "r341", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r477", "r478", "r479", "r480", "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r69", "r242", "r243" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on legal dissolution of subsidiary", "negatedLabel": "Gain on legal dissolution of subsidiary", "verboseLabel": "Gains Losses On Extinguishment Of Debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConsolidatedStatementsOfCashFlows", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r55" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative (including stock-based compensation (Note 7))" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Patents" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r69", "r172", "r177" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment of Long-Lived Assets Held-for-use" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r54", "r70", "r94", "r95", "r96", "r97", "r112", "r116", "r321" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Net income" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r178", "r180" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r68" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase in accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r68" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase in deferred compensation" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r68", "r361" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Decrease in operating lease assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r68" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Decrease in prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r51", "r134", "r353", "r355", "r413" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest expense", "terseLabel": "Interest expenses", "verboseLabel": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r57", "r230", "r237", "r240", "r241" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest Expense, Related Party" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOperating": { "auth_ref": [ "r53" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.", "label": "Interest Income, Operating", "negatedLabel": "Interest income" } } }, "localname": "InterestIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r62", "r65", "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred." } } }, "localname": "InterimPeriodCostsNotAllocableDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value." } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LessorLeasesPolicyTextBlock": { "auth_ref": [ "r362", "r363", "r364", "r365" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.", "label": "Lease Accounting" } } }, "localname": "LessorLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r34", "r85", "r139", "r157", "r196", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r324", "r329", "r330", "r344", "r367", "r368" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Total liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r85", "r157", "r344", "r369", "r412", "r427" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r36", "r85", "r157", "r196", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r324", "r329", "r330", "r344", "r367", "r368", "r369" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.", "label": "Expiration date" } } }, "localname": "LineOfCreditFacilityExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r87", "r194", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r87", "r194", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r87", "r194", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r38", "r195" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r8", "r174" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r44", "r85", "r157", "r196", "r200", "r201", "r202", "r205", "r206", "r344", "r411", "r426" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling interest, ownership percentage by parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_NatureOfExpenseAxis": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cost or expense.", "label": "Nature of Expense [Axis]" } } }, "localname": "NatureOfExpenseAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r64" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r64" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r64", "r67", "r70" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r46", "r47", "r50", "r99", "r100", "r327", "r332" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "bnet_NetIncomeLossApplicableToBionsCommonStockholders", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net loss attributable to the noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r94", "r95", "r96", "r97", "r102", "r103", "r113", "r116", "r135", "r137", "r140", "r143", "r145" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "bnet_NetIncomeLossApplicableToBionsCommonStockholders", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows", "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r104", "r107", "r108", "r109", "r110", "r113", "r116" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (loss)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing transactions:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r89", "r90", "r91", "r273", "r319" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r56" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total other expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r19", "r150", "r163" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.", "label": "Financing Receivable, after Allowance for Credit Loss, Total" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r135", "r137", "r140", "r143", "r145" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r360" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r359" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease use- of- asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInFourYears": { "auth_ref": [ "r357" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future rental payments receivable within the fourth year from the balance sheet date under an operating lease.", "label": "From January 2024 to December 2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInFourYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears": { "auth_ref": [ "r357" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future rental payments receivable within the third year from the balance sheet date under an operating lease.", "label": "From January 2023 to December 2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears": { "auth_ref": [ "r357" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future rental payments receivable within the second year from the balance sheet date under an operating lease.", "label": "From January 2022 to December 2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionMember": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).", "label": "Options Held [Member]" } } }, "localname": "OptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r334" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAdditionalCapital": { "auth_ref": [ "r43", "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of additional paid-in capital (APIC) classified as other.", "label": "Additional paid amount" } } }, "localname": "OtherAdditionalCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other (income) expense:" } } }, "localname": "OtherExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncashExpense": { "auth_ref": [ "r70" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.", "label": "Accrued interest on loans payable, deferred compensation and other" } } }, "localname": "OtherNoncashExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForCommissions": { "auth_ref": [ "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for commissions during the current period.", "label": "Commissions paid" } } }, "localname": "PaymentsForCommissions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r59" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r289", "r309" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "auth_ref": [ "r82", "r254" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.", "label": "Preferred stock, liquidation" } } }, "localname": "PreferredStockLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r17", "r249" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)", "verboseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionPricePerShare": { "auth_ref": [ "r248", "r266", "r268" ], "lang": { "en-us": { "role": { "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.", "label": "Preferred Stock, Redemption Price Per Share (in dollars per share)" } } }, "localname": "PreferredStockRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r17", "r249" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, outstanding (in shares)", "verboseLabel": "Preferred Stock, Shares Outstanding, Ending Balance (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r17", "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r6", "r169", "r170" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r60" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of warrants", "verboseLabel": "Proceeds from warrant" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r46", "r47", "r50", "r63", "r85", "r92", "r99", "r100", "r135", "r137", "r140", "r143", "r145", "r157", "r196", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r322", "r326", "r328", "r332", "r333", "r343", "r344", "r414" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r28", "r176" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r179", "r455", "r456", "r457" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r27", "r174" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r176", "r369", "r415", "r428" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net (Note 3)" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOtherNet": { "auth_ref": [], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Property, Plant and Equipment, Other, Net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentOtherNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r26", "r176", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r10", "r176" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r10", "r174" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt, Total" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r316", "r405", "r460" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development (including stock-based compensation (Note 7))" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r21", "r273", "r313", "r369", "r425", "r434", "r435" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r89", "r90", "r91", "r93", "r98", "r100", "r158", "r310", "r311", "r312", "r317", "r318", "r342", "r431", "r433" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r132", "r133", "r136", "r141", "r142", "r146", "r147", "r148", "r276", "r277", "r406" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary paid" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of anti dilutive securities" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule Of Cash Flow Supplemental Disclosure" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r278", "r280" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of earnings per share, basic and diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.", "label": "Schedule of non vested stock options" } } }, "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r28", "r176" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r289", "r309" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r294", "r302", "r304" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r39", "r82", "r121", "r122", "r245", "r246", "r247", "r249", "r250", "r251", "r252", "r254", "r258", "r263", "r266", "r267", "r269", "r270", "r271", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r68" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Stock options, authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Exercisable, options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Expired, options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Forfeited, options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Share-based Compensation, Granted", "verboseLabel": "Granted, options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-NonvestedShareActivityDetails", "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Granted, weighted-average grant-date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-NonvestedShareActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r309" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Outstanding, aggregate intrinsic value ending", "periodStartLabel": "Outstanding, aggregate intrinsic value beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r296", "r309" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options outstanding, ending (in shares)", "periodStartLabel": "Options outstanding, beginning (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Options outstanding, beginning weighted-average exercise price", "periodEndLabel": "Options outstanding, beginning weighted-average exercise price", "periodStartLabel": "Options outstanding, beginning weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r308" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Change in fair value from modification of option terms", "verboseLabel": "Share-based Payment Arrangement, Plan Modification, Incremental Cost" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r287", "r292" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Expired, weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Forfeited, weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r289", "r293" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Options expiration period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r309" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable, weighted-average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Nonvested options, ending (in shares)", "periodStartLabel": "Nonvested options, beginning (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-NonvestedShareActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Nonvested, weighted-average grant-date fair value, ending", "periodStartLabel": "Nonvested, weighted-average grant-date fair value beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-NonvestedShareActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, weighted-average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Vested (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-NonvestedShareActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Vested, weighted-average grant-date fair value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-NonvestedShareActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r77", "r88" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r16", "r17", "r18", "r82", "r85", "r105", "r106", "r111", "r114", "r116", "r121", "r122", "r123", "r157", "r196", "r200", "r201", "r202", "r205", "r206", "r249", "r250", "r254", "r258", "r265", "r344", "r477" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r41", "r48", "r49", "r50", "r89", "r90", "r91", "r93", "r98", "r100", "r120", "r158", "r265", "r273", "r310", "r311", "r312", "r317", "r318", "r342", "r346", "r347", "r348", "r349", "r350", "r351", "r431", "r432", "r433", "r489" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r89", "r90", "r91", "r120", "r406" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r40", "r227", "r265", "r266", "r273" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Conversion of debt and liabilities (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r265", "r273", "r298" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercised, options (in shares)", "verboseLabel": "Warrant exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r41", "r265", "r273" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversion of debt and liabilities" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r22", "r23", "r85", "r151", "r157", "r344", "r369" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "negatedLabel": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Bion's stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r49", "r85", "r89", "r90", "r91", "r93", "r98", "r157", "r158", "r273", "r310", "r311", "r312", "r317", "r318", "r319", "r320", "r331", "r342", "r344", "r346", "r347", "r351", "r432", "r433", "r489" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total deficit" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r83", "r250", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r264", "r273", "r275" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r352", "r371" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r352", "r371" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r352", "r371" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r352", "r371" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r370", "r373" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r152", "r153", "r154", "r155", "r156", "r235", "r263", "r341", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r477", "r478", "r479", "r480", "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r124", "r125", "r127", "r128", "r129", "r130", "r131" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r104", "r116" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted weighted average shares \u2013 \u00a0\u00a0\u00a0\u00a0end of period" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted-average number of common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e639-108305" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21564-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r275": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r315": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r334": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125514181&loc=d3e34841-113949" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919352-209981" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL119206284-209981" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r373": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)(1)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=117337116&loc=SL5958570-112826" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r461": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r462": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r463": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r464": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r465": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r466": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r467": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r468": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r469": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r470": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r471": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r472": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r473": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r474": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r475": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r476": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r477": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r478": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r479": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r480": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r481": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r482": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r483": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r484": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r485": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "i", "Publisher": "SEC", "Section": "3", "Subsection": "10" }, "r486": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r487": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r488": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.T)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868742-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" } }, "version": "2.1" } ZIP 56 0001079973-22-000149-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-22-000149-xbrl.zip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

(D5B7.&'?2)45KGI]/YQ*G M R'SL*YG^)D'MZ_HG)1%8QZSZ!M+L)D'LSI5YK*>>3 Q-3$ULPHF;Z[W9A[. MD:(21\)Y 8Q$7LP^ZT6KG)YY0(&Q4O#^C478G9WY1:-3BUYV:M$)=>;W!B_? MY._5\I]BZ_&.3:8SW\KPV?P_FW1::\?_,I<6Q+(XLLY+NTC@\H1=12G/VT(U MU=WL;JKKN;(J>UWV3>G3KU+EKMC^!)8M>M=@+,KRKBX]FWD^) S9DE7)AVFD MW8>-*0K0UEID,K0K%TZ0=I[*5TI+^9)M;;]OU,3V=_GN>Y\[O/(53U" TE*^ M4Z2=I_)=QZ1\X=O)%[_'@'WY5:M]'R>G+S&TCM,YJIACJ81:Q_,TR=(%LE+V M;^(X$E%+2TU+)ZBF^]+N4"U-FSJ23*\V W6E4B&IHO]6ZO/@]^%ZV&R&9ZK' M.A3IMSID,;]#*'ABO=$,R;(5LESR;W<]>6YGAME)]#1#)M,TMN,9T>O]%9NL^U98: -/_Y'+V0:*-9Z#RH@:$&T5U!.H#L3\;W4X;CZ5I=93B3-R+*QL% M@X(*9 IAF]$UJ %87= AW7 M/@#7]CXC#M\5@,?S]H-A&# K@3(9)BLY_%G\^,R7EB6B(&9RJVH4.=HRCK4.1 77:6+T@ L8H M(A4"Y$B9E+T$%)(Y>H5,6G21Z(44VF3*.L8NMF+1?P/^L;,IJ.R&6CD]%Z*$ M6A(]%Z*$6JHZ=J(D8N5T967GLF;!W+/>ZBH\VWVXS70J:L;A-K(CY:W*@D4M MFUB:,SD.%O"]"!28%LK?J%KC@ >LVOAI!)2&)Q/P952(4^6L&R_Z^',FS/8( M;#_^R'R5*E=6MMAAC]KRIHDUC>=:%3(>TST39E1R^7?])W-3N_XTKWQ[<)S. MNMONQIQ[!R!KFIFW!AT<6 \![!R\6"3+19R VVK.'KV:!R>*Q_J-(<#Q*/IA M$G6OQ9XR6:3\AU=%6)7-"#\#"SE.2EV(TU+ZV][$TO ?GRM3OMBY M9BNT(PWW,Y_$&]%>#W^[?S+NBM=7*SI5 MX0_\"85L?<7+;"N".(*9LF[0QDZY818>,@F7I?8C*W[A_C13.3KSXLH). H@ MK64N8[4NVG]4"D_>J0617G(7LK$RRK/].QV-G M7E")QGF("U'.*@\)2I101W(?.U%2MGUQ9&5)V#7WI,PYGF]%#LV3'A8%K!V] M8B=<,E;Z(Y9*/\>C7V4FL171BRL$G#$7$6=?A\'38A4K\L$5) M,IU)PEJXIS-Y1SK34961J-\JFC80![,9-:,.LZ'28WA^"^B$*//*%!!O) AD MZ'.EO4?P6P_89^S^+@'=Y[G!(R$7=),[BG%U1#E4L MP.3'HIQ=40Y5 ,'DCYO\H0H1F/QQDS_4*CPF?U#R[\P/5XE1R%+2OJ.I-Q>Y M2F6:+#,%W\P0\ST@WWVF'4=F?#QCJCTV@E8JB4G 6>74T@& C<'+]5-O6O[T]+<^3'"/[R:AF'>%C?/_ZH WM)%@/0X! M#/C(T+)OW$<(RAP2:J_CDBJ[CTMJ',E!@5_HAX7X>,/<3D;+'84- P?/@Y?V MI&O(D*L8JOG'54R2<[YI2>'6J0(I\R#4+/,3Y8&G)6BD90F2/;6P>_>=J=S< M#L6?XVQ:@M)>!>$3D<)#6P+,@QV6@([)$H0?#/#I_K%3ZZA?DL=%I3'-@&%)ND"1Q9+_F:A8 M;L+(S2'/&3,%)U/G1486GM 5.RPW,1F;DO%0BYU>6 M29KQ/_ !^Z>CLC-[&Y)RB24K =I(]S4B:$4!_H'PA"Q&_WZ<.87DDJ I2/N^ M. 4:T0)/1%>9LTX %B8@HOZ % MR(H.GZ K2%Z,!2Z8IPO$2)1A8BUR$GRGE;AKB9 -/NY_QMN_ M>Y@8^[A6BOH'/4KU:D@W*;=YO0,#&_8/1'\Q@T^OJMQ0Y#\0+:CC)GXM!2%5 M=-[TWKX+?6/1Q_%U=RZ!'+H5?;U-ATN"A0S@YKJR"9?C4LMTZ[3?@J_OP+P1=CVC?$+5J[S-Q<]O^ MD0(8O>9/XJ[=ZG_N02+5(2CU1JUQ=]WH+A>-#=K 'ZCD@7ESWZK>UYN0(F]C M>]F6 ;39[O>S%+% 4TS@Q=U\>NG\)M]?IFC;>KS*7S!PK@$FEK;,Q$Y(A!; MB3?W,@<#*>C@UF?%!L/-,J$\#+2XF09-E_W3ACVQ>R"2:$&@F5F0L'GK,K]G MAE@*R%<* Y=2_XM0KH3 -N;^G5N^3ACU]8C+\CW:0CS0G)7 M[!VN-2S,&]PZ@[SN=R51<+ QU9U4IQ*ENOMFR*)C];0%=!0Q=53E412 <+VX MUX#0E-LSH'(Z?%\5)M./QL31ZE#346X]$*\'+Q2HCH3:G5;1_L38WK9M4!S^ M\J;;OB/:G4:WVF^V/A'56K_YO=DWXK14C>[)>I/#.(A-X2RO"V?3V F+VE.K MCYPHF54FQ[JU59NZYC21'XC0_4VYVLN/^PX44?%F6 :U.T9]2&9_KQ5G%8O_ M[-K;BWXS0[H 6WOMT.V?W;Q=7A:H4&A?G?\G0LTX) NRTT.\DT;N\GL(ZOO4 M7^,@/[5LWZ?B.J*)9/)ELESP'T6VDU8[#V@J>PT@ZP*((R]*8(TVD"01W!A? M^#D>O]2;.A_%1@1U8YO&@#&,@0,I5/%4;;0(>=-*H*_1ASS$D)A#Q.#7A&*C M1G!+W"Y/W&.<+&+^0RL^<:*L(4$'6EMN/"/&ST5M@L2G/:J#H8Z<7VL@B(.I M9CE [N'FAIFVBN67?#(.T$_.64/.$>3HV%H)C#F)$$0-!LIS>PBZ-A]JHB!R MZL*FX$Y.!F5<>$/K2]_$!^Y3D-1YLA#@Z+L=Z]Q)42]H"UHYU+[-*$I1CCM_^VTO]P64S3LIL [H2+ \PS(&DBP12ZS3*T_YG8D71C;I#-]KZ!*AH.1X�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end

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